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Macular telangiectasia type 2 (MacTel), is a rare degenerative eye disease. In this 
thesis, we will explore and analyse MacTel ‘omics data including genomics, 
metabolomics and phenomics data to discover MacTel causal drivers that might 
be targeted for therapeutic interventions. The first chapter introduces the disease, 
the concept of data integration, and different types of ‘omics data. The second 
chapter presents the first MacTel GWA study which discovered five loci. Four of 
them indicated a possible involvement of the glycine/serine metabolic pathway on 
the disease while the last pointed to genetic influences from retinal vasculature 
calibre. In the same study, glycine, serine and threonine were externally validated 
as metabolic biomarkers for MacTel. The third chapter presents a causal model 
for MacTel via genetic variants. Using Mendelian Randomization, we tested the 
genetic contribution to the disease of more than 140 metabolites and comorbid 
traits and found causal effects from serine and glycine, whilst eliminating other 
spurious metabolites like threonine. Serine was also found to cause disease 
progression based on longitudinal retinal image data for 455 patients. Novel 
genetic loci were further revealed via conditional GWAS and MTAG. Analyses of 
serum metabolomics data presented in the fourth chapter revealed widespread 
metabolic rewiring, reflecting glycine and serine commensurate with genetic 
disruptions and identified lipids dysregulation as a new risk factor for MacTel. In 
the fifth chapter, we confirm that genetically induced depletion of serine in MacTel 
patients likely results in accumulation of deoxy-sphingolipids. These appear to be 
extremely toxic for retinal and neuronal tissues and were associated with disease 
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progression. Lastly, the sixth chapter summarises and discusses the main findings 
of these four studies while placing their discoveries on the bigger spectrum of 
macular and eye disorders as well as suggesting future studies. The results 
presented in this thesis significantly advance the understanding of MacTel 
aetiology and are supporting sensitive diagnostic re-evaluation and targeted 
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The following chapter will explore the main concepts required to understand the 
framework of this thesis. We will describe the disease that is the target of this 
work: Macular Telangiectasia Type 2, also known as MacTel, and what is known 
about it. We will then explore how research on a disease such as MacTel can be 
conducted in the current era of ‘omics data and describe the types of datasets used 
in this thesis. Lastly, we will present different methodological frameworks that 
will be used throughout the rest of this thesis.  
 
1.1 Macular Telangiectasia Type 2 
 
1.1.1 Description 
Macular telangiectasia type 2, typically abbreviated as MacTel, is an eye disease. 
This disease affects the macula, the central area of the retina which has the 
highest density of photoreceptors in the human eye. Initially described by Donald 
Gass in 1977 (1), it is a bilateral disease of mainly unknown causes (2). Depending 
on the stage of the disease it reduces visual acuity (3), reading ability (4), vision-
related quality of life (5, 6) and distorts vision (2).  
 
1.1.2 Epidemiology 
The disease prevalence has been estimated to be between 0.004% (7) and 0.1% (8). 
Given the rarity of the disease and the subtlety of its clinical signs, the disease 
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was initially largely under- and misdiagnosed (2) and to this day remains 
challenging to identify. In 2005 a privately funded project, called the “MacTel 
Project”, started a longitudinal cohort study of MacTel patients, also known as the 
“MacTel Natural History Study”. The aim of the project was to better understand 
the development of the disease and explore its natural history (9). Five years later, 
Clemons et al (10) described the cohort of the MacTel Natural History 
Observational Study (NHOS). Gender and ethnicity were not found to be risk 
factors for this disease. However, age was identified as playing an important role 
in the disease manifestation. In the MacTel cohort study, the mean age at 
diagnosis was 57 years identifying MacTel as a late-onset disease. In a subsequent 
publication, Clemons et al. (11) explored additional risk factors presented by the 
subjects enrolled in the NHOS. Interestingly, there was a significant difference 
between MacTel cases and controls in the prevalence of heart disease and 
hypertension. These two conditions are associated with increased BMI and weight, 
which were also identified as risk factors in the MacTel cohort. Cancer prevalence 
was also suggestively significantly increased in the NHOR study of MacTel 
patients, and 50% of the individuals in the cohort were either current or former 
smokers. However, which of these correlations are causal for MacTel and which 
are due to ascertainment bias or confounding was unknown. 
 
The most striking difference between the MacTel patients and the healthy cohort 
in this study was the high prevalence of diabetes mellitus (T2D) (38.2% compared 
to 10% of controls) among MacTel patients. This association was concordant with 
a previous study conducted in India (12) which reported a prevalence of (59% T2D 
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among 104 MacTel patients). Interestingly, in both studies, there was almost no 
sign of subjects suffering from diabetic retinopathy. This is a frequent comorbidity 
in T2D and some characteristics of this disease resemble MacTel disease. The 
absence of diabetic retinopathy in conjunction with the higher prevalence of 
diabetes mellitus in the MacTel cohort has suggested that the genetic component 
behind MacTel may be protective against diabetic retinopathy (11). 
 
1.1.3 Clinical signs 
Clinical signs of MacTel disease are observed in the retina. In humans, the retina 
is situated on the back of the eye and is the most light-sensitive tissue in the eye. 




Figure 1: A normal retinal colour fundus image. The dashed circle indicates the 
area of the retina known as the macula, while the white arrow points to the optical 
nerve. This mage was received through internal collaboration. 
 
The site of lesion for this disease is a region at the centre of the retina called the 
macula. In Figure 1, the macula, outlined here with a dashed circle, is generally 
identifiable as the darker round area in the middle of the retina. The bright yellow 
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circle on the right side of the image is the optical nerve, which is not affected in 
MacTel disease.  
 
In human vision, the macula is extremely important since it contains most of the 
photoreceptors present in the eye. Photoreceptors are particular neuronal cells, 
responsible for vision, which react to the light entering the eye and transmit that 
information to the brain. The mouse, a key experimental animal for biomedical 
research, lacks a macula, as do rats. The very centre of the macula is called the 
fovea. The fovea contains the photoreceptors responsible for the central vision, the 
area of the eye crucial for visual acuity, or fine-scale vision which helps humans 
read, recognise faces etc. There are two sides of the retina, the nasal side and 
temporal side. The nasal side is the area where the optic nerve is visible (right side 
in Figure 1), and to which side the nose is in the human face (hence nasal), while 
the temporal side is the opposite side (left side in Figure 1). 
 
Clinical signs of MacTel initially appear temporal to the fovea (2) and are usually 
symmetric, being present in both eyes (10), making MacTel a bilateral and 
symmetric disease. Patients affected by MacTel present with a variety of clinical 
signs in the macula that may vary with the disease course.  
 
Different ophthalmological diagnostic techniques are used to identify MacTel 
clinical signs, such techniques will be explored here since data from these 




1.1.3.1 Colour fundus photography 
Various macular alterations can be found using colour fundus photography which 
essentially takes a coloured picture of the retina.  
 
One of the earliest signs in MacTel is the loss of retinal transparency (2) (Figure 
2. 
 
Figure 2: Loss of retinal transparency as observed in colour fundus imaging on 
retina affected by MacTel. Image received through internal collaboration. 
 
The loss of retinal transparency can be seen as the grey area indicated by the 
arrows. This grey area starts temporal to the fovea and progresses to cover the 




Another common sign, sometimes visible in colour fundus photography, is the 
presence of blunted and dilated vessels, as well as right angle veins (Figure 3). 
 
 
Figure 3: Vasculature signs typically observable from colour fundus imaging in 
retinas affected by MacTel. Image received through internal collaboration. 
 
Vessels in retina should progressively narrow the more they converge to the 
centre. In Figure 3 the green arrow indicates a dilated vessel which can be seen 
to be enlarged. The same vessel can also be seen with the pink arrow to be blunt 
at its end, near the macula. As already mentioned, healthy vessels should narrow 
progressively until disappearing from sight while converging towards the fovea. 
However, it can be noted that the blunted vessel suddenly disappears after a small 
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enlarged area. This is caused by the vessel “diving” down towards the outer retinal 
layers instead of remaining in the surface. The term “outer” is used in this context 
since the retina observed through these images is facing the inner side of the eye. 
Lastly, the blue arrow indicates right-angle veins. These are simply veins that 
instead of progressively converge towards the centre suddenly turn creating an 
“angle”. This is also thought to be caused by the vessels suddenly diving into the 
retina. The process that leads to these abnormal blood vessels is called 
telangiectasia and blood vessels that show it are referred to as being telangiectatic. 
 
Another clinical sign of MacTel is defined by the presence of retinal pigment 
plaques as in Figure 4. 
 
Figure 4: Pigment epithelium migration plaques as shown by fundus colour 





In Figure 4 a large pigment plaque can be seen as a type of black “stain” in the 
macula. This plaque is the result of the proliferation of pigmented cells rising 
through the surface from the Retinal Pigment Epithelium (RPE) layer. The current 
hypothesis behind this phenomenon is related to blunted and right-angled veins 
(14). In fact, a vessel that has dived inside the retinal outer layers will eventually 
meet the RPE layer. Once the vessels are in contact with the RPE, the pigment 
cells will use them to rise towards the inner retina.  
Another sign of the disease visible from colour fundus photography is the presence 
of crystals around the macula as shown in Figure 5. 
 
Figure 5: Crystalline deposits as shown in colour fundus imaging of retina 
affected by MacTel. Image received through internal collaboration. 
 
However, the presence of crystals is an uncommon sign for this disease and it is 





1.1.3.2 Fluorescein Angiography 
 
A specific eye examination called Fluorescein Angiography (FA), is the current 
gold-standard imaging method to confirm the diagnosis of MacTel. This 
examination consists of an intravenous injection of fluorescein dye.  A fundus 
camera equipped with specific lenses that react to the colour emitted by the dye is 
then placed in front of the eye.. The camera will capture images of the retina 
immediately after and for another 10 minutes following the injection, revealing all 
blood vessels in the retina and any potential leakage.  
 
Fluorescein angiography of a retina affected by MacTel disease is displayed in 
Figure 6. 
 
Figure 6: Fluorescein angiography of a retina affected by MacTel, shortly after 
fluorescein injection (A), and long after fluorescein injection (B) (~10-minute 




Figure 6 displays the results of two fluorescein angiography photographs. One 
immediately after the injection of the dye (A), and the other some minutes after 
injection (B). In Figure 6 (A) we can observe telangiectatic vessels temporal to the 
fovea (left of the fovea). These vessels are dilated and some of them blunted, or 
even right-angled. From this figure, it is already possible to notice how these 
vessels are prominent to leakage of the dye. Additionally confirming the leakage 
is Figure 6 (B), where the dye can be seen to have spread around the macular 
tissue. 
 
1.1.3.3 Optical Coherence Tomography (OCT) 
 
Optical coherence tomography is a widely used technique that allows a cross-
sectional visualisation of the retinal layers. A healthy retina’s OCT is shown in 
Figure 7 adapted from (15). 
 
Figure 7: Healthy retina anatomy as shown by OCT imaging. Layers of the retina 
are indicated by a green vertical line. The fovea is visible as a depression in the 
middle in the macula (behind ELM green arrow). ONL: Outer Nuclear Layer. OPL: 
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Outer Plexiform Layer. INL: Inner Nuclear Layer. IPL: Inner Plexiform Layer. 
GCL: Ganglion Cell Layer. RMFL: Retinal nerve fibre layer., ILM: Inner Limiting 
Membrane. ELM: External Limiting Membrane. IS-OS/EZ: Inner Segment - Outer 
Segment layer / Ellipsoid Zone. CIST: Cones Outer Segment Tips layer. RPE: 
Retinal Pigment Epithelium layer. 
 
A comparison between a healthy and MacTel affected retina under OCT scan is 
presented in Figure 8. 
 
Figure 8: Comparison of OCT MacTel clinical sign between healthy retina (A) and 
affected retina (B). Image received through internal collaboration. 
 
One of the layers affected by MacTel is the IS/OS junction layer which divides the 
inner photoreceptors layer from the outer photoreceptors layer. Comparing the red 
arrows in Figure 8 A and B shows how in the MacTel affected retina this layer 
tends to reduce until disappearing. For this reason, this clinical sign is referred to 
as the Ellipsoid Zone Loss (EZ loss). We explored the behaviour of this clinical sign 
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and its progression in a recent publication where we noticed that this was 
exponential in its decay (16). Other early signs of the disease are the flattening of 
the temporal foveal slope (green arrow), leakage due to telangiectatic vessels 
resulting in retinal cystoids (blue arrow), and a general degradation and collapse 
of the retinal layers (pink arrow).  
 
Although not presented in the previous figure, other clinical signs often visible in 
OCT scans are the degradation of the RPE layer, subretinal vessel and 
macular/lamellar holes. 
 
An important phenotype measurable from OCT scans is the retinal thickness. The 
thickness is defined as the distance at each time point between the inner limiting 
membrane (the very top of the OCT scan) and the outer layer the varies by the 
technology used (17). In eyes affected by MacTel disease, a reduction in the 
macular thickness compared to healthy eyes is observed, due to the degradation 
of different layers in the retina. 
 
1.1.3.4 Fundus autofluorescence, blue light reflectance, and dual wavelength light 
Many other ophthalmological imaging techniques have been used to explore the 





Figure 9: Results of blue light reflectance (A-B), dual-wavelength 
autofluorescence (C), and fundus autofluorescence (D). Image received through 
internal collaboration. 
 
Figure 9 A and B are the result of blue light reflectance imaging. In this test, the 
loss of retinal transparency is clearly highlighted. Figure 9 C presents a dual-
wavelength autofluorescence image which is able to identify the loss of macular 
pigment, identifiable in this figure as the darker area temporal to the fovea. Not 
much is known about this clinical sign although it often overlaps with loss of 
retinal transparency. Lastly, Figure 9 D shows the results of fundus 
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autofluorescence imaging. This technique is often used to assess the health status 
of blood vessels and the RPE which, when damaged, appears as a brighter area, 
as in this figure.  
 
1.1.4 Staging 
MacTel progresses slowly over time, with worsening of some of the clinical signs, 
or with the appearance of new clinical indicators (2).  
The progression of the disease was initially divided into five different stages by 
Gass and Blodi in 1993 (3), depending on the clinical signs present in the patients’ 
retinas. This staging system was created when the understanding of this disease 
was very limited and only colour fundus photography and fluorescein angiography 
techniques were available. The five stages were defined as follows:   
1. Stage 1: hyper-fluorescence in fluorescein angiography usually temporal to 
the fovea indicating small leakages of the vessels in the retina. 
2. Stage 2: loss of retinal transparency highlighted by a greying of the 
parafoveal region on fundus colour imaging. Mild telangiectatic vessels 
might be seen in this stage. 
3. Stage 3: strong telangiectasis defined by dilated, blunted and right-angled 
vessels. These vessels can belong to both the venular or the arterial system. 
4. Stage 4: retinal plaques caused by the proliferation to the surface of RPE. 
5. Stage 5: neovascularization. 
 
Additional to the age of this classification system, stages 1-3 of this MacTel 
classification system have been characterised by very low inter-observer reliability 
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(2), however, this system is still used to this day to define disease progression and 
will be used throughout this thesis.  
 
Interestingly, it has been noted that neo-vascularization can occur in most of the 
stages, with different intensities (2). For this reason, neo-vascularization should 
not be considered the natural endpoint of the disease. To solve this problem 
MacTel has been divided into two subcategories: proliferative and non-
proliferative. The proliferative category is characterised by neovascularization, 
which is absent in the non-proliferative category. 
 
The natural endpoint of the disease is the inevitable atrophy of the photoreceptors 
layer (2). This atrophy is caused by the death of the photoreceptor cells contained 
in the retina which is the direct consequence of all the retinal abnormalities 
involved in the disease. Since photoreceptors are the cells which react to the light 
and send a signal to the brain in order to create the vision, absence of 
photoreceptors directly translate into vision loss. 
 
1.1.5 Vision Loss 
It has been observed that patients initially lose their peripheral vision and first 
report to their ophthalmologists with signs of scotoma and metamorphopsia. The 
former indicates the presence of a “blind spot” while the latter signifies a distortion 
of the image perceived by the eye. Metamorphopsia has been observed to appear 
before the presence of scotoma (2). Scotomas are measured by an ophthalmological 
examination called microperimetry which tests whether light projected into 
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different parts of the retina is perceived by the subjects. An example of 
microperimetry performed on three patients’ right eyes along different time points 
is presented in Figure 10.     
 
 
Figure 10: Example of microperimetry output on subjects affected by MacTel. The 
three patients are displayed separately in each row. The columns represent 
different time points, with scotomas (red areas) increasing in size (as measured by 
microperimetry) over time. Image received through internal collaboration. 
 
In these three patients, scotomas start on the temporal area of the fovea (central 
red cross) to then progress around it. Reading ability and especially reading speed 
is often reduced in MacTel patients. This is the direct consequence of the 
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paracentral scotoma that, by impairing the peripheral vision, makes it difficult to 
recognise subsequent letters or to follow the same written line (4). Central vision 
and hence visual acuity are only affected in very late stages (from stage 3) of 
MacTel. However, in a recent study, we noted that central vision of contrast 
sensitivity testing using the Pelli-Robson chart shown in Figure 11 can detect 
very early stages of MacTel disease in mesopic conditions (a room with the low 




Figure 11: Sample of the Pelli-Robson chart used to test contrast sensitivity. 
 
1.1.6 Therapeutic approaches 
Various therapeutic treatments have been tested in the past to treat this disease. 
Given that neo-vascularization can appear at any stage of the disease, therapeutic 
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approaches have been tried on both non-proliferative and proliferative disease 
(19). For the non-proliferative MacTel, argon laser photocoagulation, 
photodynamic therapy, and intravitreal injection of steroids have been attempted 
as therapies. None of these provided evidence of any significant improvement on 
the disease. Furthermore, some of these methods have been thought to accelerate 
progression of MacTel.  
 
Non-proliferative MacTel disease is characterised by different vessels 
abnormalities including, vessel leakage, and blunted and ectatic vessels. For this 
reason, it was assumed that VEGF inhibitors could be used as a potential 
therapeutic method. Early observations showed evidence of reduction of vessel 
abnormalities of the patients treated by regular intravenous injections of anti-
VEGF. However, long-term observations demonstrated poor performance (if not 
an even worse effect) on disease progression and visual impairment (20). For this 
reason, VEGF inhibitors have been excluded for the treatment of non-proliferative 
MacTel disease.  
 
For proliferative MacTel disease therapeutic approaches such as focal laser 
photocoagulation, photodynamic therapy, transpupillary thermotherapy, 
posterior juxtascleral administration of steroids, and intravitreal injection of 
VEGF-inhibitors have been tried. Most treatments were found to have an effect on 
the early stages of the vascular membrane and proliferation. However, only anti-




Recently, a phase 1 (21) and a phase 2 (22) clinical trial have been conducted to 
test the effect of ciliary neurotrophic factor (CNTF), delivered via encapsulated 
retinal implants. CNTF has been observed to slow photoreceptor loss for retinal 
degenerations using animal models with similar retinal phenotypes to MacTel 
(21). However, providing retinal treatment with CNTF is challenging as the blood-
retina barrier might prevent the molecule to reach the photoreceptors. The retinal 
implants used by the Phase 1 and Phase 2 clinical trials contains genetically 
modified RPE cells that release CNTF directly in the retina (22). The implants 
were well tolerated and beneficial effect on the treatment was observed in both 
trials. The phase 2 clinical trial found that 24 months after the implant in the 
treated eyes there was a significant reduction in photoreceptor loss as well as a 
reduction in the expansion rate of the ellipsoid zone break, increased macular 
thickness, and increased reading speed ability (suggesting an improvement on the 
parafoveal scotoma). Given the success of these implants on the prevention of 
photoreceptors loss, a phase 3 clinical trial (23) is now underway.  
 
Although this treatment is showing promise, it is important to recognise that the 
final end stage of the disease consists of neurosensory atrophy or fibrosis and 
translates into a definitive loss of vision with no possible treatment (2). For this 





1.1.7 Inheritance and genetics 
A positive family history has been frequently observed in MacTel cohorts (2). Many 
cases of siblings and twins concordant for the disease have been reported as well 
as several multi-generational families. This suggests that genetics play an 
important role in the occurrence of the disease. However, families with multiple 
MacTel patients also display incomplete penetrance, which is attributed to by the 
late age onset of the disease. In general, inheritance appears to fit a low 
penetrance dominant genetic model (24). 
 
Given how important early treatment is for outcome, understanding the genetic 
basis to the disease has been considered crucial for future advancement in disease 
diagnosis. However, up until 2015 genetic studies, consisting of family-based 
analysis, had been unsuccessful, with no genes identified.  
 
A publication in 2010 (25) performed candidate gene association studies using a 
list of candidate genes identified as related to retinal vasculature, involved in the 
transport of lutein in the retina, genes identified with microarray expression in 
mice with induced similarities of MacTel patients, genes identified through 
linkage studies and genes related to comorbidities of MacTel disease. 
 
 
Importantly, no specific biological pathway was identified for this list of candidate 
genes. A study performed on 17 families (24) also identified a promising linkage 
peak on chromosome 1 at the locus 1q41-42 with a LOD score of 3.54. 
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Unfortunately, subsequent sequencing of candidate genes for causal mutations in 
this genomic region failed to identify any plausible pathogenic variants suggesting 
that the inheritance model may not be monogenic, but rather polygenic. 
 
In this section, we have explored the clinical and biological, including genetic, 
understanding of MacTel disease available prior to the work developed f in this 
thesis and work by other researchers that have also advanced MacTel research. 
The next section will focus on different types of data and data analysis that formed 
the basis of the work conducted as part of this thesis to advance understanding of 
MacTel, in particular its genetic basis. 
 
1.2 Dissecting the causes of MacTel disease in the age of ‘omics 
data  
 
In the first part of this chapter, we have described how MacTel is characterized by 
a multitude of phenotypes affecting different layers of the retina. Additionally, we 
have demonstrated that MacTel has a late onset of symptoms, comorbidity with 
heart disease, hypertension, elevated BMI, obesity and T2D. Lastly, a number of 
families have been observed where MacTel was diagnosed in multiple individuals, 
giving the first hint of a genetic contribution to the disease development. However, 
genetic linkage studies that aimed to detect causative variants did not identify 




Since the disease runs in families but no causal variant could be found in family 
studies, MacTel is likely to be a polygenic disease with multiple genetic factors 
affecting its aetiology. High prevalence of metabolic traits such as high BMI, T2D 
and chronic cardiovascular diseases is indicative of environmental or other non-
genetic influences on disease aetiology, with the comorbid traits all known 
polygenic traits themselves. Lastly, the late onset might indicate that patients 
with this disease experience a complex continuous exposure to genetic and 
environmental factors that may result in disease manifestation.  
 
All these considerations place MacTel in the realm of complex diseases whose 
aetiology often arises from intricate interactions of multiple factors. In the past 20 
years, the realisation that many common diseases lie in this realm has highlighted 
the need to interrogate biological systems with multiple approaches, in a 
comprehensive manner (also referred to here as “systems biology”), in order to 
identify contributors to the underlying mechanism of these diseases. In the last 
decade substantial innovations and improvements in methods now permit system 
biology investigations that might help identify contributing factors in these 
complex diseases (26). The data that is derived from these unbiased approaches 
are referred to as ‘omics data. 
 
Each type of ‘omics data is intended to measure a different “layer” from the basic 
genetic profile of each individual, which is not affected by any environmental 
factors, to the final disease phenotype which is a complex mixture of different 
genetic, phenotypic, and environmental influences. An adaptation from Hasin Y 
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et al., Genome Biol., 2017 (26) illustrates this continuum of the different ‘omics 
data types represented as layers between the genetic background and the final 
disease outcome (Figure 12). 
 
Figure 12: Visual representation of ‘omics data on the space between the genetic 
background and final trait adapted from Hasin Y et al., Genome Biol., 2017 (26).  
 
Each type of ‘omics data measures different biological information, described 
below, which can be used to search for association with disease: 
 
● Genomics: identify genetic variants in DNA 
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● Epigenomics: measure reversible modifications of DNA or DNA-associated 
proteins  
● Transcriptomics: measure the level of RNA transcripts, which can be used 
to infer gene expression 
● Proteomics: measure peptide abundance, modifications and interactions 
● Metabolomics: measure the abundance of molecular compounds present in 
the body’s metabolism 
● Phenomics: measure the full set of phenotypes present in each individual 
 
Piecing together multiple kinds of ‘omics data makes it possible to unveil the 
complex web of genetic and environmental interactions that lie at the heart of the 
causal disease mechanism (26–28). 
 
In the next section, we will describe some of the most commonly used types of 
‘omics data that were analysed in the research presented in this thesis.  
 
1.2.1 Genomics data 
 
The human genome consists of almost 6.5 billion bases. However, humans have 
more than 99.9% of their DNA in common (29). One type of common variation 
between individuals are called Single Nucleotide Polymorphisms or, more 
commonly called, SNPs. A visual representation of a SNP is provided in Figure 
13. SNPs are defined as substitutions at single positions in the genome that are 





Figure 13: Visual representation of Single Nucleotide Polymorphisms (SNPs) adapted 
from (30). 
 
SNPs are often classified by “rs identifiers” and each has a specific chromosome 
and base-pair position. For example, SNP rs715 is a common variant in 
chromosome 2 at the base-pair position 211,543,055 which represents a change 
from the common allele T to the less common allele C. As research and knowledge 
regarding the human genome progresses, different annotations for each SNP are 
released by governmental agencies and consortia such as the Genome Reference 
Consortium. Annotations define the SNP name, position, and allele change. 
Currently, the two commonly used annotations are the GRCh37 and the most 
recent GRCh38. In this thesis, unless otherwise stated we will always refer 




Depending on their position, SNPs can be defined as intragenic or intergenic, 
depending on whether the SNP is located within a gene or between genes. 
Intragenic SNPs can be further divided into exonic SNPs, located within the 
coding regions of a gene, and intronic SNPs, located between coding regions. 
Lastly, exonic SNPs can be divided into synonymous or non-synonymous SNPs. 
Synonymous SNPs do not change the amino acid during transcription whereas 
non-synonymous SNPs will, and as a consequence are usually considered more 
important since their presence is much more likely to lead to pathogenicity. 
 
1.2.2 Metabolomics data 
 
Metabolomics involves the measurement and profiling of chemical compounds in 
the human body called metabolites (31). As presented in Figure 12 metabolites 
are much closer in “phenotype” to the final disease outcome than genetic data. In 
fact, metabolites are essential for the physiological functioning of the human 
metabolism. They can be measured with mass-spectrometry which detects the 
mass of different compounds in a sample and quantifies them.  
 
There are two main approaches used to quantify metabolite abundances. The first 
is targeted metabolomics, which records and quantifies only specific metabolites, 
chosen by the user to investigate a specific hypothesis (32, 33).  Targeted 
metabolomics can give very high sensitivity and selectivity and usually requires 
simpler and less intensive computational efforts (31). However, tagging only 
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specific metabolites requires the researchers to know a priori which metabolites 
might be associated with the trait of interest. In the case where not much is known 
about which metabolites might affect a trait, the second technique, referred to as 
untargeted metabolomics might be more appropriate. This technique relies on the 
measurements of hundreds of metabolites covering most of the metabolomics 
profile for each sample. Although less specific and more computationally intense, 
this approach guarantees the exploration of a wider spectrum of chemical 
components and their relative pathway, making untargeted metabolomics very 
attractive for the study of traits with limited a priori knowledge. For this reason, 
untargeted metabolomics studies have been used to “generate” hypotheses  (33).  
 
1.2.3 Phenomics data 
 
Phenomics is an extremely broad term that has been previously used to describe 
any kind of ‘omics data not strictly definable as genomics (27). Genomics data is 
intrinsically different from any other kind of ‘omics data as the former can be 
generally considered as “fixed” or “stable” between different conditions. In 
comparison, phenomics data is “flexible” and “unstable” as most biological 
phenotypes can change depending on factors at the time of collection and 
generation of the data, such as: cell type, tissue origin, time, age and other external 
factors affecting the sample. This means that a complete characterisation of the 





Given recent advancement and establishment of specific ‘omics measurements 
such as metabolomics, transcriptomics, epigenomics etc the definition of the term 
phenomics has slightly sharpened, now often referring to phenotypic 
measurements closer to the disease.  
 
In recent years, there has been a focus on the discovery of genetic variants 
associated with different traits and disease (34, 35). Phenotypic variability 
attributable to genetic contribution has been defined as heritability (defined and 
discussed in chapter 2). However, it has been observed that only a very small 
proportion of disease heritability can be explained by genetic variants currently 
detectable by genomic studies (36). Highly complex diseases often present with an 
extreme phenotypic heterogeneity leading to attempts to divide these into sub-
disease groups, often using ad-hoc approaches, based on clinical observations 
which may not reflect true underlying biological heterogeneity, such as that due 
to different biological pathways being affected in different patients. Measuring 
phenomics information provides the opportunity to better group subjects 
phenotypically similar to each other; the assumption being that they will also be 
more genetically similar and thus allow simplification of the disease to increase 
understanding and potentially even lead to targeted therapeutic development and 
treatments. In this thesis we refer to phenomics data as phenotypic data 
gathered through retinal imaging technologies. We provide extensive 




In this section, we have explored how different types of ‘omics data might be 
collected to better explore the genetic and biological mechanism underlying 
MacTel. The next section will explore how ‘omics data can be analysed and how 
different kinds of ‘omics data can be integrated to construct a more comprehensive 
and hence better understanding of a trait. 
 
1.3 Analysis and Integration of ‘omics data 
 
Analysis and integration of different ‘omics data poses specific data analysis 
challenges and consequently substantial effort has been applied to develop 
analysis methods to make the most of these data. To put this in some perspective, 
in 2006 there were about 1000 publications that mentioned “data integration” in 
their abstract. Six years later, that number had doubled with around 2,300 
publications addressing the same issue (28). In this chapter, we will provide an 
overview of the most common methodologies used to analyse ‘omics data in this 
thesis. To clearly divide the methods used to analyse single omics data from 
methods integrating two different ‘omics data from those integrating three, four 
etc, we will divide these methods into different sections (1.3.1 - 1.3.4) subclasses. 
We only introduce the methods that were used in this thesis, noting that a 






1.3.1 Analysis of single ‘omics data 
 
1.3.1.1 Genomics + Disease = GWA studies 
 
Genome-wide Association Studies, commonly referred to as GWAS, are 
experimental studies which aim to discover the association between genetic 
variants (usually SNPs) and a trait of interest within samples from specific genetic 
populations (34). The first wave of GWAS happened around the early 2000s with 
enormous expectations on the biological and translational results they would 
bring. However, by the end of the decade careful evaluation of GWAS results so 
far highlighted both achievements and pitfalls (37). Half a decade later, the doubts 
of GWAS utility peaked and addressing the misunderstanding about their efficacy 
became crucial (35). By the end of the 2010s, at the time of this thesis, the utility 
and applicability of GWAS were addressed again, and novel applications and new 
methods were discovered regularly (34).  
 
When talking about GWAS it is important to address the fact that such studies 
commonly focus on identifying common genetic variants associated with a disease 
rather than rare variants. Common variants are usually defined as those variants 
that are “commonly” found in a specific population. Generally, SNPs have Minor 
Allele Frequency (MAF) greater than 0.01. GWAS focus on these variants because 
of the need for very large samples sizes required to identify enough affected 
subjects with the same disease to satisfy power requirements. In contrast, 
extremely rare variants are more likely to be unique to specific individuals and 
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can thus not be analysed with standard GWAS approaches. Identifying common 
variants in contrast to rare variants has the potential to elucidate a shared 
biological mechanism underpinning a specific disease. Interventions on such 
shared mechanisms should be beneficial for most of the affected individuals, in 
contrast to specific and personalised interventions.  
 
It is now well understood that common variants surviving evolutionary selection, 
tend to have a reduced impact on disease risk compared to rare variants which are 
often observed to be extremely pathogenic. A visual representation from Manolio 
et al 2009 (36) of the effect sizes of genetic variants on general traits in relation to 
their allele frequency in the population is presented in Figure 14 
 
Figure 14: Genetic variants effect size in relation to minor allele frequency 




Extensive review about GWAS methodologies are beyond the scope of this thesis 
and can be found elsewhere (38–41). However, a typical GWA study might be 
summarized as following (37): 
 
1. Collect DNA samples from patients and healthy controls 
2. Genotype SNPs using sequencing technologies 
3. Clean genotype data by running quality control steps 
4. Impute genotype data to infer SNPs not directly genotypes 
5. Clean imputed data by running quality control steps 
6. Perform GWAS analysis by testing for association of each SNP with the 
trait of interest by correcting for potential confounders 
7. Identify genuine SNPs and genomic loci of interest  
8. Interpret how such genomic loci might be involved in the disease 
 
Since the goal of GWAS is to find common variants associated with a specific 
disease, such studies usually scan across the entire genome and independently 
test all SNPs for significant associations. However, typical GWAS test for millions 
of genotyped and imputed variants, resulting in an enormous multiple testing 
burden and an increase in the false discovery rate, where variants that might not 
be truly associated with a specific disease are significant at a nominal level. For 
this reason, is common practice to correct for false discovery rate using a strict p-
value correction called Bonferroni correction. The standard correction 
internationally adhered to is p<5e-08. This threshold was determined based on 
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empirical linkage disequilibrium patterns, determined by projects such as the 
HAPMAP (42) and 1000 Genomes project (29). 
 
As already mentioned, SNPs identified by GWAS studies often have small effect 
sizes on disease risk. Small effect sizes usually translate into p-values which would 
not survive correction for multiple testing necessary to robustly identify SNPs 
with a causative role in a disease. For this reason, very large sample sizes are 
usually required to perform GWA studies. Such sample sizes also usually reflect 
the rarity of a disease. Rare diseases may require smaller sample sizes as the 
number of genetic variants affecting such traits might be small, with larger effect 
sizes.Other and more common traits might be contributed to by hundreds of 
variants and can be considered as extreme polygenic traits. GWA studies on such 
traits often require samples sizes in the order of hundreds of thousands of 
individuals. Recent examples of such mega GWAS include studies into height (43) 
and education attainment (44).  
 
In the specific setting of this thesis, MacTel is a relatively rare disease for which 
no single rare genetic variant could be robustly identified using family-based 
analysis approaches. Because of this, we might expect that common genetic 
variants might play an important role in the disease and that moderate sample 
size would be sufficient to reliably identify a subset of important SNPs which 
might help elucidate the disease. Results of the first GWAS ever performed on 




1.3.1.2 Metabolomics + Disease = Metabolomics Study 
 
Untargeted metabolomics studies focus on measuring metabolic abundances 
across the entire metabolome spectrum in both healthy subjects and disease 
patients to subsequently identify metabolites which might be involved in the 
disease. Metabolites found to be associated with a trait by untargeted 
metabolomics studies are often called metabolic “biomarkers”. Unlike genetic 
variants, biomarkers are closer to the observed disease outcome and are expected 
to have bigger effect sizes, requiring a smaller sample size compared to typical 
GWA studies.  
 
However, metabolomics studies do not come without challenges. Firstly, as 
mentioned before, metabolomics as well as all other phenomics profile cannot be 
uniquely characterised and are reflective of a specific time and place. For example, 
the metabolic profile of the same individual would be different if extracted from 
different biological samples such as blood or urine. The same profile would be 
additionally different if the same sample was to be extracted before or after 
fasting. This profile will also differ if the sample was taken during childhood or 
during adulthood. Moreover, sample storage conditions, machines and techniques 
used to measure metabolic abundances and even human interference in sample 
processing can alter specific metabolic profiles inducing unwanted variation (45, 
46) that might hide genuine biological signal. As for GWAS, intensive research 
effort has been invested in developing methods aimed at overcoming such 
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complications. (45–48). A general untargeted metabolomics study might be 
summarised as follows: 
 
1. Collect biological samples and measure metabolomics abundances across 
the entire metabolome spectrum. 
2. Perform QC steps, identify batch effect and confounders, and normalise the 
data to account for technical variation 
3. Identify metabolic biomarkers by performing differential abundance 
between cases and controls for each metabolite 
4. Explore whether the metabolic biomarkers are indicative of a specific 
metabolic pathway or group 
 
The identification of metabolic biomarkers has been historically the main goal of 
metabolomics studies (31). However, metabolomics has seen a rapid expansion of 
research goals in recent years and advances in both technical and instrumental 
performance, as well as the development of bioinformatics tools and publicly 
available databases. This has helped to move from the simple biomarker discovery 
to the more complex analysis of interconnectivity in the metabolome and in 
metabolomic pathways.  
 
As previously mentioned, we can expect MacTel disease to be affected by complex 
genetic factors as well as and non-genetic factors which will affect the ‘omics 
between DNA and eventual disease. Metabolomics offers an opportunity to explore 
this intermediate ‘omics space and indeed may better capture the mechanism 
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behind the disease aetiology. Results of a standard semi-targeted metabolomics 
analysis are presented in Chapter 2 while the results of a comprehensive 




1.3.2 Joint ‘omics data integration 
 
1.3.2.1 Genomics + Transcriptomics = eQTLs Study 
 
One of the most important questions usually asked in GWA studies is the 
functional mechanism that might be behind the association between genetic 
variation and a trait. One of the first steps towards answering this question is to 
investigate which genes’ expression might be affected by the SNPs of interest in 
the association peak. This question might be trivial for intragenic SNPs which 
might even be located within the coding region of a gene. However, for intergenic 
SNPs, which account for the majority of GWAS signals (37) the answer to these 
questions is often far from straightforward. In fact, it has been reported that only 
~1/3 of eQTL signals it is the nearest gene to the SNP of interest (34). A frequently 
used approach, is expression Quantitative Trait Loci (eQTL) analysis (49), with 
different methods having been proposed to perform such analysis (50). Typically, 
eQTL studies use linear regression to test whether changes in SNPs can predict 
the level of gene expression of candidate genes whose expression can be 
summarised with gene expression levels determined from microarray, or more 
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frequently now, RNA-seq data. However, it is important to remember that gene 
expression is highly variable, tissue-specific and noisy. For this reason, in 2008 
the Genotype-Tissue Expression (GTEx) project was proposed, with the intention 
to characterise gene expression across different tissues and cell lines of the human 
body (51). A visual representation of the tissues and cell-lines explored in GTEx is 




Figure 15: Visual representation of all tissues gene expression and relative 
sample size explore by the GTEx consortium. Note the absence of any eye tissue, 
including retina. Image adapted from Battle A et al., Nature Publishing Group, 




Apart from collecting gene expression from different tissues, the GTEx project also 
explored the effect that common genetic variants like SNPs might have on gene 
expression, stratifying for tissues and cell lines. This project has greatly 
contributed to our understanding of both the transcriptome and eQTL effects 
across the human body and provides an invaluable tool for exploring the functional 
effect of identified SNPs such as those found to be associated with traits in GWAS 
studies. 
 
An important distinction needs to be made when describing eQTLs. SNPs affecting 
gene expression through a direct pathway are called cis-eQTLs while SNPs which 
affect gene expression through a distant pathway are called trans-eQTL (49). 
However, the specific biological pathway through which SNPs affect genes is 
mostly unknown. Usually, SNPs located within the transcription boundaries of a 
gene or located near in a region near a gene, which might contain a promoter or 
an enhancer for that particular gene, are assumed to affect the expression of such 
genes directly, while distant SNPs are assumed to have an indirect effect. For this 
reason, SNPs affecting the expression of neighbouring genes (usually less than 
500Kbp or 1Mbp apart) are called cis-eQTL, while those affecting more distant 
genes are called trans eQTL (49). 
 
Testing for eQTLs usually involves testing associations between millions of SNPs 
with thousands of genes. This, in turn, results in an enormous multiple testing 
burden which is known to increase false positive discovery. For this reason, testing 
is usually performed separately between cis-eQTLs and trans-eQTL. Because of 
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this approach, cis-eQTL are in general easier to find than trans-eQTL. Firstly, the 
amount of testing required for cis-eQTL is usually much smaller than for trans-
eQTL. Secondly, the effect size of cis-eQTL tends to be in general larger than for 
trans-eQTL, with evidence of intergenic cis-regulation of SNPs on genes to lie 
between 800Kbp and 1.3Mbp away from the genes’ transcription start site (51).  
 
1.3.2.2 Genomics + Metabolomics = mQTL Study 
 
Similarly to the concept of eQTL studies, researchers have been interested in 
common genetic variants associated with any measurable quantitative trait. Such 
studies have been defined generally as Quantitative Trait Loci studies (QTLs). 
Understanding the genetic background of metabolic regulations has the potential 
to inform on the mechanisms and pathways involved in the biosynthesis of 
different metabolites as well as genomic factors that might be involved in the 
modulation of metabolic profiles. However, unlike in the eQTLs setting, there is 
no prior information that can be assumed to divide trans from cis effects of specific 
SNPs on metabolomics abundance. For this reason, metabolomics Quantitative 
Trait Loci (mQTL) studies are often performed as several GWAS, where 
metabolomics datasets are combined with genomics information and a GWA study 
is performed on the abundance of each metabolite. Only recently, datasets of a 
sufficiently large size, which can overcome the tremendous amount of multiple 
testing and the problem of relatively small effect sizes of SNPs on metabolomics 
abundances have become available. However, the few studies performed so far (52) 
have already created exciting resources, such as the metabolomics GWAS server 
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(53), that can be interrogated to discover whether specific SNPs of interest are 
related to the abundance of specific metabolites. 
 
1.3.3 Three-way ‘omics integration 
 
1.3.3.1 QTLs + Genomics + Disease = Mendelian Randomization 
 
By combining information from QTL studies for specific traits with genomic 
information from other traits it is possible to perform Mendelian Randomization 
(MR). MR is a relatively new and growing field of research in genetics gaining 
prominence in the last decade. It aims to detect unbiased causal effects and 
possibly estimate their magnitude (54).  
 
Before explaining how to perform MR through data integration, it is important to 
first address causality. To do this we will make use of the work of (54–56). Imagine 
a child that wants to play in a park, but the child is sick and needs to stay home 
and take antibiotics. In this example the child’s health condition, taking 
antibiotics, and playing in the park are all associated with each other but the 
health condition of the child that is causing both circumstances: taking antibiotics, 
and not playing in the park. Hence, in general, a child taking antibiotics and not 
playing in the park are associated to each other (co-occur), but there is no 
causation between the two. Causality has been historically represented by using 
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Directional Acyclic Graphs (DAGs) and theoretical considerations on DAGs has 




Figure 16: Directional Acyclic Graphs demonstrating association (dotted line) and 
causation (solid arrows) between three different phenomenons. Dotted lines 
represent associations while solid arrows represent causation. 
 
In Figure 16 we see that causal associations are presented as solid arrows while 
associations are presented as dotted lines. As we see in this example the health 
condition is connected with both antibiotics intake and not playing in the park, 
and this connection arises from a causal effect of the health condition on the two. 
Antibiotics intake and not playing in the park are also associated but this 
association is not due to any causative effect.  
 






Association not due to causation may arise from several different scenarios and in 
this case, arises from a phenomenon known as confounding. In fact, in this case, 
the confounding effect is the health condition which, if not taken into account, will 
make antibiotics and not playing in the park associated with each other. 
 
Another example of association not due to causation is known as reverse causation. 
In our example, antibiotics intake and the health condition are clearly associated. 
If a naive researcher observed that everyone who takes antibiotics also has a 
health condition, this researcher concludes that antibiotics are associated with a 
health condition. By not knowing why this is the case, the naive researcher may 
think that antibiotics are causing the health condition where of course, the 
opposite is true. So, in this case, the association between antibiotics and the health 
condition arises from a reverse-causation of the health condition on antibiotics as 
shown in Figure 17.  
  
 
Figure 17: Directional Acyclic Graphs demonstrating reverse causation. Dotted 
lines represent associations while solid arrows represent causation. 
 
To illustrate the differences between association and causation, we have used so 
far a very naive example for which anyone would be able to distinguish between 
 Antibiotics Health Condition 
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the two. However, most research studies focus on associations for which the 
directionality of the causative effect is not known (54–56). Imagine we studied the 
effect of blood levels of vitamin C on cancer risk. It might be possible to observe 
that people with cancer have low vitamin C. This might suggest that having low 
vitamin C levels may predispose to increase cancer risk (direct causation). 
However, can we really claim this? Maybe cancer cells use vitamin C in order to 
duplicate faster (inverse causation). Also, we know that people with high levels of 
vitamin C are likely to have a healthy diet, which itself is common among people 
living a healthy lifestyle, who again are likely to avoid many of the common risk 
factors for cancer like smoking (confounding). Also, people suffering from cancer 
may modify their diet due to illness resulting in a depletion of vitamin C (indirect 
inverse causation). Even in this relatively simple example is it easy to recognise 
that the association between vitamin C and cancer risk is anything but obviously 
causal. Classic epidemiological studies have generated thousands of replicated 
associations between traits. However, these studies are often unable to claim a 
clear causative effect.  
 
Causation has been historically tested by performing Randomized Clinical Trials 
(RCTs) (54–56). These studies involve randomly exposing individuals lacking any 
trait of interest (eg. totally healthy individuals) to the exposure of interest (eg. 
Vitamin C), then waiting for a specific amount of time and assessing how many of 
these individuals develop the final trait of interest (eg. cancer). It is easy to 
recognise why RCTs are protected from both confounding and reverse causation 
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as people are assigned to receive the exposure and the outcome completely at 
random, preventing confounding.  
 
There have been many examples of associations repeatedly reported by 
epidemiological studies, which have not been confirmed as causal associations by 
RCTs. Some of these include the association between the antioxidant vitamin β-
carotene and smoking-related cancers, or the association between Vitamin E and 
coronary heart disease (55). 
 
Clinical trials are not possible for many traits for ethical and feasibility reasons 
(eg. cigarette smoke and cancer causation).  
Fortunately, genetics provides an indirect RCT in that every single human being 
is randomly assigned to a combination of genetic factors. Genetic factors contribute 
to thousands of different exposures and are largely unaffected by any external 
influence. Because of this, we can think of such genetic factors as “life-long 
exposure treatments”. In our example, we imagine that people with specific 
genetic factors, predisposing them to smoke, are the equivalent of a randomized 
group of people in a trial exposed to cigarette smoke. If we observe that people 
carrying these genetic factors also develop cancer later in life, we can claim that 
smoking might actually have a causal effect on cancer risk. This analogy between 
RCTs and MR has been beautifully explained in a YouTube video by Prof. George 




A more technical explanation of MR comes from Instrumental Variables (IVs) 
which have been historically used to test for causality (54). This method states 
that IVs capturing a specific exposure are associated with a trait only in the 
presence of direct causation. Theoretically, IVs satisfy the following properties: 
1) The IV needs to be reliably associated with the exposure of interest 
2) The IV needs to be independent of unobserved confounders that influence 
exposure or outcome.  
3) The IV needs to be associated with the outcome only through its effect on 
the exposure 
 
Genetic variants such as SNPs satisfy almost all these properties. In fact, reliable 
associations between SNPs and traits are obtainable through QTL studies and a 
SNP is independent of most confounding factors that may influence either outcome 
or exposure. However, there is no unique way of testing whether a specific SNP 
affecting an exposure of interest also affects an outcome only through the initial 
effect on the exposure. In fact, genetic variants such as SNPs are often observed 
to have pleiotropic effects which are considered to be the main limitation of 





Figure 18: DAGs demonstrating of different scenarios. A Direct causation 
scenario. B Inverse causation scenario. C Pleiotropy type 1 scenario. D Pleiotropy 
type 2 scenario.  
 
In Figure 18, the SNP will be associated with the exposure as well as with the 
outcome in all four scenarios, and because of this, the exposure would be 
considered as causative for the outcome. However, only the scenario presented in 
Figure 18 A is truly indicative of a causative effect of the exposure on the outcome.  
A strategy has been implemented in MR techniques to overcome misdetection of 
causative effects in situations B, C and D. This strategy first extracts multiple 





























association with the outcome. If most of them are also associated with the outcome 
then the causative relationship is deemed to be genuine. We can, in fact, expect 
that not all SNPs associated with exposure present the same pleiotropic effects. 
Imagine if the exposure is not causative for the outcome. In this case, we expect 
that even if a single SNP is associated with both exposure and outcome because of 
a pleiotropic effect or inverse causality, all the other SNPs associated with the 
exposure not presenting the same pleiotropic effect should not be associated with 
the outcome. Hence the combination of all these SNP associations should suggest 
a non-causal relationship between exposure and outcome. 
 
There are many ways of implementing MR between an exposure of interest and a 
specific outcome. Most methodologies can be grouped depending on the data 
available. There are methodologies developed to test MR on data where all three 
types of ‘omics data are available for the same individuals i.e. genomics, phenomics 
(exposure), and outcome. Other MR method apply when the phenomics 
information on the exposure is missing and only the general QTL effects, capturing 
SNP effects on exposure, are available, as well as genomics data and outcome. A 
third MR method applies when the genomics data is missing as well and the 
available information only comes from QTL effects and GWAS results from SNP 
effects on the outcome. An extensive review of these implementations is beyond 
the scope of this thesis and can be found elsewhere (54–56).  
 
MR allows investigation of different questions which might be more complicated 
than a simple direct causative effect. A methodology of particular interest to our 
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study is called hypothesis-free MR that can be used to test for causal association 
between exposures and outcomes which has never been explored before (eg. 
expression of specific genes or metabolites to disease risk). One can use hypothesis-
free MR to test for causative associations between any trait that is measurable 
using genomics data and MacTel disease. This translates to the invaluable 
opportunity of testing for factors that were never directly measured in the MacTel 
cohorts.  
 
1.3.4 Multi trait genomics integration and the concept of genetic 
correlation 
 
By integrating summary statistics from GWAS performed on several traits, one 
can explore the concept of genetic correlation between traits. Genetic correlation 
has been defined as the proportion of variance that traits share due to genetic 
causes (58). Historically, genetic correlations have been tested by measuring 
different phenotypes across different families and estimate the frequency of such 
phenotypes between them (59). However, such studies are often costly and require 
researchers to investigate multiple phenotypes on the same individuals.  
 
With the advent of GWAS data, methodologies have been developed to explore 
genetic correlation using SNP data. In fact, MR can be seen as a particular method 
of testing for genetic correlation. However, as mentioned earlier MR requires 
SNPs that act as IVs which are usually those presenting an association with the 
trait of interest that reaches genome-wide significance. Because of this, MR can 
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only be performed for traits where such SNPs are available. However, this is not 
possible for a large number of traits where there are currently no or not enough 
genome-wide significant SNPs from GWAS results, perhaps due to as yet to low 
sample size and thus insufficiently powered studies,  
 
For this reason, tools have been developed to estimate genetic correlations using 
all SNPs instead of only the significant ones. Recently, a tool that is able to 
estimate genetic correlations between traits using genome-wide summary 
statistics data called LD-score regression, has been published (59). This method 
not only reliably estimates genetic correlation between traits from publicly 
available datasets, but is also able to take into account that sample overlap might 
be present between two different GWAS summary statistics.  
 
This study highlights the discovery potential that multi-omics data integration is 
able to achieve. By using such methods one can not only explore connections 
between traits but also prioritise biological pathways that, if shared between two 
genetically correlated traits, might be causal. 
 
Lastly, a final example of multi-omics data integrations initiated by the GWAS 
community, also based on genetic correlations, is a tool called MTAG (60). This 
method aims to discover new GWAS hits by comparing GWAS results of 
genetically correlated traits. In short, this tool firstly checks for genetic correlation 
between the traits using the aforementioned LD score regression, then it 
prioritises SNPs showing shared effects on both traits. For example, if a SNP has 
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a positive genome-wide significant effect on trait 1 and has a suggestive positive 
effect on trait 2 and these two traits are positively genetically correlated, then this 
method will highly prioritise such a SNP also for trait 2, even though it did not 
originally reach genome-wide significance. This method becomes extremely 
powerful when we need to detected SNPs reliably associated with traits for which 
GWAS currently holds small discovery power (perhaps due to the difficulty of 
collecting a large enough study cohort). MTAG is able to, in part, address such 
problems and potentially identify SNPs that might have been missed by a specific 
GWAS because of this replication problem.  
 
Using MTAG the authors were able to show that combining three genetically 
correlated neurological disorders together resulted in an increase in discovery 
power from the initial 32, 9, and 13 genome-wide significant loci to 64, 37, and 49 
genome-wide significant loci respectively on the three traits. 
 
To conclude, we can expect that combining the genomic information for several 
traits and MacTel using MTAG, might lead to the discovery of new potential 
genomic loci that might have been missed due to the small sample sizes that such 
a rare disease is limited to. 
 
1.4 Conclusions 
In conclusion, in this chapter, we have explored MacTel disease, the different types 
of ‘omics data that might be collected to study such a disease as well as the 
different methodologies that might be used to analyse and integrate such multi-
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omics data. The next four chapters will present studies performed on MacTel using 




2 Contributions to Scerri et al. Genome-wide 
analyses identify common variants associated with 




This chapter will describe the contributions that RB brought to the study 
“Genome-wide analyses identify common variants associated with macular 
telangiectasia type 2” by Scerri et al published in Nature Genetics in 2017 (61). 
The chapter will firstly describe the study and the results found, without the 
contribution of RB. Then, an introduction to the main framework of the analysis 
performed by RB will be given. Methods used to perform such analyses, as well as 
results and discussion arising from this study will then be presented later in the 
same chapter. The Scerri et al publication can be found in the supplementary 
appendix. 
 
2.1.1 The MacTel GWA Study 
 
In 2017 we published the first GWA study on MacTel using SNP chip genotyping 
performed using the SNP chip Illumina Infinium Omni5Exome-4 on a cohort of 
476 MacTel patients and 1,733 controls to discover potential genetic loci involved 
in MacTel (61). This chip was able to directly genotype around 2.5 million SNPs. 
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Further imputation using the 1000 genome project reference panel returned 
almost 85 million SNPs in total. SNPs were then discarded based on low 
imputation quality, extremely low Minor Allele Frequency (MAF) and Hardy-
Weinberg equilibrium, leaving around 6 million SNPs for disease association 
testing. After performing the GWAS analysis, which tested with logistic regression 
models the association between each SNP and the disease while correcting for sex 
and the first two principal components, we identified 28 suggestive (P <5e–05) loci 
involved in the disease, three of which reached genome-wide significance (P <5e–
08). A Manhattan plot of the MacTel GWAS results is presented in Figure 19. 
 
 
Figure 19: Manhattan plot displaying significant hit in MacTel GWAS as taken from 
Scerri et al, Nat Genet 2017 (61). 
 
Given the moderate sample size of this study, only three loci reached genome-wide 
significance. These were tagged by SNP rs73171800 in locus 5q14.3, (p=7.74e–17), 
SNP rs715 in locus 2q34 (p= 9.97e–14) and SNP rs477992 in locus 1p12, (p = 
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2.60e−12). We subsequently replicated associations at these three loci in an 
independent cohort of 172 cases and 1,134 controls. In the same cohort, we also 
replicated a further two loci that had not reached genome-wide significance in the 
initial cohort, but which were considered mechanistically related to the SNPs 
located in locus 1p12 and 2q34. These were SNP rs9820286, located in locus 3q21.3 
(p=5.38e−06), and SNP rs4948102 in locus 7p11.2 (p=2.25e−06). 
 
The SNPs identified in locus 5q14.3 had been previously associated with retinal 
venular and arteriolar calibre (62, 63). Subsequent work has shown that ablation 
of the homologous chromosomal region in zebrafish severely disrupts retinal 
development (64). The other four loci 1p12, 2q34, 3q21.3, and 7p11.2 had been 
previously associated with the abundance of glycine and serine in blood serum (52, 
65, 66). Specifically, SNPs in locus 3q21.3 were in close proximity, but not in 
linkage disequilibrium with the SNPs found to affect glycine and serine ratio by 
Xie W, et al. Diabetes, 2013 (65). Additionally, loci 2q34, 1p12, and 7p11.2 all 
contained, or were in close proximity to, genes catalysing enzymes involved in 
glycine and serine biosynthesis. SNP rs715 in locus 2q34 was located in the 3’ UTR 
region of gene CPS1 which catalyses the Carbamoyl-phosphate synthase (CPS) 
enzyme; SNP rs477992 in locus 1p12 was an intronic SNP on the PHGDH gene 
catalysing Phosphoglycerate dehydrogenase (PHGDH) enzyme; SNP rs4948102 in 
locus 7p11.2 was an intronic SNP in the gene PSPH, catalysing the Phosphoserine 
phosphatase (PSPH) enzyme. Lastly, rs9820286 in locus 3q21.3 was located 
nearby to the gene ALDH1L1, which catalyses the Formyltetrahydrofolate 
dehydrogenase (FTHFDH) enzyme. All the aforementioned enzymes were found 
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Figure 20: Proposed connections between candidate genes and the glycine-serine 
pathway as shown in Scerri et al, Nat Genet 2017 (61). 
 
2.1.2 Considerations arising from the initial results and chapter aims 
 
The results arising from the initial GWAS analysis and the genes implicated, 
clearly highlight a potential involvement of glycine and serine biosynthesis on 
MacTel risk. As part of the publication we also investigated several additional, 
important questions for MacTel genetic aetiology. Firstly, we investigated the 
genetic contribution to the disease or in other words, how much of MacTel risk 
could be explained by common genetic variations compared to other external 
factors. Secondly, we explored more deeply whether common genetic variants may 
be used to reliably predict disease risk or presence. Thirdly, by mining publicly 
available datasets like GTEx exploring relationships between SNPs and the 
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expression of genes we pinpointed multiple candidate genes for which expression 
might be affected by significant or suggestive significant SNPs. Lastly, we 
performed a metabolomics analysis with an independent set of MacTel patients 
and healthy controls to validate the involvement of glycine and serine on MacTel. 
 
RB performed these four analyses which formed part of the MacTel GWAS 
publication (61). The following section will introduce and present the results of 
these four investigations.  
 
2.1.3 “How much” MacTel can be explained by genetics: The heritability 
concept 
A common question asked in GWA studies is how much of the phenotypic 
variability can be explained by genetics, or in simpler words, how important is the 
genetic component for disease risk?  
This question is usually explored with the concept of heritability. Heritability has 
two main definitions: 
 
● The narrow-sense heritability defines heritability as the proportion of 
total phenotypic variation explained by additive genetic factors effects. 
● The broad-sense heritability defines heritability as the total contribution 
of genes on the phenotypic variation. 
 
For our publication, we were mainly interested in the narrow-sense heritability, 
since multiplicative gene-gene and gene-environment interactions are usually 
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hard to identify and measure, especially with SNP genotyping data. The 
heritability of a trait is usually estimated from pedigrees and twin studies. 
However the rarity of MacTel, it's late-age onset and the difficulties in diagnosis 
provide too few families to investigate this using these approaches, and very few 
twins with MacTel have been reported (2). These heritability estimates, vary 
between different traits. For example, height is an intensely investigated, highly 
polygenic trait, for which heritability has been estimated to be around h2 = 0.8 (67, 
68). Recently, methods have been developed to estimate heritability using SNP 
data (68, 69). By 2010, GWA studies had discovered over 40 common variants 
associated with height. However, these variants together only explain h2known = 
0.05 of the phenotypic variance i.e. they explain h2explained = 6.26% (=0.05/0.8) of the 
estimated total heritability. This proportion was called “Explained Heritability” 
by Zuk et al in 2012 (70). Manolio et al 2009 (36), coins this problem as one of 
“Missing Heritability”. Missing heritability is defined as the proportion of 
estimated heritability not explained by common variants, h2miss = 1 − h2explained. 
Several hypotheses have been formulated for this phenomenon. The general 
consensus is that most of the missing heritability might be explained by SNPs that 
are below the GWAS significance threshold (71), or by low-frequency variants, too 
rare in any given population, whose effect will not be captured by standard GWA 
studies as previously shown in Figure 12. Other sources contributing to this 
missing heritability are also copy number variations (CNVs) and short-tandem 
repeats (STRs). As demonstrated(67), the heritability for height estimated by 
using all SNPs (after some correction regarding the MAF of the causal SNPs) 
reached 80%. An interesting argument raised is that genetic interactions create 
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“Phantom Heritability” (70). No heritability estimate had ever been calculated for 
MacTel hence we were interested in estimating not only the total MacTel 
heritability (h2), but also the known (h2known) and explained (h2explained) heritability, 
estimated using the five replicated loci, as well as the proportion of missing 
heritability (h2miss). 
 
2.1.4 Predicting the risk of disease using SNP data 
 
Another common question explored in GWA studies is whether common genetic 
variants can be used to build prediction tools that may be relevant to clinical 
usage. This question becomes even more important in the case of rare diseases like 
MacTel. In fact, as already mentioned the first visual symptoms of MacTel are a 
direct consequence of structural changes in the retina, which often already involve 
photoreceptor death. Given the lack of treatment available for these structural 
changes, prevention and early diagnosis of the disease is key. Prediction is 
particularly important for prevention. If a prediction model adequately predicts 
the likelihood of a subject developing a disease, prevention measures can be 
adopted and recognition of early signs of the disease might be made easier. In our 
study, we were interested in predicting the likelihood of each subject being affected 
by the MacTel disease, based on their SNP information.  
 




As mentioned in Chapter 1, on average only a third of SNPs associated with a 
disease act by influencing the expression of the nearest gene (cis-eQTLs). Other 
SNPs are more likely to affect the expression of more distant genes (trans eQTLs), 
or they affect the gene’s final protein structure, instead of transcription levels, 
thus showing no association with transcript levels.  
Exploring eQTL effects not only has the potential to shed light on the biological 
mechanisms underpinning the identified loci, but also allows prioritisation of 
specific genes of interest. We mined the GTEx database to further implicate the 
candidate genes and enzymes presented in Figure 20, but also to discover which 
were the potential gene effects by the identified loci and in which tissues these 
were most pronounced. 
 
2.1.5 Exploring MacTel metabolic signal with metabolomics data 
 
The results of the GWA study pointed to a possible genetic dysregulation of 
metabolomics signalling in MacTel patients. Specifically, we observed that 4 out 
of 5 SNPs were previously associated with abundances of circulating glycine and 
serine metabolites. As mentioned in Chapter 1, metabolomics is a growing field 
which has in recent years seen substantial methodological improvements in both 
machine measurements and bioinformatics techniques for the assessment of these 
measurements. A group of collaborators from the University College London and 
Moorfields Eye Hospital collected blood serum and plasma from unrelated MacTel 
cases and healthy controls. Both serum and plasma samples were then sent to 
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Metabolon Inc. to perform an ultrahigh-performance liquid chromatography-
tandem mass spectroscopy (UPLC-MS/MS) which measured metabolomic 
abundances for hundreds of metabolites in each sample. The untargeted 
metabolomics dataset produced by the UPLC-MS/MS method was used to 
externally validate and explore the hypothesis of a disruption of glycine and serine 




In 2011 Yang et al proposed a method implemented in the software GCTA to 
estimate the heritability of a trait (h2) by using “all” SNPs (69). This method is 
based on the variance decomposition of a trait into a random term (all the SNPs) 
and a noise term. The methodology behind this approach is based on the 
construction of a genetic relationship matrix capturing similarities between all 
pairs of individuals.  
 
If we assume that all causal variants for a trait are known, a genetic relationship 
matrix between individuals may be constructed using these causal variants and 
the fitted Linear Mixed Model (LMM). The method assumes that the phenotypic 
variability can be modelled using the formula: 
𝑣𝑎𝑟(𝑦) = 𝐺𝜎2*	 + 	𝐼𝜎2.	  
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Where G is the genetic relationship matrix between individuals estimated using 
all causal variants. Since the causal variants are not known, GCTA uses, in the 
estimation process of 𝐺, all available genotyped SNPs. The matrix 𝐺 is then 
multiplied by 𝜎2*	,indicating the variance explained by the genetic contributions. 
The residual variance not explained by the genetics is modelled through an 
identity matrix 𝐼 multiplied by the term 𝜎2.	, which indicates this residual 
variance. The complete methodology to estimate 𝜎2*	 and 𝜎2.	can be found 
elsewhere (69). Given this formulation, GCTA defines heritability as 
 
ℎ2 = 𝜎2*	/	(𝜎2*	 +	𝜎2.	) 
captures the proportion of the total phenotypic variance explained by genetic 
contributions.  
 
This framework was developed to estimate ℎ2 only for quantitative traits. In our 
case, however, we have a dichotomous phenotype, where 0 and 1 indicate 
respectively the absence or the presence of MacTel. Work by Lee at al (72) 
presented a simple extension which allows heritability for dichotomous 
phenotypes to be estimated on the liability scale. This scale is constructed by 
fitting a probit distribution which assumes that the underlying trait risk is indeed 
continuous and normally distributed but can be dichotomized and transformed 
into the final observed phenotype (being affected with MacTel) by using a 
threshold. A classic example of a trait with an underlying probit distribution is 
fever, the presence of which is the result of thresholding over the continuous and 
normally distributed measure of human body temperature. However, 
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transforming a dichotomous variable on a liability scale requires the assumption 
of disease prevalence defined as the proportion of disease cases in the general 
population. Disease prevalence cannot usually be estimated using the proportion 
of cases versus controls in a GWAS setting as this would result in an extreme 
overestimation. MacTel prevalence is also difficult to estimate due to its rarity. In 
our case, we used two MacTel prevalence estimates: a prevalence of 0.004% as 
estimated by Klein at al. study (7) and 0.1%, as estimated by the Aung et al. 
study(8). We then explored heritability estimates using these two estimates which 
were treated as lower and upper bounds to MacTel prevalence.   
 
2.2.2 Prediction of MacTel 
A common method to predict disease status from genetics data is to use logistic 
regression and estimate the probability for each subject to develop a disease given 
their genotype. However, SNP chip data contains millions of variables (SNPs) that 
cannot be included simultaneously in classic regression models (73). A natural 
approach to this problem has been developed by Zou and Hastie in 2005 (73) called 
the Elastic Net method. It is a mixture of two previously described penalised 
regression models, the Lasso and Ridge regression models. The Elastic Net model 
tries to fit the data using the formula: 
 




Where 𝑋 is a matrix containing all SNPs for all individuals and 𝛽5 is the vector of 
estimated regression coefficients. This vector is estimated by minimizing the 
following function:  
 
𝛽5 = 	𝑎𝑟𝑔𝑚𝑖𝑛𝛽(	|𝑦 − 𝑋𝛽	|
2	 + 	𝜆1	|	𝛽	| +	𝜆2	|	𝛽
2	|	) 
 
In this function, 𝜆1	is the Ridge regression parameter and 𝜆2	is the Lasso regression 
parameter. Ridge regression “shrinks” the model parameters towards zero in order 
to avoid overfitting. On its own, ridge regression would include all the available 
variables (SNPs) and would be unable to fit the large number of SNPs which are 
usually much higher than the number of samples. The Lasso parameter takes care 
of this problem by shrinking or collapsing to zero the 𝛽 parameters and thus 
selecting the “best” SNPs to predict a particular outcome. However, Lasso alone 
would fail to retain important variables that correlate with each other, as often 
happens in SNP chip data.  
 
In order to perform this analysis, we used the R package GLMNET developed by 
Friedman et al. in 2009 (74) which reformulates the previous formula into the 
following: 
𝛽5 = 	𝑎𝑟𝑔𝑚𝑖𝑛𝛽(	|𝑦 − 𝑋𝛽	|
2	 + 	𝜆	(	(1− 𝛼)	|	𝛽	|	) + 	𝛼	|	𝛽2	|	) 
 
𝜆	is now a general penalization parameter and 𝛼becomes the parameter which 
balances the weight between the ridge regression (𝛼 = 0) and the lasso regression 
(𝛼 = 1). We tried different combinations of 𝜆	and 𝛼 to predict MacTel status using 
the best combination of available SNP information. Parameter tuning was 
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performed by assessing prediction power using the Area Under the Curve value. 
To test that  overfitting was not occurring we split the discovery dataset into a 
training dataset (75% of observations) and a validation dataset (25% of 
observations) and assessed whether similar prediction power eventuated, even 
though parameter tuning was performed separately in both the training and the 
discovery set both. 
 
2.2.3 eQTL analysis 
The general framework of eQTL studies has been presented in Chapter 1. In eQTL 
settings, the association between a SNP of interest and the expression of a gene is 
usually tested through a linear regression 
 
𝑒𝑔@ = 𝑆𝑁𝑃𝑠	𝛽E𝑠𝑔 + 𝜖	 
𝑒*is the expression of gene 𝑔 and 𝛽FG*is the estimated additive effect of each copy 
of the minor allele of SNP 𝑠. A SNP is deemed to significantly affect the expression 
of a gene if the p-value related to the rejection of the null hypothesis 𝐻0	:	𝛽5G* = 0 
falls below a certain threshold (typically much lower than 0.05, to correct for the 
many tests that are performed in eQTL studies). However, both gene expression 
and SNP genotype calls are often affected by noise from different sources, such as 
for example SNP chips, population stratification, RNA sequencing platform, 
sample processing batches. To test which genes’ expression levels were affected by 
the SNPs identified as affecting MacTel risk, we mined the GTEx database (75) 
which take this technical noise into account by pre-processing both SNP genotypes 
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and gene expression matrices for each tissue. Additionally, GTEx tests the 
association between SNPs and genes by including several covariates into the 
regression model. The specific methodology used by GTEx database can be found 
elsewhere (51).  
 
In mining the GTEx database to find which genes were affected by the MacTel 
associated SNPs, we first selected all SNPs from the GWAS with association p-
value falling below the 1e-5 threshold (suggestive significance). To ensure we 
would find all the associations for each locus in the GTEx database we searched 
for all SNPs in high LD (𝑅2	 > 	0.8) with the selected SNPs that might be used as 
a proxy. To this end, we uploaded the list of rs identifiers of SNPs on the online 
SNAP tool (76). Using all the proxy SNPs as well as the original SNPs of interest 
we mined the GTEx v6.0 database to identify any significant cis-effects of these 
SNPs in all tissues available on the database (44 tissues). eQTL significance varied 
from tissue to tissue due to the differences in sample sizes. More information about 
tissues sample sizes as well as significance assessment in the GTEx database can 
be found elsewhere (51, 75). For ease of interpretability, GTEx eQTL effects sizes 
were flipped if the SNPs allele used by GTEx was the opposite of the MacTel risk 
allele. 
 
2.2.4 Metabolomics analysis 
We analysed two untargeted metabolomics datasets (generated by our 
collaborators Dr Marcus Fruttiger, UCL, and Dr Catherine Egan, Moorfields’ Eye 
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Hospital), one derived from blood serum, with the other from blood plasma. The 
specific methodology used to process the blood sample and measure the 
metabolomics abundances can be found later, in Chapter 4. . The serum-derived 
dataset contained 50 healthy individuals and 50 MacTel patients, with all subjects 
reported to be genetically unrelated to each other. Metabolic abundances for 1,281 
metabolites were measured for each individual by Metabolon Inc.. The 
missingness rate among cases and controls was calculated for each metabolite. 
Although Metabolon Inc. provided imputed and normalised metabolomics 
abundances, metabolites with an original missingness rate higher than 10% in 
either cases or controls were excluded. Since missing values are indicative of an 
extremely low concentration of a metabolite in a specific sample, metabolomics 
imputation was performed by imputing the minimum of the observed abundances 
across all samples for each metabolite. Metabolomics abundances were assessed 
for variation across samples to ensure no redundant metabolite was used for the 
analysis. To this end, metabolites with an extreme density concentration around 
the mode were discarded. To further limit multiple testing, we discarded all 
metabolites which a correlation coefficient with at least one other metabolite, 
greater than 0.95, since these were deemed to convey redundant biological 
information. Outlier subjects were identified by estimating the first two principal 
components with the remaining metabolite data and visually identifying outlier 
individuals on the principal components’ projection. Metabolomics abundances 
were further normalised across samples using quantile normalisation as defined 
by the package limma (77) in R. Since cases and controls were well balanced for 
different factors such as sex at birth, diabetes status, age, and ethnicity, 
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differential abundance analysis was performed with a univariate two sample t-
test assuming equal variances. Inflation of T-test p-values was controlled for using 
a ‘genomic inflation’-like procedure. In this particular publication, the  procedure 
involved the estimation of an inflation coefficient by regressing the observed p-
value distribution against a theoretical one by excluding the top most significant 
10% metabolites. Each p-value was then divided by the inflation coefficient. 
Glycine and serine were then assessed for significance. Significance despite 
multiple testing was further assessed by comparing the observed p-values of such 
metabolites against the inflation-controlled Quantile-Quantile (QQ) plot of the 
entire metabolomics data.  
 
2.3 Results 
2.3.1 MacTel Heritability 
2.3.1.1 MacTel Total heritability 
The estimated heritability using all directed genotyped SNPs after QC filtering 
(~1M) and assuming a disease prevalence of 0.1% was ℎ2 =0.742. Hence 74% of 
the MacTel phenotypic variability on the liability scale could be explained by the 
genetic influence of SNPs. Interestingly, when assuming a prevalence of 0.0045% 
the estimated heritability collapsed to ℎ2 =0.215, indicating that only 21% if the 
phenotypic variability could be explained by genetic contributions. Given the 
extreme differences between these two estimates, we empirically explored how 
MacTel estimated heritability changed according to prevalence rate. The result is 
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presented in Figure 21. This analysis clearly demonstrated how the heritability 
is affected if the population prevalence fell below the 0.02% first assumed. We 
additionally tried to estimate the total heritability by using all imputed SNPs 
(~6M). Interestingly, by assuming a prevalence of 0.1% the estimated total 
heritability was reduced to ℎ2 =0.412. 
 
 
Figure 21: Total narrow-sense heritability estimated by assuming different 




2.3.1.2 MacTel known, explained, and missing heritability 
To estimate the known heritability we used the 5 SNPs tagging the replicated loci 
that were identified by the GWAS analysis rs73171800, rs715, rs477992, 
rs9820286, and rs4948102 tagging loci 5q14.3, 2q34, 1p12, 3q21.3, and 7p11.2 
respectively. The known heritability explained by these loci assuming a prevalence 
of 0.1% was ℎMNOPN2 =0.039. Unsurprisingly, assuming a heritability of 0.0045% 
resulted in a drop of estimated known heritability to ℎMNOPN2 =0.011. These 
estimates were then used to calculate the proportion of heritability explained by 
known loci, by dividing ℎMNOPN2 by ℎ2. By using both disease prevalences we 
obtained an explained heritability of ℎ.QRSTUN.V2 = 0.053 translating to a missing 
heritability of ℎWUGGUN*2 = 0.947. This meant that only 5.3% of the total genetic 
heritability could be explained by the 5 replicated SNPs leaving unexplained or 
“missing” the other 94.7%. 
 
2.3.2 Predicting MacTel using SNP data 
A simple prediction tool constructed using logistic regression and trained on the 5 
replicated SNPs resulted in an Area Under the receiving operating Curve (AUC) 
of 0.71. The same model lost some prediction power on the replication dataset used 
to replicate such SNPs resulting in an AUC of 0.68. Although the prediction power 
of this model was relatively large compared to other prediction tools using genome-
wide significant SNPs on different polygenic diseases, we tried to improve the 
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prediction power by employing Elastic Net models. The replication dataset of 172 
cases and 1,134 controls only contained the 5 SNPs that needed to be replicated. 
Since the elastic net would select many more than these five SNPs, we divided the 
discovery dataset of 476 MacTel patients and 1733 controls further into a training 
dataset containing 75% of the original discovery data and a validation set 
containing the other 25% of the original dataset. For each combination of 𝛼 and 
𝜆	we assessed the prediction power as AUC on a 20-fold cross-validation of the 
training data. For each value of 𝛼 we selected only the topmost predictive values 
of 𝜆	. The AUC results from the different models on the training data are presented 
in Figure 22. 
 
 
Figure 22: Prediction power as described by AUC value of different elastic net 




The best performing prediction model, whilst keeping the minimum number of 
SNPs was a complete Lasso model (𝛼 = 1) with 𝜆	= 0.0325. This model used 174 
SNPs and reached an AUC of 0.723. When assessing the prediction performance 
of the same model on the whole training dataset the model reached an AUC of 
0.972. However, when assessed on the validation set the prediction power dropped 
to 0.677. The receiving operating curves under which these AUCs were calculated 
are shown in Figure 23. 
 
Figure 23: Prediction power comparison of selected lasso model between training 
and validation set. 
 
Lower data folding (5-folds and 10-folds) on the training dataset were additionally 
tried to prevent overfitting. However, none of these models resulted in better 
performance on the validation set. We additionally tried to train a similar model 
by also including all SNP-SNP interactions between the SNPs selected by this 
model as well as forcing the model to always select the 5 replicated SNPs to be 
among the chosen SNPs. However, these attempts also resulted in a very high 
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prediction power on the training set and extremely low power on the validation set 
(results not shown). 
 
2.3.3 Candidate genes identified from mining the GTEx eQTL database 
 
Thresholding the SNPs associated with the disease with a nominal p-value less 
than 1e-5 resulted in 597 SNPs tagging 24 different loci. The SNAP tool did not 
return any new SNPs in LD (R2>0.8) with the initial 597 SNPs. When mining the 
GTEx database v6.0 we identified 240 of these SNPs to have significant cis-eQTLs, 
with expression in at least one tissue for each gene. These 240 SNPs were tagging 
11 out of the 24 loci initially identified. A visual representation of the significant 





Figure 24: Significant eQTL results of the genome-wide significant and 




Among the 5 replicated SNPs of interest, we found MacTel risk SNPs in locus 1p12 
(chr1: 120208Kbp - 120281Kbp) to affect two genes: ZNF697 and PHGDH. 
Interestingly, the latter of these was affected in a positive direction in the Skin 
and in a negative direction in Testis. SNPs in locus 5q14.3 in chromosome 5, 
presenting with the biggest effect in the GWAS analysis, were found to 
significantly increase the expression of the gene TMEM161B-AS1 in 20 tissues. 
Locus 7p11.2 in chromosome 7 contained SNPs affecting transcription of CCT6A, 
GBAS, PSPH, NUPR1L and SUMF2 in different directions, depending on the 
gene. Lastly, two significant eQTL loci were identified for the loci 2q34, on 
chromosome 2, and 3q21.3 on chromosome 3. SNPs in the other six suggestive loci 
were found to affect the expression of the genes SH3YL1, ACP1, RP11-222K16.1, 
AC098973.2, LEPREL1, TTC39B, SLC31A1, NRBF2, REEP3, TRAV19, RP11-
49G10.3, and ACTL10.  
 
2.3.4 Metabolomics results  
The metabolomics sample comprised of 50 MacTel cases and 50 healthy controls 
was well matched for sex (25 males and 25 females in both groups), age (cases were 
on average 64 years old while controls were 63 years old on average), type 2 
diabetes status (12 diabetics patients and 38 non-diabetics in both groups), and 
ethnicity (47 Caucasian controls, 48 Caucasian cases). Of the initial 1,281 
metabolites, 403 were excluded due to high missingness in either control or case 
groups, 49 were excluded due to extremely high abundance density (or low 
dynamic range) over the mode, and 30 were excluded due to high correlation with 
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at least another metabolite. The remaining 799 metabolites were used to assess 
sample quality. A visual representation of all subjects with the first two principal 
components calculated from all remaining metabolites is presented in Figure 25. 
No outliers were identified.  
 
 
Figure 25: Samples position on the first two principal components projection of 





Differential abundance testing revealed glycine (p=3.5e-10, T= –6.98), and serine 
(p=4.8e-7, T= –5.39) to be the first and third most differentially abundant 
metabolites with both achieving multiple testing adjusted significance. The second 
most significant metabolite was threonine (p=1.6e-7, T= –5.64). By regressing the 
observed p-value distribution onto the theoretical quantile of a uniform 
distribution we calculate a p-value inflation factor of 1.73 for all tests (displayed 
by the red line in Figure 26). 
 
 
Figure 26: Quantile-quantile plot of the observed and expected p-value form 




By correcting the observed p-values for the inflation factor we obtain p=4.0e-6 for 
glycine, p=1.3e-4 for threonine, and p=2.5e-4 for serine. The deviation of these 
three metabolites from the genomic inflation corrected identity line highlighted 
how the significance of these three metabolites would be retained even after 
correcting for the multiple testing burden and correction for inflated -log10(p-
values). The same metabolites were also found to be significant, or borderline 
significant, if we corrected the inflation corrected p-values for multiple testing 
using the Benjamini-Hochberg procedure. We observed all three metabolites to be 
depleted in MacTel patients compared to controls with a log2FC of -0.54, -0.35 and 
-0.38 respectively for glycine, threonine and serine. The distribution comparison 
between cases and controls of the log2 normalized metabolomics abundances for 





Figure 27: Normalised log2 abundance of glycine, serine and threonine grouped 
by MacTel case and control status. 
 
2.4 Discussion 
2.4.1 MacTel appears to have a substantial genetic contribution to its 
phenotypic variability, driven by additive polygenic contributions 
 
The GWAS results identified MacTel as a polygenic rather than a monogenic 
Mendelian disease for the first time. The heritability analysis estimated the 
contribution of the genetic polygenicity that might be contained by common 
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genetic variants explain the largest portion disease risk variance. We found that 
MacTel heritability could not be estimated precisely, with our estimates ranging 
from 0.21 to 0.74. This large range was a result of the very different prevalence 
estimates used. However, as shown in the sensitivity analysis in Figure 21, most 
of the heritability estimates were contained between 0.6 and 0.7, indicating that, 
although the difference in heritability estimates was very large, the lowest 
appears to be more an extreme lower bound estimate. This large difference in 
heritability may arise from the fact that the liability scale is assumed to follow a 
normal distribution of disease risk (here modelled as prevalence). Such an 
extremely low prevalence would, in fact, sit on the tail of the normal distribution 
resulting in an extremely low heritability estimate. In general, MacTel heritability 
results show strong support for the hypothesis that MacTel can be largely 
explained by genetic influences.  
 
When including all the imputed SNPs surviving GWAS QC steps we observed a 
drop in the estimated heritability. This problem has been addressed by Chen et al 
(68) who noticed that the GCTA framework is not robust with the inclusion of non-
causal variants, stating in their simulation study that “the addition of non-causal 
SNPs seems to have partly swamped the LMM’s dissection of signal from noise”. 
We also recognised that this heritability estimate could be further increased by 
accounting for the fact that MacTel causal variants may have a MAF smaller than 
the retained SNPs, as discussed by Yang et al (69). However, the small sample 
size available precluded us from performing analyses that would allow the 
identification of low MAF variants associated with the disease. 
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The proportion of heritability explained by the five replicated loci represented only 
5% of the total heritability. This is consistent with previous work which indicates 
that most of the causal SNPs (or the genotyped SNPs in LD with the causal ones) 
fall below the genome-wide significance threshold and are often missed by GWA 
studies. It has been suggested that an infeasible amount of data would be required 
to discover all the causal SNPs for a polygenic trait such as MacTel disease, in 
order to fully account for the missing or unexplained heritability (68). 
      
We also recognised that in this thesis we have not addressed the problem of 
“phantom heritability” and “heritability estimated by all pseudo-significant SNPs” 
which tries to estimate the heritability with all the SNPs that achieve a p-value 
less than 0.05. These analyses were not performed since they were not deemed 
necessary for the Scerri at al publication. 
 
To conclude, we found that MacTel has a substantial genetic component that 
explains a large percentage of disease heterogeneity. However, the candidate loci 
individuated so far by the GWA study only account for a small fraction of this 
heterogeneity and more powerful GWAS are needed to identify additional loci for 




2.4.2 Prediction of MacTel disease based on SNP chip data is promising, 
but not yet clinically relevant 
With the heritability analysis revealing a strong genetic component affecting 
disease heterogeneity, we sought to assess the predictive power of using the 5 
replicated SNPs tagging the loci of interest. Using only these 5 SNPs, we were able 
to reach an AUC of 0.7 in both training and external validation set. When we tried 
to include more SNPs, using an Elastic Net method, this resulted in greater 
prediction power on the training dataset, but no improvement in the validation 
dataset. This highlighted a problem of overfitting of our model in the training data, 
most likely caused by the relatively small sample size of the discovery GWAS data, 
which was additionally reduced in order to separate training from the validation 
set. We acknowledge that there are advanced methodologies implemented in 
recent years to address this problem. However, the genetic risk prediction of 
MacTel was not the main goal of our study but rather more of an exploratory 
analysis, therefore we decided not to pursue any additional and more complex 
analyses.  
 
To conclude, we found that common genetic variants were able to estimate a 
reliable risk score for MacTel disease. However, as already highlighted by the 
heritability analysis, more studies with bigger sample sizes will be needed to 




2.4.3 eQTL analysis reveals effects on genes known to affect metabolite 
abundance and eye disease genes 
 
When mining the GTEx V6.0 database for candidate genes involved in MacTel we 
found loci 1p12 and 7p11.2 to respectively affect the expression of genes PHGDH 
and PSPH, which, as shown in Figure 21, are both ubiquitously linked to glycine 
and serine metabolic biosynthesis. Interestingly, we could not find any significant 
eQTL effect of the SNPs in locus 2q34 on gene CPS1 despite these SNPs being 
located on the 3’ UTR region of this gene. However, there are many ways in which 
SNPs may affect the functional properties of a gene apart from influencing its 
transcription. For example, SNPs often tag multiple nucleotide changes as they 
usually belong to long haplotypes. If many nucleotide changes are happening in a 
specific haplotype, the rate at which a gene is transcribed might remain invariant 
but the final 3D structure of its protein might be significantly different. Correct 
3D structure of proteins translates to the proper functioning of such proteins. 
Through this mechanism, SNPs might affect the biological functioning of a gene’s 
protein product via its structure, rather than the gene transcriptional magnitude. 
Hence, it might be speculated that the SNPs identified in locus 2q34 might be 
responsible for structural changes in the CPS enzyme, catalysed by CPS1, 
impairing its functioning and resulting in an alteration of the metabolic 
biosynthesis of glycine and serine. Lastly, we also found significant eQTL effects 
for the identified SNPs in locus 5q14.3 on gene TMEM161B-AS1 which is a gene 




Among the suggestive significant SNPs, we found some other genes of interest. 
SNPs in locus 3q28 were found to have eQTLs with LEPREL1. This gene, also 
known as P3H2, is a member of the prolyl 3-hydroxylase subfamily of 2-
oxoglutarate-dependent dioxygenases and has been observed to be associated with 
non-syndromic severe myopia with cataract and vitreoretinal degeneration. 
Another interesting gene found to have eQTL in locus 9p22.3 was TTC39B which 
has been observed to regulate HDL cholesterol metabolism. Lastly, gene SLC31A1 
which we observed to have an eQTL in locus 9q32 has been linked to Wilson's 
disease, a copper related pathology which often results in cellular damage of the 
eye.  
 
By mining the GTEx database, we were able to identify different genes whose 
expression might be modulated by the SNPs identified in our GWAS analysis. 
Interestingly, some of these genes were related to serine and glycine biosynthesis, 
whilst others were related ocular phenotypes. However, it is important to realise 
that the GTEx database V6.0 did not contain any eQTL data for retina and that a 
specific retinal tissue analysis to confirm such results would be required to 






2.4.4 Semi-targeted metabolomics analysis reveals disruption of glycine, 
serine and threonine metabolic pathway 
 
The emerging hypothesis from the GWAS results highlighted a possible 
metabolomic disturbance in the glycine and serine biological pathway in MacTel 
patients. By performing an exploratory analysis in the untargeted metabolomics 
data, we observed glycine, serine and threonine to be the top 3 most significant 
metabolites to distinguish between cases and controls. This result supported the 
emerging hypothesis of a metabolomics aberration - arising from genetic 
disturbances - on MacTel risk. Although the SNPs identified in the GWAS analysis 
only suggested glycine and serine as metabolites whose abundance might be 
affected in MacTel patients, we discovered that threonine was also similarly 
depleted. Moreover, we observed that glycine, serine and threonine were all part 
of the same biological pathway in mammals as displayed by the KEGG pathway 




Figure 28: KEGG pathway for “Glycine, Serine and Threonine Metabolism” 
visualising metabolic connections between glycine, serine and threonine. 
 
Given the translational relationship between glycine and threonine, as well as 
glycine and serine, this result suggests that depletion in threonine might be a 
consequence, or bystander effect, of the genetic perturbation of glycine and serine 
among MacTel patients identified by our study. 
 
This analysis only focused on the validation of the main metabolites of interest 
and did not examine the other metabolomics dysregulation that might have been 
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identified with an in-depth untargeted metabolomics analysis. Such an analysis is 




Our study was the first GWAS ever performed for MacTel. A schematic of the 
study findings is presented in Figure 29. This figure will be updated at the end of 
each research chapter to summarise the main findings and disease drivers 
highlighted by this thesis. The GWAS analysis resulted in five genetic loci, four 
previously linked to glycine and serine which were in fact observed to be depleted 
in MacTel patients through a metabolomics study. The analysis also revealed that 
MacTel is a highly heritable trait and also indicated that the identified SNPs had 
an elevated prediction power although not high enough to be of clinical usage. 
Among the identified SNPs we also confirm the presence of eQTL on genes 
implicated in glycine and serine biosynthesis as well as on other pathways whose 




Figure 29: Main findings schematics displaying the drivers and traits associated 
with MacTel. Genetic traits are displayed as green rounded squares. Metabolites 
are displayed as blue circles. Metabolic pathways are displayed as purple 
diamonds. Lastly, remaining phenotypic traits are displayed as red squares. 




3 Dissecting MacTel genetic signals to understand 




3.1 Introduction and study aims 
The results presented in chapter 2 clearly highlighted the need for a deep 
investigation of specific genetic components that might affect metabolic 
biosynthesis or retinal vasculature traits, and through these, impact the disease 
insurgence. Moreover, the advancement of bioinformatics tools and resources 
allowed us to explore more deeply this complex disease which the GWAS dataset 
only scratched the surface of.  
 
The following chapter will firstly introduce specific concepts related to MacTel 
heterogeneity arising from different sources like genetics, metabolomics and 
phenomics. It will then present a publication describing an in-depth analysis of 
MacTel genetic signatures and how we integrated that information with publicly 
available datasets as well as with phenomics retinal data acquired on MacTel 
patients to discover a possible causal mechanism for the disease aetiology and its 
progression as well as the prioritization of new genetic loci of interest. It will then 





3.1.1 MacTel is a complex disease 
 
Our initial GWAS study presented the first clue of a genomic and metabolomic 
component on MacTel disease. However, one of the findings of that research was 
that MacTel is likely to be a genetically complex disease. Specifically, we found 
that some loci seemed to be involved with the biosynthesis of glycine and serine 
while other loci seemed to be involved with retinal vascular calibre. However, our 
previous results on MacTel heritability highlighted that this complexity should be 
contained and MacTel variability can be mostly explainable by common variants. 
 
The same study also highlighted how MacTel patients presented with alterations 
in metabolic abundances of serine, glycine and threonine. However, other 
metabolites might be important for MacTel due to connections with glycine and 
serine pathway or because of different mechanism predisposing for the disease.  
Lastly, as presented in Chapter 1, MacTel is characterised by a multitude of 
clinical signs detectable through different imaging techniques. Although some of 
these are fundamental for MacTel diagnosis and form part of the core of the retinal 
phenotypes presented by each patient, some of these signs are unique and might 
differ from patient to patient.  
This finding encourages a deep investigation on how the heterogeneity observed 
in different ‘omics data might be connected with each other and how analyses 
120 
 




3.1.2 Missing data imputation concept 
Phenomics information on MacTel patients used in this study came from the 
Natural History Study and Registry of Macular Telangiectasia (NOHS) (10). This 
data contained longitudinal retinal phenotypic observations (colour fundus 
images, optical coherence tomography and fluorescein angiography images) that 
were collected over the period 2005-2015 from 1,716 patients (3,410 eyes in total). 
This very large dataset presented, like many other longitudinal datasets, a large 
amount of missing information. The missingness arose mainly to either 
imperfection of the retinal images or was related to changes in retinal photography 
machines. The problem of missing data and how to handle such missingness has 
been extensively explored in epidemiology (78) and a review of such a problem 
would be beyond the scope of this thesis. For this study, we decided to impute the 
missing data. Again, much research has been performed on the topic of missing 
data imputation (79) with most methodology trying to address missingness arising 
from different scenarios. Missingness has been described to arise from three 
different scenarios (79): 
1. Missingness completely at random: this missingness arises randomly and 
does not depend on anything related to the observations (e.g. machine 
randomly not working) 
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2. Missingness at random: this missingness can arise from any factor apart 
from the ones which are missing (e.g. machine working badly on children) 
3. Missingness not at random: this missingness arises depending on what 
value would have been measured (e.g. the machine cannot detect values 
smaller than a threshold) 
 
For our study, we assumed that missingness was “at random”, implying that the 
missing did not depend on the actual value of the missing entry. Modern 
imputation methods often rely on the observed relationship between the variable 
containing missing values and other variables. This relationship can be used in a 
prediction setting and imputation can be performed by predicting the missing data 
using all other available information. However, further complications arise when 
missing values are represented in multiple variables which might be used to 
impute each other. A well-known method to overcome such a complication is 
known as the Multivariate Imputation by Chained Equations (MICE) (80). This is 
a well-known method which was cited more than three-thousand times at the time 
of this thesis. 
 
3.1.3 Constructing endophenotypes using factorial analysis  
 
The NOHS contained a very large number of phenotypes that would have also 
posed a dimensionality problem. To reduce the number of variables, we 
hypothesise that some of the observed phenotypes are different observations of 
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common endophenotypes. The definition of endophenotype is not uniform across 
the literature (81). However, endophenotypes have  been defined as “measurable 
components unseen by the unaided eye along the pathway between disease and 
distal genotype” (82). Other definitions of endophenotypes comprise the notions 
that endophenotypes should be heritable, quantitative, associated with the 
disease, cosegregate in families where a disease is observed and may be related to 
causative mechanism  (81). These definitions support the idea that the MacTel 
clinical signs, here called phenotypes, may be  consequences of common 
endophenotypes. If a group of phenotypes is produced by the same endophenotype, 
it is assumed that these phenotypes are also correlated with each other. Based on 
these assumptions we decided to create these endophenotypes from the initial 
phenotypes using a technique called factorial analysis. Factorial analysis 
examines all the correlations between the phenotypes and, based on these, tries to 
discover and create endophenotypes by “melting” together the initial phenotypes. 
If correctly performed, this process is able to substantially reduce the dimension 
of a dataset by, at the same time, creating interpretable endophenotypes that 
“summarise” the observed phenotypes. 
 




3.2 Extract from Bonelli et al, Genetic Disruption of Serine 
Biosynthesis is a Key Driver of Macular Telangiectasia Type 2 
Aetiology and Progression  
 
 
Note: The following manuscript contains figures which are indexed 
differently from the rest of the thesis as this subchapter is presented in the 
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Macular telangiectasia type 2 (MacTel) is a rare heritable degenerative retinal disease, often 
comorbid with type 2 diabetes, that causes blindness and is largely untreatable. We previously 
found genetic loci associated with MacTel linked to retinal vasculature calibre and the glycine, 
serine and threonine metabolic pathway. 
We piece together causal genetic contributions to MacTel and its consistent retinal 
phenotypes, by integrating disease genetic markers with those of vascular and metabolic 
traits, and apply advanced statistical genetics techniques including Mendelian randomization, 
MTAG, conditional and interaction genome-wide association analysis, and genotype-
phenotype analyses.  
We identify serine to be a main causal driver of disease incidence and progression, with a 
lesser, but significant, causal contribution of type 2 diabetes genetic risk. We further show that 
glycine, threonine and retinal vascular traits are instead unlikely to be causal for this disease. 
Through conditional regression analysis, we resolve three novel disease loci independent of 
endogenous serine biosynthetic capacity. We lastly demonstrate how disease loci cluster into 
functional groups affecting retinal endophenotypes.  
Follow up studies after GWAS integrating publicly available data with deep phenotyping are 
still rare. Here we describe such analysis, where we integrate retinal imaging data with MacTel 
and other traits genomics data, performing an integrated analysis informing on the biochemical 
mechanisms likely causing this disorder. Our findings will aid in early diagnosis and accurate 
prognosis, as well as improving prospects for designing effective interventions and will serve 
as a useful template for such studies in other disorders post-GWAS. 
 







MacTel Disease and previous GWAS study 
 
Macular telangiectasia type 2 (MacTel; (J. Gass, 1977)), is a rare degenerative eye disease 
affecting the macula (Aung, Wickremasinghe, Makeyeva, Robman, & Guymer, 2010; Klein et 
al., 2010). MacTel is bilateral and progressively affects visual acuity (Charbel Issa et al., 
2013/5)(J. D. Gass & Blodi, 1993), reading ability (Finger et al., 2009), and vision-related 
quality of life (Clemons et al., 2008; Lamoureux et al., 2011). A successful phase II clinical trial 
has recently been reported for a retinal implant, showing efficacy in slowing disease 
progression (Chew et al., 2018). However, less invasive, non-surgical and less costly 
therapies are currently missing. Given the rarity of MacTel and its subtle clinical signs, often 
requiring several ophthalmological diagnostic tools, the disease has been largely 
under/misdiagnosed (Charbel Issa et al., 2013/5). Hence insights into the genetic basis of 
MacTel is key to identify future therapies and to develop predictive models for the disease, 
allowing better prognostication than currently possible. 
  
We previously published the first genome-wide association study on 476 MacTel patients and 
1733 controls (Scerri et al., 2017), identifying and replicating 5 loci. A single nucleotide 
polymorphism (SNP) at locus 5q14.3 (rs73171800) showed the strongest association with the 
disease (OR = 2.41) and was previously identified to be associated with the quantitative traits 
of retinal venular and arterial calibre (Ikram et al., 2010; Sim et al., 2013). The other four loci, 
1p12 (OR=1.70, rs477992), 2q34 (OR= 0.50, rs715), 7p11.2 (OR = 1.46, rs4948102), and 
3q21.3 (OR = 0.61, rs9820286) were implicated in glycine and serine metabolism (Shin et al., 
2014; Xie et al., 2013). Importantly, loci 3q21.3 and 7p11.2 did not reach genome-wide 
significance and the SNPs identified by Xie et al. at locus 3q21.3 were only in proximity, but 
not in linkage disequilibrium (LD) with those associated with MacTel. In the same study, with 
a metabolomics approach we further provided evidence that serum serine, glycine and 
threonine were depleted in MacTel patients compared to controls. These data provided the 
first insight into the genetic complexity underpinning MacTel and highlighted the potential 
involvement of metabolic and vascular trait disturbances in disease aetiology.  
 
Glycine and serine are essential amino acids involved in many fundamental biochemical 
reactions. Some of the most well known biochemical pathways relying on glycine and serine 
are the sphingolipids metabolism pathways (KEGG:map00600) and the glycerophospholipids 
metabolism pathway (KEGG:map00564). Pathogenic variants in genes involved in serine and 
glycine synthesis lead to severe childhood disorders like phosphoglycerate dehydrogenase 
deficiency (PHGDH, 601815) and glycine encephalopathy (GLDC, 605899). Both glycine and 
serine can be synthesized from one another as well as from other metabolic compounds such 
as sarcosine and hydroxypyruvate. Additionally, they can both be obtained through dietary 
intake. 
 
One pathway of interest is the sphingolipids pathway, where serine is required to synthesize 
sphingomyelin, an abundant lipid in photoreceptor outer segments. Serine deficiency is 
associated with accumulation of Deoxy Sphingolipids due to alanine being incorporated into 
palmitoyl-CoA instead of serine. Deoxy Sphingolipids are known to be toxic to different cell 
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types and in particular neurons (Alecu et al., 2017; Güntert et al., 2016; Penno et al., 2010; 
Wilson et al., 2018; Zitomer et al., 2009; Zuellig et al., 2014). MacTel patients exhibit elevated 
serum deoxy-sphingolipids concentrations (Gantner et al 2019), attributable to serine 
depletion as well as alanine overabundance in MacTel patient serum. Another metabolic 
pathway of interest is suggested by the previous observation of co-morbidity between Type II 
diabetes (T2D) and MacTel (Clemons et al., 2013) .  
 
It is still unknown whether traits such as metabolomics abundances, T2D, or retinal vascular 
calibres have a genuinely causative role on MacTel aetiology. Causation hypothesis is now 
routinely investigated using Mendelian Randomization (MR). MR exploits the usage of 
Instrumental Variables (IVs) and, in simple terms, assumes that if a disease is caused by a 
particular intermediate phenotype, and the latter is caused by genetic variants, then the same 
genetic variants should be also associated with the disease (Davey Smith & Hemani, 2014; 
Ebrahim & Davey Smith, 2008; Evans & Davey Smith, 2015). Genetic variants involved in 
retinal vascular calibre traits and T2D have been previously published (Ikram et al., 2010; 
Morris et al., 2012; Sim et al., 2013) while the largest metabolomics GWAS meta-analysis to 
date has recently been published (Lotta et al, in preparation) identifying almost 500 loci that 
predict the abundance of 142 serum metabolites in humans. The results from these studies 
can be used to investigate causal drivers of traits such as MacTel susceptibility with the MR 
approach. 
 
GWA studies on rare complex traits such as MacTel are inevitably underpowered due to the 
difficulty in recruiting a large number of samples (>500) necessary to interrogate ORs < 2. 
However, many well-powered GWAS have been performed and are now collated in resources 
such as the European Bioinformatics Institute GWAS catalogue and methods leveraging such 
resources to aid underpowered GWA studies have now been developed. An example is Multi-
Trait Association GWAS (MTAG) (Turley et al., 2018). MTAG exploits the genetic correlation 
between traits to prioritise of new loci by leveraging higher powered GWAS from correlated 
traits to the trait of interest. 
 
Additionally, MacTel patients show substantial heterogeneity of retinal phenotypes, including 
between pairs of eyes. This, and the lack of clear indicators of early MacTel stages, have 
frustrated clinical diagnosis. This heterogeneity is likely to be due, at least in part, to different 
genetic substrates. Apportioning genetic variation to separate retinal malformations has the 
potential to shed light on the different biological mechanisms via which each locus contributes 
to the disease. Performing joint genetic and retinal phenotypic data can thus investigate 
whether different retinal abnormalities are consequences of common or largely independent 
biological perturbations.  
 
In this study, we test for causality of several traits of interest on MacTel (Figure 1 A). We exploit 
independent studies on MacTel-related traits to increase discovery power in our disease 
cohort and both identify new disease loci and resolve already identified ones (Figure 1 B). 
Then, we use the retinal phenotypic data from MacTel patients to identify key genetic drivers 
of specific retinal phenotypes (Figure 1 C). Lastly, we collect genetic loci into functional groups 
by testing their combined effects on ocular phenotypes (Figure 1 D). This study represents the 
first integrated analysis of MacTel genotypic data with MacTel-related traits as well as retinal 






Figure1: Study conceptual map. Each panel represents a study aim and depicts the data and the analysis technique 
used. Data is presented as pastel color pieces with black writing while analysis techniques are presented as darker 
panels with white writing. MacTel genetics refers to individual level SNP data available from our previous GWAS 
study. MacTel GWAS refers to the MacTel GWAS summary statistics. Vasculature GWAS refers to the summary 
statistics data available from two previous retinal vasculature calibre genetic studies (Ikram et al., 2010; Sim et al., 
2013). Metabolomics GWAS refers summary statistics data available from a recently published metabolomics 
GWAS (Lotta et al). T2D GWAS refers to summary statistics data available from GWAS study on T2D (Morris et 




Unless otherwise stated all statistical and computational analyses were performed using the 
R statistical software, version 3.5.1. Corrected p-values less than 0.05 were considered 
statistically significant. For genome-wide association analyses uncorrected p-values< 5e-08 
were considered genome-wide significant. 
 
DNA samples and SNP genotyping 
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Genotypic data was available for 476 MacTel patients and 1733 controls. SNPs were 
genotyped using the Illumina 5.0M chip as described previously (Scerri et al., 2017). Retinal 
phenotypic data was available for 455 patients MacTel patients. Genetic predictors (betas or 
ORs, with corresponding SNP ID and relevant allele) of metabolites and retinal vasculature 
calibre were provided by the corresponding authors of each study (Lotta et al, (Ikram et al., 
2010; Sim et al., 2013)). 
 
Mendelian Randomization Procedures 
To perform mendelian randomization analysis with MacTel and metabolites, T2D and retinal 
vasculature we used the allele-score method for individual-level data as described by Burgess 
et al. 2016 (Burgess, Dudbridge, & Thompson, 2016). Specifically, we used the weighted 
score method and estimated Genetically Predicted Metabolites (GPMs) and Genetically 
Predicted Traits (GPTs), for T2D and retinal vasculature (Table S1). Using a p-value threshold 
of 5e-08 we extracted SNPs that were significantly associated with metabolites or traits (retinal 
venular calibre, retinal arteriolar calibre, and T2D). We constructed GPMs and GPTs using 
the magnitudes of the significant SNPs as weights in the manner of a Polygenic Risk Score 
(Supplementary Methods). We used logistic regression models to test for association between 
each GPM and GPT and MacTel susceptibility, correcting for genetically determined sex at 
birth and the first principal component, as in our previous publication (Scerri et al., 2017) to 
account for batch effects including population stratification. We used Benjamini-Hochberg 
multiple testing correction to account for the false discovery rate. A sequential conditional 
modelling approach was used to identify GPMs independently associated with the disease. 
Specifically, the most significant GPMs were iteratively added as covariates in the logistic 
regression model and re-tested, until no GPM was nominally significant after FDR correction.  
 
Conditional and Interaction GWAS and MTAG analysis 
The conditional GWA studies were performed by including GPMs or GPTs in the logistic 
models as covariates. For the interaction GWA studies, an interaction term was included 
between each SNP and the GPM or GPT of interest. Consistent with the original GWAS 
analysis on this data, each model also included genetically determined sex at birth and the 
first principal component (Scerri et al., 2017). Analyses were performed using Plink v1.9 
(Purcell et al., 2007). Results from the conditional and interaction GWAS were analysed using 
FUMA (Watanabe, Taskesen, van Bochoven, & Posthuma, 2017). LocusZoom plots were 
produced by using the LocusZoom software (Pruim et al., 2010). MTAG analysis (Turley et 
al., 2018) was performed by integrating the available summary statistics from the same study 
as those used to perform mendelian randomization for each trait of interest using the MTAG 
software.  
 
Retinal phenotype clustering 
As part of the Natural History Study and Registry of Macular Telangiectasia (Clemons et al., 
2010) longitudinal retinal phenotypic data (colour fundus images, optical coherence 
tomography and fluorescein angiography images) was collected over the years 2005-2015 
from 1,716 patients (3,410 eyes in total). The data consisted of 143 spatial measurements of 
retinal phenotypes. A list of all phenotypes and measurement methods is provided in Table 
S2. A detailed description of the corresponding methods can be found elsewhere (Clemons et 
al., 2010). Each phenotype was measured in 9 different subfields of the retina (defined by the 
ETDRS grid (Mathew et al., 2013) Figure S1). The phenotype data was cleaned by performing 
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missing data imputation (Supplementary Methods). The cleaned dataset contained 119 
phenotypes that were collapsed into 30 biologically relevant endophenotypes using factorial 
analysis as described in detail in Supplementary Methods. With this technique, we were able 
to distil the set of observed macular phenotypes into a much smaller set of endophenotypes 
encapsulating the key features of clinical diagnostics of MacTel Figure S6. An example 
endophenotype arose from leakage measured in multiple discrete retinal areas leading to a 
common ‘leakage’ endophenotype (Figure S6-B). 
 
Investigating the relationship of retinal endophenotypes with genetic 
drivers 
We tested for association between retinal endophenotypes with significant disease-associated 
GPMs, GPTs and prioritised SNPs. The dataset containing retinal endophenotypes and 
genetic information included 3,280 observations from 455 MacTel patients (907 eyes in total) 
with an average of 3.6 observations per eye over 10 years. Association testing was performed 
using a linear mixed model approach, assuming an additive effect of SNP alleles that 
increased MacTel risk. P-values were corrected using an adaptive Benjamini-Hochberg 






Results   
 
Discovering key drivers of MacTel disease: Metabolites 
The MR procedure (Figure 1A) applied to the metabolite panel highlighted 14 GP metabolites 
significantly associated with MacTel Table 1. A list of all metabolite associations is provided in 
Table S3. The two most highly significant metabolites were GP serine (OR = 0.52, p = 8.38e-
28) and GP glycine (OR = 0.56, p = 5.44e-19). Interestingly, in contrast to the metabolomics 
results from our previous study, GP threonine did not reach significance (OR = 0.98, p = 
0.996). Other significant metabolites were Phosphatidylcholine diacyl C32:1 (OR=1.23, 
p=0.0025), lysoPhosphatidylcholine acyl C14:0, Phosphatidylcholine diacyl C34:1 (OR=1.23, 
p=0.0025), Phosphatidylcholine with acyl-alkyl residue C38:1 (OR=1.23, p=0.0025), Arginine 
(OR=1.18, p=0.0283) and Phenylalanine (OR=0.84, p=0.0285). GP alanine was borderline 
significant (OR = 1.55, p = 0.069) 
 
 
The significant GPMs correlated with each other in our sample (Figure S2), mirroring 
correlations observed with directly measured metabolomics abundances. When all GPMs 
were re-tested in a model including GP serine as a covariate, GP glycine was the only 
associated metabolite (OR = 0.76, p = 2.2e-02) suggesting that the effect of GP glycine on 
MacTel is largely due to biochemical interactions with serine. GP serine remained significant 
when included alongside glycine (OR = 0.6, p = 3.3e-11). No other GP metabolites remained 








Metabolite Beta OR P-value Family 
Serine -0.651 0.521 8.38E-28 Amino Acids 
Glycine -0.576 0.562 5.44E-19 Amino Acids 
Phosphatidylcholine diacyl C32:1 0.208 1.231 0.0025 Glycerophospholipids 
lysoPhosphatidylcholine acyl C14:0 0.208 1.231 0.0025 Glycerophospholipids 
Phosphatidylcholine diacyl C34:1 0.208 1.231 0.0025 Glycerophospholipids 
Phosphatidylcholine with acyl-alkyl residue C38:1 0.202 1.224 0.0030 Glycerophospholipids 
Arginine 0.168 1.183 0.0283 Amino Acids 
Phenylalanine -0.166 0.847 0.0285 Amino Acids 
 
Table 1: Significant associations between genetically predicted metabolites (GPMs) and MacTel. Regression 
coefficients are presented in the “Beta” column. Odds Ratios (OR) are relative to a single standard deviation 
increase on the GPM scale. 
 
 
The GWAS used to predict the genetic complement of serine was largely underpowered 
compared to the glycine GWAS. Hence, we attempted to boost serine GWAS results by 
combining them with the glycine GWAS results in an MTAG analysis. By using the newly 
identified serine loci derived by its biochemically-based genetic correlation with glycine we 
constructed a new and more powerful genetic predictor of serine (GP MTAG serine, Table 
S1). We found GP MTAG serine sufficiently encompassing all the metabolic predictive signal 
for MacTel as the original GP glycine was no longer required in the model once GP MTAG 
serine was included (Figure 1A). Further MR testing of an even broader set of 248 GP 
metabolite abundances using results from Shin et al study (“metabolomics gwas server,” n.d.; 
Shin et al., 2014) (Table S1) found few significant contributions from other metabolites 
although none remained significant after inclusion of GP MTAG serine in the model (results of 
MTAG and MR from Shin et al metabolites available in Supplementary Materials and Table 
S4). 
 
Discovering key drivers of MacTel disease: T2D and retinal vasculature  
 
Genetically predicted T2D was significantly associated with the disease (OR = 1.96, p = 
0.0008). When tested separately, both GP arteriolar (OR = 1.38, p = 2.22e-10) and GP venular 
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calibre (OR = 1.19, p = 0.0007) were also significantly associated. However, we found that 
this result was driven by the association with two single SNPs: rs2194025 (used in predicting 
arteriolar calibre) and SNP rs17421627 (used in predicting venular calibre), both in strong LD 
with SNP rs73171800 at locus 5q14.3, identified in our original GWAS (OR = 2.41, p = 7.7e-
17 (Scerri et al., 2017)). When including both vascular traits in the same model, only arteriolar 
calibre remained significant, due to the reduced number of SNPs (N = 2) used to construct 
that GPT (Figure S3). When GPTs for retinal arteriolar calibre and type 2 diabetes were 
included in a model with GP glycine and serine, all remained significant.  
 
Additionally, we visually compared the effect sizes for each SNP used to define GPMs and 
GPTs on both MacTel and the metabolites or trait. Such comparison is displayed in Figure 2. 
As expected, a negative relationship could be detected between the effect on metabolic 
abundance and MacTel risk for the SNPs used to define glycine and serine. A positive effect 
was observed for T2D and vasculature traits, while no relationship was detected for threonine. 
We additionally observed that the regression line for all significant traits except from the 
vasculature related traits did not have intercept terms that were significantly different from 0 
(b0,serine= –0.07, p=0.2 ; b0,glycine=0.070, p=0.131 ; b0,T2D=0.002, p=0.88) suggesting a non-





Figure 2: Effect size comparisons between MacTel and specific trait of SNPs used to define GPM and GPT. In this 
plot, each dot represents a SNP. Traits are divided into panels and each panel contains the SNPs that were found 
to have a genome-wide significant effect on the specific metabolite or trait. The x-axis captures the effect sizes of 
the SNPs on the trait while the y-axis captures the effect of the same SNPs on MacTel risk. The blue line represents 
a simple regression line between the two. Metabolites or traits causally affecting the disease are expected to have 
correlated effect sizes. Colour of the dots represents chromosomal positions where different chromosomes are 





Using causal traits to discover new disease susceptibility loci for MacTel 
 
MTAG results 
To discover new loci putatively involved in MacTel, we performed MTAG analysis by including 
GWAS summary results for glycine, serine, retinal venular calibre, and retinal arteriolar calibre 
along-side MacTel disease status (Figure 1B). T2D was not included, as full genome-wide 
summary statistics from the Morris et al 2012 Nat Genetics study (Morris et al., 2012)were not 
available to us. The number of SNPs shared across all datasets was 799,436. This analysis 
confirmed the three previously identified loci (Scerri et al., 2017) and revealed 5 novel loci 
attaining genome-wide significance Table 2. A detailed table of results output by the FUMA 
software on these results is available In Table S5.  
 
 





P-val Art P-val Ven P-val Gly P-val Ser P-val 
MacTel 
    Sim et al 
2013 
Ikram et al 
2010 
Lotta et al 
2019 
Lotta et al 
2019 
Scerri et al 
2017 
rs3815630 2q34 7.62E-143 No 1.51E-01 6.23E-01 2.23E-308 6.50E-31 4.43E-08 
rs1035387 5q14.3 1.16E-16 No 1.50E-09 1.15E-08 5.43E-01 7.53E-01 1.16E-16 
rs477992 1p12 2.21E-15 No 7.44E-01 7.95E-04 6.09E-07 2.01E-80 2.60E-12 
rs4543497 7p11.2 2.22E-15 Yes 3.56E-01 2.07E-01 9.01E-28 3.29E-54 8.11E-06 
rs4841132 8p23.1 8.43E-14 Yes 5.55E-02 2.95E-02 1.73E-34 1.23E-04 4.54E-02 
rs1563075 16q23 1.79E-13 Yes 6.86E-01 3.77E-01 2.57E-28 1.19E-01 4.66E-03 
rs2954021 8q24.1 1.53E-12 Yes 3.89E-01 6.33E-01 2.35E-21 2.40E-10 8.70E-05 
rs4742212 9p24 1.19E-09 Yes 4.73E-01 6.88E-01 3.06E-34 1.69E-04 2.82E-01 
 
Table 2: Genome-wide significant loci for MacTel from MTAG analysis. MacTel GWAS results were combined with 
GWAS results from retinal venular (Ven) and arteriolar (Art) calibre, and serine (Ser) and glycine (Gly) abundance. 
Bold text indicates genome-wide significant P-values on respective original studies. Grey italicised p-values are 
associations expected to be null a priori. 
 
The three confirmed loci were locus 2q34 (rs3815630), 1p12 (rs477992) and 5q14.3 
(rs1035387). Among the new genome-wide significant loci is locus 7p11.2 (rs4543497, p = 
2.22e-15). In our original MacTel GWAS this locus did not reach genome wide significance (p 
= 8.11e-06) but was deemed important given its established relationship with glycine and 
serine. The other four novel loci from the MTAG analysis were: 8p23.1 (rs4841132, p = 8.43e-
134 
 
14), 16q23 (rs1563075, p = 1.79e-13), 8q24.1 (rs2954021, p = 1.53e-12), and 9p24 
(rs4742212, p = 1.19e-09). We did not observe any significant MTAG result for locus 3q21.3 
(rs9820286), originally proposed to affect MacTel though a connection with glycine and serine 
(Scerri et al., 2017). This SNP was in fact not genome-wide significant for either glycine (p = 





Conditional and Interaction GWAS 
To uncover genetic correlates of MacTel independent of glycine and serine, we performed a 
GWAS conditioning on these genetically predicted traits (Figure 1B). This analysis identified 
four genome-wide significant peaks (Figure S4 a). 
 
As expected, the original signal on locus 5q14.3 (rs73171800) remained significant, confirming 
the independence of this locus from genetic drivers of serine and glycine. A second genome-
wide significant signal on locus 3p24.1 (rs35356316, p = 3.10e-08) was also identified, which 
did not reach significance in our original study (p=1.54e-07). It is situated in a ‘gene desert’ 
proximal to the genes EOMES and SLC4A4. Another SNP in very close proximity reached 
genome-wide significance as in the original MacTel GWAS study (Scerri et al., 2017) but was 
believed to be a false positive, given the lack of LD with any other significant SNP (Figure S4 
b).  
 
The remaining two conditionally significant SNPs tagged independent signals in locus 19p13.2 
(Figure S4 c-d). SNP rs36259 is an exonic non-synonymous SNP located in the CERS4 gene 
which achieved close to genome-wide significance (p=6.270e-08) and was nominally 
significant in our original study (p = 1.69e-7). In close proximity, we found an independent 
intergenic SNP rs4804075 (p = 3.72e-07) for which we found no evidence for an eQTL effect 
on any neighbouring genes and which did not reach genome-wide significance. These results 
remain significant when conditioning on SNP rs73171800 (locus 5q14.3) and GP T2D (results 
not shown).  
 
We performed additional GWAS analyses testing for interactions between all SNPs with GP 
serine, GP glycine, GP T2D, and SNP rs73171800 (Figure 1B). However, no further significant 
interacting loci were found(Figure S5 a-d). 
 
Effect of key drivers on retinal endophenotypes 
 
Given the small sample size of the endophenotypic data (N = 455), we decided to only test for 
association between endophenotypes and GP glycine and serine, as these bore the clearest 
association with disease aetiology (Figure 1C). No significant association between GP glycine 
and endophenotypes were found when accounting for GP serine, and we therefore excluded 
it from additional testing. High GP serine levels were found to be protective against loss of 
retinal transparency (b = -0.54, p = 0.013), leakage at the retinal pigment epithelium (RPE) in 
progression areas (b = -0.43, p = 0.036) and suggestively in MacTel area (b = -0.28, p = 
0.055), and leakage at the outer capillary network in progression areas (b = -0.40, p = 0.046). 
We also found suggestive significance for protection from irregularities of the RPE leakage in 
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the MacTel area (b = -0.38, p = 0.060) and progression area (b = -0.26, p = 0.089). Higher GP 
serine levels were associated with protection from macular thinning in the MacTel area (b = -
0.44, p = 0.036), inferior inner area (b = -0.4, p = 0.036), and suggestive protection on nasal 
inner area (b = -0.32, p = 0.054), and foveal area (b = -0.42, p = 0.051). 
 
Together these results highlighted that not only GP serine was associated with the disease 
risk but was, more specifically, also associated with endophenotypes characterising disease 
progression.  
  
Determining the effects of GWAS loci on endophenotypes  
 
To determine the likely functional impacts of the original GWAS loci we tested them for 






Figure 3: Association plot summarising all nominally significant association between MacTel SNPs and 
endophenotypes. SNPs are divided into categories based on MR results. Each dot represents the corrected p-
value for each association between all SNPs and endophenotypes. Red dots indicate that MacTel risk alleles for 
that SNP also increase the risk of the retinal phenotype, while blue dots indicate a reduced risk. The top right corner 
displays the ETDRS grid for the right eye (OD) (Mathew et al., 2013) used to divide the endophenotypes into 9 
retinal areas; 1: foveal area, 2: superior inner area, 3: nasal inner area, 4: inferior inner area, 5: temporal inner 
area, 6: superior outer area, 7: nasal outer area, 8: inferior outer area, and 9: temporal outer area. The pink area 





Unsurprisingly, in this analysis no association remained significant after correction for multiple 
testing, highlighting the extremely modest effect sizes of single SNPs on disease 
endophenotypes.  
 
However, using the nominally uncorrected p-values (p* <0.05) in an explorative approach we 
observed that locus 1p12 (rs477992) was associated with an increased risk of irregularities of 
the RPE in the progression area (b = 0.12, p* = 0.003), but protected against risk of blunted 
vessels (b = -0.08, p* = 0.028).  
 
Locus 2q34 (rs715) increased the risk of macular thinning in the MacTel area (b = 0.16, p* = 
0.014) and nasal inner area (b = 0.12, p* = 0.032) and the risk of irregularities in the RPE layer 
in the MacTel area (b = 0.19, p* = 0.007).  
 
The MacTel risk allele at locus 7p11.2 (rs4948102) increased the risk of retinal transparency 
(b = 0.17, p = 0.0005), leakage at the RPE in both the MacTel area (b = 0.13, p* = 0.001) and 
progression area (b = 0.12, p* = 0.015), as well as presence of inner empty spaces and IS/OS 
break (b = 0.10, p* = 0.043). This locus however protected against leakage in the outer layer 
of the foveal area (b = -0.13, p* = 0.004).  
 
Together, the three loci thought to be underpinned by genetic variants acting on genes 
important in the glycine/serine metabolism (1p12/rs477992/PHGDH, 2q34/rs715/CPS1, and 
7p11.2/rs4948102/PSPH) shared an overall susceptibility increment to RPE endophenotypes 
and other macular phenotype risks. 
 
Interestingly the MacTel risk allele at locus 3q21.3 (rs9820286) was associated only with 
protection from retinal disease endophenotypes. Specifically, locus 3q21.3 was associated 
with protection against retinal holes (b = -0.08, p* = 0.021), retinal detachment (b = -0.12, p = 
0.030), irregularities at the RPE layer in the MacTel area (b = -0.23, p* = 0.005) and 
progression areas (b = -0.12, p* = 0.047); leakage at the RPE level in the MacTel area (b = -
0.12, p* = 0.031) and progression area (b = -0.17, p* = 0.019); and foveal slope flattening in 
MacTel area (b = -0.17, p* = 0.009), inferior inner area (b = -0.17, p* = 0.009), and nasal inner 
area (b = -0.19, p* = 0.006).  
 
Locus 5q14.3 (rs73171800) corresponded to protection against macular thinning in the foveal 
area (b = -0.19, p* = 0.005) and nasal-inferior outer areas (b = -0.14, p* = 0.030) and increased 
risk of foveal flattening in the nasal inner area (b = 0.15, p* = 0.011). The effect of SNP 
rs73171800 on macular thickness was consistent with recent findings (Gao, Huang, & Kim, 
2018). We did not find any nominally significant association between SNP rs35356316 located 
in locus 3p24.1 and the aggregated retinal endophenotypes.  
 
Additionally, we attempted to cluster the loci with hierarchical clustering performed on their 
regression coefficients (Figure S7). This analysis highlighted the unique endophenotype 
effect profiles of the 5q14.3 (rs73171800) and 3q21.3 (rs9820286) loci, and their 
distinctiveness in comparison to the other three loci, known to act on the serine/glycine 
pathway. 
 




This study exploited well-powered publicly available GWAS data from traits of interest as well 
as deep phenotyping data to further investigate the genetic aaetiology of MacTel, a moderately 
rare retinal disorder on which the first GWAS was only performed in 2017. These analyses 
have discovered causal genetic drivers for MacTel, delineating metabolic independent genetic 
contributors to the disease, and quantifying the contribution of each trait and locus to retinal 
degeneration.  
 
Mendelian randomization and publicly available data were used to “genetically predict” 
abundances of different metabolites. Even though all GPMs in this study were generated using 
estimated SNP allele dosage effects from blood-based metabolomic studies rather than retina, 
we believe that our results highlight that this is a highly relevant approach useful for other 
retinal disorders. 
 
We found genetically-predicted serine depletion as the strongest causal driver of MacTel risk, 
with an association magnitude much greater than any other single SNP. This pronounced 
effect reflects the power of combining multiple genetic variants associated with the disease 
through a shared biological mechanism; and further emphasizes the causative role of serine 
in this disease. The direction of association between GP serine and MacTel agrees with the 
one of direct serum serine measured in our previously published study. This act as compelling 
additional evidence for this causal association. Indeed, the disease odds of MacTel doubled 
for every standard unit decrease in GP serine and individuals in the lowest 20% of GP serine 
presented an OR of 6.34 for MacTel compared to individuals in the top 20%. Our study results 
also confirm the pronounced role that serine plays in disease progression apart from its 
aetiology. As this analysis was performed only among MacTel patients the heterogeneity of 
retinal phenotypes at early disease stages may be under-represented. GP serine was 
nevertheless able to partly discriminate between subjects with more advanced retinal 
abnormalities from those without. For example, lower GP serine had a clear association with 
retinal greying in all retinal areas, which is not observed in all MacTel patients (Charbel Issa 
et al., 2013/5). GP serine also affected retinal thinning in the temporal parafoveal area, a 
marker of photoreceptor degeneration. However, although our results suggest a highly 
plausible biochemical explanation for differences in disease heterogeneity and progression, 
we acknowledge that our study used only aggregated retinal phenotypes and proxy measures 
of progression. Longitudinal data documenting progression phenotype is now required to 
confirm these findings. High concentrations of deoxy-sphingolipids, a byproduct of serine 
deficiency, have recently been shown to cause MacTel (Gantner et al 2019). Our results 
provide evidence of causal genetically-encoded serine depletion, which likely contributes to 
the disease by promoting deoxy-sphingolipid biosynthesis. 
 
Our results indicate that the association between glycine and MacTel is likely an artefact of 
the shared genetic signal between this metabolite and serine. Glycine may have emerged as 
a highly associated metabolite instead of serine due to the considerably greater sample size 
used to construct the genetic predictor of the former. We failed to find any effect of glycine 
independent of serine in our phenotypic analyses. Given these results, it is possible that 
genetic depletion of glycine results in lower serine abundance as the latter can be 
biosynthesized by the former. This, in turn, could be causative for MacTel via heightened 




Threonine was the second most differentially abundant metabolite in MacTel patient 
serum(Scerri et al., 2017). However, GP threonine was not statistically associated with the 
disease, indicating that lower levels of threonine do not have a direct causative role on MacTel. 
Rather, as for glycine, this result may be due to biochemical interactions between threonine 
and serine as indicated by the multiple biochemical connections of these metabolites in 
glycine, serine and threonine metabolic pathway (KEGG:map00260). 
 
By using Multi-Trait Association GWAS (MTAG) we confirmed the central role of locus 7p11.2 
(rs4543497), which was previously found to be only nominally significant, and identified a new 
locus, 8q24.1 (rs2954021). The latter locus is of great interest since rs2954021 is predictive 
of endogenous serum serine concentrations (Lotta et al) and thus might confer MacTel risk by 
contributing to the same serine pathway as previously identified SNPs. We did not find any 
new signal arising from shared genetic correlation with retinal vascular calibre traits. 
 
Although not significant after correction for multiple testing, we observed a pronounced effect 
of SNP rs73171800 on macular thickness, specifically, a protective effect of C allele against 
macular thinning, which is tantamount to an increase in macular thickness. Interestingly, a 
large GWAS study, performed on 68,423 subjects in the UK Biobank database found that the 
G allele of SNP rs17421627 - corresponding to the C allele of SNP rs73171800 (LD with 
rs73171800 r2=0.67), was significantly associated with increased macular thickness(Gao et 
al., 2018). Further, a targeted study of SNP rs17421627, leveraged the deep conservation of 
this locus to demonstrate enhancer activity which modifies the retinal vasculature. Madelaine 
et al substituted the homologous zebrafish locus with a construct containing rs17421627, and 
showed enhancer activity and changed expression of a proximal microRNA, mir-9-2 
(homologous with human mir-9-5) (Madelaine et al., 2018). Both mir-9-2 knock-down and 
endogenous enhancer knock-out animals showed dysmorphic retinal vasculature, indicating 
that rs17421627 may act on miRNA expression to modify the formation of the retinal 
vasculature in humans(Gao et al., 2018) Although our MR analysis did not find a causal 
relationship between retinal vasculature calibre and MacTel, it may be that other features of 
the vasculature, for example, leakage, branching or integrity, are modified in rs17421627 
carriers, and account for the gross differences in macular thickness. Further deep phenotyping 
of the retinal vasculature in these individuals may yield the physiological basis for this 
phenotype and its impact on MacTel. 
 
By conditioning on GP serine, glycine and T2D we revealed genetic signals that are 
contributing to MacTel independent of these. Among these was a new genome-wide 
significant locus 3p24.1, tagged by SNP rs35356316. This SNP lies between the genes 
EOMES (604615) and SLC4A4 (603345). Interestingly, EOMES encodes a transcriptional 
activator which is shown in mouse studies to interact with the retinal transcription factor Pou4f2 
(Mao et al., 2008). The downstream gene SLC4A4 encodes a sodium-coupled bicarbonate 
transporter which is expressed in Müller glia and the RPE, and functions to balance pH in the 
subretinal space (Pushkin et al., 1999).  
 
Conditional analysis also revealed a glycine/serine/T2D independent MacTel signal at locus 
19p13.2. The SNP rs36259 which tags this locus is an exonic, non-synonymous SNP located 
within the gene CERS4 (615334). This gene encodes a dihydroceramide synthase, which 
operates in the sphingolipid biosynthesis pathway, downstream of SPTLC (Riebeling, 
Allegood, Wang, Merrill, & Futerman, 2003). Just as serine depletion is associated with 
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defective sphingolipid synthesis, this locus may reduce sphingolipid production and thus 
contribute to MacTel. 
 
Type 2 diabetics are over-represented among MacTel patients (Clemons et al., 2013) and we 
found a weak positive association between GP T2D and MacTel risk. A possible explanation 
for this is that T2D involves major perturbations of patient metabolism. Specifically, a recent 
meta-analysis of metabolite abundances associated with pre-diabetes and/or T2D, found that 
glycine depletion tends to occur in this disease (Guasch-Ferré et al., 2016). We show that 
glycine depletion is not likely to be causative for MacTel and is likely to be a consequence of 
metabolomics co-regularisation counterbalancing the genetically induced serine depletion. We 
thus speculate that diabetes may be a consequence rather than a cause of the metabolic 
phenotype underlying MacTel. Methods such as bi-directional MR address the question of 
directionality of effect when two traits are closely related. However, caution is advised when 
using these techniques with relatively weak prior genetic knowledge (Davey Smith & Hemani, 
2014). We recognise that although knowledge needed to perform such an experiment may be 
available for T2D, this is not the case in MacTel for which currently identified genetic signals 
have only modest explanatory power. Indeed, T2D risk remained significant even after 
controlling for GP serine and GP glycine, which indicates the possibility of a separate 
mechanism unrelated to glycine/serine metabolism.  
 
Our analysis revealed that locus 3q21.3, which was previously believed to act on the disease 
by modifying serum glycine and serine, is instead likely disconnected from these metabolites, 
as is the case for loci 3p24.1 and 5q14.3. Furthermore, these three loci do not cluster with 
each other, implying that additional potential disease mechanisms exist, beyond the already 
strongly implicated glycine/serine metabolic dysregulation. 
 
To conclude, by integrating different sources of genetic and phenotypic data related to macular 
telangiectasia type II with advanced statistical methods, we find evidence that genetically-
encoded serine depletion causes disease onset and likely also progression. The role of 
glycine, threonine and type 2 diabetes, as well as other vascular traits, is diminished in our 
results. We apportion genetic signals to different retinal phenotypes, and present evidence of 
independent contributions from genetic variants potentially related to vasculature, pH 
regulation and sphingolipid synthesis. We look forward to further targeted studies of disease 
progression and experimental validation of serine-independent contributions, to further resolve 
the complex aaetiology of this disease and enhance treatment efficacy. Our in-depth analysis 
of deep phenotyping available from our patient cohort, in addition to the usage of several 
recently made available GWAS datasets serve as a model as to how such resources can be 
used to dissect GWAS results, especially for rarer traits. 
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3.3 Discussion  
The work presented above highlighted how serine depletion is likely to be 
causative for disease and progression. The updated schematic of the study findings 
is presented in Figure 34. Using the framework of Mendelian Randomization we 
found that genetic influences known to affect serine abundance were associated 
with MacTel risk. Additionally, serine was highlighted as a potential driver of 
disease progression. Using the same strategy, we were also able to discard the 
hypothesis of a causal involvement of glycine/threonine depletion or retinal 
vasculature calibre on MacTel aetiology and prioritise a possible role of alanine 
abundance on disease risk. We also confirmed that MacTel heterogeneity is likely 
to be driven by several genetic influences, some of which are not related to serine 
abundance or more generally to metabolic traits. By exploiting modern post-
GWAS techniques we were able to additionally identify new risk loci for the 
disease, confirm the involvement previously identified loci and partition them into 
functional groups. Lastly, the work highlighted a possible inverse causal 
relationship between MacTel and its comorbidity trait type 2 diabetes and found 





Figure 30: Main findings schematics displaying the drivers and traits associated 
with MacTel. Genetic traits are displayed as green rounded squares. Metabolites 
are displayed as blue circles. Metabolic pathways are displayed as purple 
diamonds. The phenotypic traits are displayed as red squares. Associations are 
represented by dotted black lines. Causality is indicated by unidirectional solid 





4 Deep investigation of MacTel metabolic 
signatures through untargeted metabolomics 
 
4.1 Introduction and study aims 
The results presented in Chapters 2 and 3 provide substantive evidence of 
metabolic disturbances occurring in MacTel patients. Chapter 2 focused only on a 
few metabolites while Chapter 3 explored metabolic signature only through their 
genetic components. The evidence presented so far suggests that depletion of 
serine is likely to have a central role for MacTel occurrence, hence it is important 
to explore what other metabolic signatures might be present in patients affected 
by this retinal disease. The following chapter presents the first untargeted 
metabolomics study performed on MacTel disease. This was a deep investigation 
of serum metabolic features present in MacTel patients using statistical 
approaches to uncover potential disease biomarkers as well as elucidating 
metabolic mechanisms and pathways that could be targeted for therapeutic 





4.2 Extract from Bonelli et al, Systemic lipid dysregulation is a 
novel risk factor for macular neurodegenerative disease 
Note: The following manuscript contains figures which are indexed 
differently from the rest of the thesis as this subchapter is presented in 
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Background: Macular Telangiectasia type 2 (MacTel) is an uncommon bilateral retinal 
disease, in which glial cell and photoreceptor degeneration leads to central vision loss. The 
causative disease mechanism is largely unknown, and no treatment is currently available. A 
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previous study found variants in genes associated with glycine-serine metabolism (PSPH, 
PHGDH and CPS1) to be associated with MacTel, and showed low levels of glycine and serine 
in the serum of MacTel patients. 
Methods: We used a global metabolomics platform in a case-control study to 
comprehensively profile serum from 60 MacTel patients and 58 controls.  
Results: Analysis of the data, using innovative computational approaches, revealed a 
detailed, disease-associated metabolic profile with broad changes in multiple metabolic 
pathways. This included alterations in the levels of several metabolites that are directly or 
indirectly linked to glycine-serine metabolism, further validating our previous genetic findings. 
However, we also found changes unrelated to PSPH, PHGDH and CPS1 activity. Most 
pronounced, levels of several lipid groups were altered, with increased 
phosphatidylethanolamines being the most affected lipid group. Additionally, assessing 
correlations between different metabolites across our samples revealed putative functional 
connections. Correlations between phosphatidylethanolamines and sphingomyelin, and 
glycine-serine and sphingomyelin, observed in controls, were reduced in MacTel patients, 
suggesting metabolic re-wiring of sphingomyelin metabolism in MacTel patients.  
Conclusions: Our findings provide novel insights into metabolic changes associated with 









Macular telangiectasia type 2 (MacTel) is an uncommon, bilateral neurodegenerative retinal 
disease affecting between 0.004% and 0.1% of the population 1,2. It is characterized by 
alterations of the macular capillary network and neurosensory atrophy beginning temporal to 
the fovea, eventually affecting the so-called “MacTel area”; an oval area approximately 3mm 
across the temporal-nasal axis and 2mm across the superior-inferior axis centred on the fovea 
and of similar size in all patients 3. Symptoms typically start in the fifth and sixth decade of life, 
most commonly with reading difficulties and distortions 3–6. The pathogenic mechanism of this 
disease is still not fully understood, but post-mortem histopathological studies show 
abnormalities in the retinal pigment epithelium (RPE) throughout the retina 7 and a complete 
loss of Müller cells specifically in the MacTel area; which also contains some regions of 
photoreceptor loss 8. A recent phase 2 clinical trial with an ocular implant secreting ciliary 
neurotrophic factor showed promising results in delaying disease progression, but no evidence 
of recovery 9. No other therapeutic treatments are currently available.  
 
Several factors suggest that MacTel has a substantial genetic component. The disease occurs 
bilaterally and is heritable based on studies of monozygotic twins, siblings and families 3,10–13. 
We recently performed a Genome-Wide Association Analysis (GWAS) for MacTel, which 
identified five genetic loci associated with the disease 14; of which four are associated with 
glycine and serine abundance in serum 15–17. Furthermore, we observed lower glycine and 
serine levels in the serum of MacTel patients relative to controls 14. However, glycine and 
serine play a role in several different metabolic pathways, and thus the MacTel disease 
mechanism remains unclear; in particular, which factors contribute to the local retinal 
specificity of the disease in otherwise healthy individuals. The degree to which metabolites, 
other than glycine and serine, may contribute to MacTel also requires further investigation. 
 
To comprehensively characterise the metabolomic profile of MacTel patients, we analysed 
hundreds of serum metabolites using a global metabolomics platform. The vast data captured 
by this technology requires advanced data processing and statistical analysis 18,19. Here we 
employed state-of-the-art statistical methodologies 18,20,21, to characterise the impact of 
reduced glycine and serine in a broad metabolic context, and identify novel metabolic 
pathways associated with MacTel.  
 
 
Materials and Methods 
Study participants and serum collection 
All experiments were conducted according to the principles expressed in the Declaration of 
Helsinki. All participants gave informed consent and the study was approved by the Research 
Ethics Office Bromley, UK (study number 05/Q0504/101). Blood serum was collected from 60 
random patients from the MacTel Natural History and Observation Study (NHOS). Control 
samples were collected from 58 unrelated individuals who do not suffer from MacTel. We 
attempted to roughly match the control and MacTel patient cohorts for age, gender, diabetic 
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status and ethnicity. However, this match was not perfect (Table S1), and differences were 
corrected for in the downstream statistical analysis. 
 
The number of samples in our study was based on previous experience by Metabolon 
(Durham, USA) regarding effect size of serum metabolomic analysis on the analytical platform 
used. Samples were collected at different clinical sites (Moorfields Eye Hospital London, UK; 
Royal Victorian Eye and Ear Hospital and Ophthalmology, Melbourne, Australia; Scripps 
Health Facility, Scripps Clinic Torrey Pines, La Jolla, USA, and St. James’ Hospital, Leeds, 
UK) according to a standardised protocol. All individuals fasted overnight, and blood was taken 
before noon. Around 5ml of blood was collected in a clot activating vacutainer tube (Vacutainer 
Plastic SST II Advance Tube with Gold Hemogard Closure, Becton Dickinson), left at room 
temperature for 30min and then centrifuged for 5 min at 1200g. The supernatant was collected, 
frozen and stored at -80°C.  
Metabolite measurements 
Serum metabolites were measured by Metabolon (Durham, USA). Briefly, this involved initial 
protein precipitation with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 
2000) followed by centrifugation. The resulting extract was divided into five fractions: two for 
analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode 
electrospray ionization (ESI); one for analysis by RP/UPLC-MS/MS with negative ion mode 
ESI; and one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI. Raw data was 
extracted, peak-identified and QC processed using Metabolon’s hardware and software. 
Compounds were identified by comparison to library entries of purified standards and peaks 
were quantified using the area-under-the-curve technique, providing relative abundances of 
946 individual metabolites.  
Metabolomics Data Processing 
Missing values for some metabolites indicated levels below the detection limit of the Metabolon 
platform. For this reason, missing abundances were imputed with the minimum value for each 
metabolite following Metabolon’s standard imputation protocol. In subsequent analyses, we 
discovered how imputed minimum values for each metabolite were driving a substantial 
amount of variance captured by principal components (PCs). Because of this, we decided to 
discard 194 metabolites which had more than 20% of their total values missing from the 
analysis; using the previously proposed “80% rule” 22,23. Metabolomics missingness in controls 
correlated with missingness in patients, which ensured compatibility between patients and 
control (Fig. S2) and ensured that missingness would not confound the disease signal. The 
average missingness per subject was 13.3% with SD 1.5%. Boxplot outlier detection was 
performed on the distribution of missing values among subjects: this analysis did not detect 
any outlier subjects for missingness, and no particular subject was excluded for excessive 
amount of missingness. 
 
A total of 738 metabolites passed quality control steps and were further analysed. We used 
the R software package limma 24 for further normalisation of the data, not captured by the 
initial area-under-the-curve normalization. This software package was initially developed for 
gene expression analysis but has been cross-purposed for metabolite analyses 24–26. To 
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interrogate whether the heterogeneity in the remaining metabolites was driven by the diversity 
between subject demographics we visually inspected the first two principal components 
against all available covariates. Visual exploration of principal components plots ensured that 
no unwanted variation was observable after the scaling and normalisation step (Fig. S3). 
Lastly, we scaled each metabolite to have zero mean and unit standard deviation to ensure 
comparability for each specific metabolomic result.  
Statistical Analysis 
Differences in demographics between patients and controls were tested using Chi-squared 
tests (for dichotomous demographics) and t-tests with Welch correction for unequal variances 
(for continuous variables). We tested each metabolite against disease status using the limma 
package for the statistical software, R 27. This package has been widely used in gene 
expression study and is based on an empirical Bayes approach; whose properties for the 
analysis of both microarray data and RNAseq data have been described elsewhere 27,28. We 
corrected each p-value for false discovery rate by applying the Benjamini-Hochberg p-value 
correction procedure on the nominal uncorrected p-values using the R function p.adjust 29. All 
metabolites with a corrected p-value less than the false discovery rate cut off of 0.05 were 
considered as significant. Each model corrected for all available covariates which included sex 
at birth, age, diabetes status, ethnicity and BMI. A clustered heatmap of significant metabolites 
is presented in (Fig. S4). 
 
After defining the groups, we tested for enrichment by using a popular tool for gene enrichment 
pathway analysis - ROAST - available in the limma package. The properties and details of this 
tool have been discussed elsewhere 30. We corrected for false discovery rate by correcting 
each p-value using the Benjamini-Hochberg procedure. All groups with a corrected p-value of 
less than 0.05 were considered as significant. To account for groups in which metabolites 
were changed in opposite directions, we represented the abundance of grouped metabolites 
as a single value (the first principal component) and performed differential expression analysis 
using the same method applied to individual metabolites.  
 
To test for differential co-abundance, we firstly calculated the correlation between pairs of 
metabolites within patients and within controls. However, metabolomics correlation can be 
confounded by a set of external factors. To account for this, we firstly residualised all 
metabolomics profiles for each covariate jointly. This was achieved by regressing each 
metabolite on the set of covariates and MacTel status using a linear regression model and 
sequentially extracting the model residuals. This approach ensured that no correlation 
between metabolite was either created or masked by the covariates. After residualisation, we 
excluded from the analysis all those metabolites pairs for which the absolute value of their 
correlation was less than 0.5. We then tested for differential co-abundance between pairs of 
metabolites similarly to previous work 31 by using the Fisher R to Z transformation as defined 
in the Psych package 32. We corrected for false discovery rate by correcting each retained p-
value using Benjamini-Hochberg procedure. Given the very high number of correlation pairs 
tested and the reduced sample size, all pairs with a corrected p-value less than 0.1 were 
considered as significantly differentially co-abundant. Following the definition of previous work 
on gene expression by Jiang et al. 31 we explored the hypothesis that specific groups might 
present an abnormal amount of differential co-abundance. Accordingly, we discarded all 
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metabolites belonging to the xenobiotic super classification from this analysis. To test the 
hypothesis of groups enriched with differential co-abundance, we used a binomial test. The 
number of successes was the number of significant differential co-abundant pairs which 
contained a metabolite in that group. The number of tests was the total number of co-abundant 
pairs tested which contained a metabolite belonging to that group. Lastly, the probability 
parameter was defined as the ratio between all significantly differentially co-abundant pairs in 
the dataset - 161 - and all tested pairs 19.127 (p_parameter= 0.008). We corrected for false 
discovery rate by correcting each p-value using Benjamini-Hochberg procedure. All 




Metabolite levels  
We conducted an untargeted global metabolomic analysis (Metabolon, Inc.) of serum from 60 
extensively phenotyped MacTel patients and 58 healthy controls, measuring the relative levels 
of a total of 946 known metabolites, of which 738 survived quality control. The patient and 
control cohorts were roughly matched for demographics (Table S1), and statistical tests (see 
Materials and Methods) revealed no significant differences between them, regarding average 
age (p=0.06), gender (p=0.14), body mass index (BMI, p=0.34) and - since diabetes is a 
comorbidity of MacTel 33,34 - diabetic status (p=0.22). We were not able to completely match 
ethnicity status between cases and controls (p=0.009). Nevertheless, we used normalisation 
and multivariate regression strategies to correct for all available covariates (age, gender, 
diabetes status, ethnicity, BMI and collection site, as described in Materials and Methods). 
The fully normalised dataset (Table S2) was then analysed for differential abundance of 
individual metabolites in patients versus controls. This revealed 49 metabolites with 
significantly lower serum concentrations in MacTel patients compared to controls, and 72 with 
elevated serum concentrations (p<0.05, corrected for false discovery rate, FDR) (Fig. 1). 
 
Glycine and serine were the first and third most depleted metabolites in MacTel patients (log(2) 
fold changes (logFC) of -1.31 and -1.03, respectively). This agrees with our recent GWAS 14, 
which also showed reduced glycine/serine concentrations in MacTel patients, using a subset 
of the samples presented here. The second and fourth most changed metabolites were 
gamma-glutamylglycine and alpha-ketoglutarate (logFC of -1.08 and -0.98, respectively), both 
of which are linked to glycine-serine metabolism (see discussion). However, we also found 
many changed metabolites belonging to other metabolism groups (Fig. 1, Fig. 3). For 
instance, we found reduced levels of arginine (logFC=-0.76), ornithine (logFC=-0.59) and 
guanidinoacetate (logFC=-0.47), which - together with glycine - are needed for creatine 
biosynthesis (see discussion). Similarly, methionine (logFC=-0.58) and betaine (logFC=-0.53), 
which are linked to cysteine-methionine metabolism (see discussion), were reduced in MacTel 
patients. In contrast, the majority of measured lipids were increased. Furthermore, of the 121 
significantly changed metabolites, 88 were lipids (73%), whilst the total dataset of 738 





To fully assess whether the observed changes affected specific metabolic pathways, we 
divided all metabolites into 50 functional groups -largely reflecting pathways assigned by the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) database - and tested (described in 
Materials and Methods) whether any groups presented enrichment of differential abundance 
(Fig. 2, Table S3).  
 
The most differentially abundant metabolite group in MacTel patients was glycine-serine-
threonine metabolism (p=2.5E-5), with 7 of 11 measured metabolites depleted. The second 
most significantly different group was the phosphatidylethanolamines (p=8.8E-5), with 13 out 
of 14 metabolites upregulated in MacTel patients. Other differentially abundant groups 
included long chain fatty acids (increased, p=0.02) and diacylglycerols (increased, p=0.012), 
as well as changes in alanine-asparagine (reduced, p=0.012), methionine-cysteine (mixed, 
PC p=0.018) and benzoate metabolism (reduced p=0.002). We further detected several 
pronounced lipid group differences including increases in lysophosphatidylethanolamines 
(p=0.0054), diacylglycerols (p=0.012), monoacylglycerols (p=0.463) and long chain fatty acids 
(p=0.020) (Table S3). Although the majority of lipids were increased in MacTel patients, 
etherlipids with a choline headgroup were markedly reduced (p=0.020). A second group of 
lipids showing a reverse trend of general lipid increases in MacTel patients were the 
sphingomyelins (p=0.012), where 20 of the 21 measured species were reduced (7 of which 
were significant; Fig. 1).  
Correlations between metabolites  
Having established that the abundance of several metabolites was altered in MacTel patients 
we investigated how metabolites correlated with each other (co-abundance) across patients 
and controls. This technique can reveal molecular interactions that change in the context of 
disease 35 and can inform potentially dysregulated biochemical mechanisms 31,36,37. Differential 
correlation testing was limited to those metabolite pairs which were significantly correlated 
after correction for multiple comparisons in either patients or controls. Whereas most 
correlations between metabolites were similar across both groups (Fig. S1), three were 
significantly different in MacTel patients compared to the controls (Table S4). Orotate and 
orotidine were correlated in patients (r=0.73) but not controls (r=0.02; p=0.001); and the 
correlation between xanthine and orotidine was negative in controls (r=-0.43) but positive in 
patients (r=0.43; p=0.001). These metabolites all function within pyrimidine metabolism. 
However, closer inspection of these results revealed a potential xenobiotic confound, driven 
by four patients with elevated oxypurinol levels, likely due to Allopurinol drug exposure, which 
is known to disturb pyrimidine metabolism. 
 
We additionally tested for enrichment in differential co-abundance at the metabolite group 
(pathway) level. Tests of enrichment for differential co-expression were performed using a 
binomial framework 31. Of 45 metabolite groups, seven were enriched in differentially 
correlated metabolite groups in patients compared to controls (p<0.05; Fig. 4, Table S5). 
Among these, methionine-cysteine metabolism and the sphingomyelin group overlapped with 
our metabolite abundance results. The sphingomyelin group exhibited the most homogeneous 
pattern of differential co-abundance, characterised by a unique enrichment in disrupted 
connections. Specifically, differential correlation between sphingomyelins and the most 
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differentially abundant groups - phosphatidylethanolamines and glycine-serine-threonine 
pathway metabolites - were driving this result. Positive correlations between the 
sphingomyelins and serine-glycine pathway metabolites, observed in controls, were lost in 
MacTel patients; while negative correlations between sphingomyelins and the 
phosphatidylethanolamines, were reduced or lost in patients (Fig. 5). This striking result 
represents disruption of the normal metabolic links between serine, 
phosphatidylethanolamines and sphingomyelins in sphingolipid metabolism of MacTel 
patients. 
Discussion  
Data analysis tools 
Isolating relevant signals in metabolomics data requires state-of-the-art statistical methods. 
For this study we used limma software 27, the gold standard in gene expression analysis, to 
normalize for confounding factors, construct sample quality weights and perform multivariate 
modelling. Additionally, by using an empirical Bayesian framework that “borrows” information 
between metabolites, the software ensures maximal discovery power even for extremely 
variable metabolites 27,28. To extend our finding beyond simple biomarkers, we performed 
enrichment analysis using Roast 30 which takes into account metabolite abundances rather 
than summary statistics 28,30. In addition, we conducted semi-supervised principal components 
analysis to assess significance in groups containing metabolites with mixed correlations - 
which might have been missed by Roast - as well as exploring metabolic network changes 
through differential co-abundance analysis. Although the computational tools we employed 
here have so far not been commonly used for metabolomics data analysis, in this study we 
demonstrate that their deployment in the field of metabolomics can be extremely useful and 
powerful. 
 
Genetic variants in PSPH, PHGDH and CPS1 deeply impact 
metabolic profiles in MacTel patients 
Our previous GWAS 14 identified MacTel disease risk-associated single nucleotide 
polymorphisms (SNPs) within three genes, PSPH (encoding phosphoserine phosphatase), 
PHGDH (encoding phosphoglycerate dehydrogenase) and CPS1 (encoding carbamoyl-
phosphate synthase), which are all known to contribute to glycine-serine metabolism. PSPH 
and PHGDH catalyse consecutive steps in the serine biosynthesis pathway (Fig. 3), and 
mutations in PSPH are associated with reduced plasma serine levels 38. Similarly, SNP 
rs477992 reduces PHGDH transcription 39 and serine plasma levels 16,17. This matches well 
with the clear reductions in glycine and serine in MacTel patient serum we are presenting here. 
Furthermore, PHGDH is also known to convert alpha-ketoglutarate to 2-hydroxyglutarate 40,41. 
While the former was only marginally increased in patient serum (logFC=0.40), the latter was 
strongly depleted (logFC=-0.98), further supporting a likely PHGDH defect in MacTel patients. 
Serine depletion, caused by dysfunctional PSPH and PHGDH, increases conversion of glycine 




Another likely mechanism contributing to low glycine in MacTel patients is based on the activity 
of CPS1, which is connected to the urea cycle and creatine biosynthesis (Fig. 3). CPS1 
converts ammonia and bicarbonate into carbamoyl phosphate, which then feeds the urea 
cycle. The C allele of SNP rs715 (located in the 3’ UTR of CPS1; estimated MAF = 0.24) has 
been found in a previous independent study to be strongly associated with increased glycine 
serum levels 16. CPS1 is also implicated, via GWAS studies, in modulating creatine 16, arginine 
and ornithine levels 43. These effects are based on the role of CPS1 in creatine biosynthesis, 
which requires urea metabolites. In a key intermediary step, glycine and arginine are 
converted to guanidinoacetate and ornithine (Fig. 3), all four of which we found to be reduced 
in MacTel serum (logFC=-1.31, logFC=-0.76, logFC=-0.46 and logFC=-0.59, respectively). 
Reduced CPS1 activity slows the urea cycle and the linked guanidino-acetate production. This 
likely results in reduced glycine consumption and may explain the protective role of rs715(C) 
in MacTel 14.  
 
Mutations in CPS1 might also explain the depleted threonine levels (logFC=-0.96) in our 
MacTel patients (Fig. 2 and 3) since a previous GWAS has linked CPS1 with threonine plasma 
levels 43. However, the biochemical connections between CPS1 and threonine are not clear. 
Whilst most mammals can directly convert glycine to threonine, the enzyme responsible for 
this reaction (threonine aldolase) has lost function in humans 44, making threonine an essential 
amino acid. Alternatively, it is conceivable that microbiome influences may contribute to 
glycine-threonine conversion 45.  
 
In addition, several further metabolites linked to CPS1 via GWAS 43,46 were reduced in our 
MacTel samples (asparagine, logFC=-0.85; glutamine, logFC=-0.74 and betaine, logFC=-
0.53). Asparagine and glutamine have been linked to CPS1 by a GWAS 43, matching the 
correlations found in our study (glycine-asparagine, r=0.65 and glycine-glutamine, r=0.51, in 
controls). As glutamine is needed to create intracellular asparagine, which in turn is needed 
for serine uptake 47, depletion of these metabolites - as observed in our study - is likely to 
additionally contribute to the low serine availability observed in MacTel. However, the 
correlation between these metabolites was not changed in MacTel patients compared to 
controls (glycine-asparagine, r=0.63 and glycine-glutamine, r=0.56). Of interest, there was a 
trend towards reduced correlation between glycine and betaine (r=0.56 in controls, r=0.16 in 
MacTel patients), but this change did not attain statistical significance (p=0.22).   
 
In addition, we observed a trend towards changed correlations between serine and pyruvate, 
which rose from r=-0.16 in controls to r=0.39 in patients. Although the change did not reach 
statistical significance (p=0.13), it is interesting that these two metabolites are linked via serine 
dehydratase (SDS), which converts serine to pyruvate (Fig. 3). An increased correlation 
between serine and pyruvate possibly indicates a more pronounced usage of this pathway in 
MacTel patients, which would reduce serine levels. Of note, SDS can also degrade threonine 
to α-ketobutyrate and ammonia (Fig. 3), which might be reflected by the increased α-




Changes in metabolites related to cysteine/methionine 
metabolism imply oxidative stress and phospholipid species bias 
in MacTel 
GWAS has also linked CPS1 to the metabolites betaine, choline and homocysteine  46,48, which 
are all relevant for cysteine/methionine metabolism (Fig. 3). In MacTel patients, betaine and 
choline were both reduced (logFC=-0.53, logFC=-0.46, respectively), which might relate to the 
fact that methionine was also lower in MacTel patients (logFC=-0.58). The strong correlations 
we observed between methionine and asparagine (r=0.73 in controls, r=0.69 in MacTel 
patients) and between methionine and threonine (r=0.61 in controls, r=0.74 in MacTel patients) 
support the notion of a potential involvement of CPS1. However, the mechanism by which 
CPS1 could influence methionine levels is not known.   
 
Methionine is an essential amino acid and can be recycled from homocysteine via two different 
pathways. One depends on betaine (as mentioned above, low in MacTel patients), while the 
other requires 5,10-methylenetetrahydrofolate (CH2-THF in Fig. 3), which was not directly 
measured in our study, but is likely to be reduced given its close metabolic links to serine and 
glycine 49. Additionally, low choline and betaine observed in MacTel patients increases the 
reliance of the methionine cycle on one-carbon metabolism, adding a further demand on 
glycine. Furthermore, histidine - also used to add one carbon to tetrahydrofolate - was also 
reduced in MacTel patients (logFC=-0.55). Together, these findings suggest lower methionine 
cycle capacity in MacTel patients compared to controls.  
 
In this context it is interesting that MacTel patients exhibited increased concentrations of 
alpha-ketobutyrate (logFC=0.59) and 2-hydroxybutyrate (logFC=0.63), which may relate 
either to increased threonine degradation or to increased glutathione production (Fig. 3). 
Possible reasons for the latter are increased oxidative stress or detoxification in the liver 50. 
Increased glutathione synthesis consumes serine and glycine. Furthermore, it also limits the 
supply of cysteine, diverting homocysteine away from the transmethylation pathway towards 
glutathione synthesis, leading to a stressed transmethylation pathway.  
 
A key product of the methionine cycle is S-adenosylmethionine (SAM), required for 
transmethylation reactions. The conversion of phosphatidylethanolamine to 
phosphatidylcholine requires three SAM molecules and is, therefore, particularly affected by 
methionine cycle limitations. This strongly agrees with the aforementioned increase of 
phosphatidylethanolamines found in MacTel patients. Although phosphatidylcholine levels 
were nominally elevated (p=0.076), the phosphatidylethanolamine increase was much more 
pronounced (p=8.8e-05), apparent in nearly all measured phosphatidylethanolamine species 
(Fig. 3, Table S3). Interestingly, ether lipids with an ethanolamine head group were less 
severely reduced, mirroring the shift in the ethanolamine/choline ratio mentioned here. 
 
The lower abundance of methionine observed in MacTel patients may be connected to 
changes in both glutathione and phosphatidylcholine synthesis. As a relative lack of 
methionine may impair glutathione synthesis, this might expose MacTel patients to a higher 
oxidative stress load. Additionally, the methionine derivative SAM provides the methyl group 
substrates required to produce choline from ethanolamine. In fact, we found increased 
phosphatidylethanolamine in MacTel patients, suggesting an imbalance in the 
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phosphatidylethanolamine/phosphatidylcholine ratio. Further, substantial reduction in choline 
relative to ethanolamine etherphosphoilipids in patients is also consistent with methionine 
depletion. 
Lipid dysregulation is a novel disease risk factor for MacTel 
Several lipid groups were significantly changed in MacTel patients; with increased 
phosphatidylethanolamines, lysophosphatidylethanolamines and diacylglycerols, and 
decreased sphingomyelins (Table S3). These changes cannot be linked (directly or indirectly) 
to the activity of PSPH, PHGDH and CPS1, based on current understanding of human 
metabolic pathways. It is, therefore, plausible that the observed lipid dysregulation in MacTel 
patients represents a novel MacTel risk factor, in addition to the previously identified risk 
factors related to glycine-serine metabolism. The abnormal lipid levels in MacTel patients may 
be caused by as yet unidentified genetic risks, as well as by environmental or dietary 
influences.  
Sphingomyelins link dysregulated lipids and serine metabolism 
Differential co-abundance analysis identified sphingomyelins as an important metabolic group 
for MacTel. Not only were sphingomyelins depleted in MacTel, but metabolic connections - 
indicated by correlations of metabolites - between this group with the glycine-serine 
metabolism group, and the phosphatidylethanolamine group, were lost (Fig. 5). Although 
serine was depleted in MacTel patients, phosphatidylethanolamines and their fatty acid 
constituents were enriched. This striking change in correlation is particularly interesting in 
context of our recent finding that sphingolipid metabolism is an important component in MacTel 
51. Serine is an essential building block for the biosynthesis of sphinganine, which forms the 
backbone of all sphingolipids 52. We found that low serine in the serum of MacTel patients 
correlates with increased levels of deoxysphingolipids. These atypical sphingolipids are a risk 
factor for MacTel 51 and are known to have cytotoxic properties 52. How exactly they contribute 
to retinal pathology is not fully understood yet, but it is well established that dysregulation of 
sphingolipid metabolites can differentially regulate apoptosis and autophagy 53. In this context 
it is also interesting that ceramides were partially enriched in MacTel patients (2 out of 6 
measured). Ceramides can act as pro-apoptotic signalling molecules, and it has been shown 
that blocking ceramide biosynthesis prevents photoreceptor cell death in a mouse model of 
retinitis pigmentosa 54.  
 
MacTel metabolic dysregulation might affect type 2 diabetes risk 
Previous studies have observed a high prevalence of type 2 diabetes among MacTel patients 
34,55. However, the mechanism explaining this association is not understood. We therefore 
roughly matched for diabetic status in our MacTel and control cohorts (Table S1), and used a 
computational approach (described in Materials and Methods) to correct for any remaining 
imbalances. Despite this, our study identified an intriguing overlap between MacTel 
metabolites and previously described metabolic phenotypes associated with type 2 diabetes 
56–58. For instance, MacTel patients displayed increased fatty acids, diacylglycerols and 
phosphatidylethanolamines, as well as reduced etherlipids, glycine and glutamine, a similar 
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pattern to that observed in type 2 diabetes metabolomics studies, hinting at a potential 
mechanistic link between MacTel and diabetes. One possible such interaction might be 
mediated via the formation of deoxysphingolipids mentioned above, which apart from MacTel 
have also been linked to type 2 diabetes mellitus 59–61. 
Using serum metabolomics to study a complex eye disease  
MacTel is a genetically complex and moderately clinically heterogeneous disease involving 
focal degeneration of retinal glia and photoreceptors, and vascular damage of the central 
retina (macula). MacTel heterogeneity may arise from a complex mechanism impacting 
multiple biological pathways. Our previous study 14 provided initial evidence that the disease 
was associated with global alterations of metabolism, determined in part by complex genetic 
contributions. To explore this hypothesis, we comprehensively compared the metabolome of 
MacTel patients to that of healthy controls. Metabolomics is an emerging field and has been 
recognised as a powerful tool in ophthalmological research 62,63. In this study, we used serum 
samples, although MacTel is a retinal disease not characterised by any known systemic 
pathology. This may appear counterintuitive, as retinal metabolism is considered to be isolated 
from the peripheral blood circulation due to the blood-retinal barrier. However, MacTel is 
associated with systemic hyperglycaemia 34,55, and metabolomics profiles of blood samples 
have been used to study other retinal diseases, identifying changes as potential metabolic 
biomarkers or interrogating broad dysregulations 64–67. Furthermore, serum samples are more 
readily available than retina samples in people with the disease, and metabolomics platforms 
for analysis are readily and commercially available. Lastly, a recent metabolomics study 
performed on mouse models demonstrate that systemic serine and glycine changes mirroring 
MacTel metabolic dysregulation reflect deeply in mice retina [50]. 
 
It is important to keep in mind that, although our study has identified systemic risk factors for 
the disease, the metabolic changes in MacTel retina are so far unknown. It is also unknown 
by what route such changes might affect the retina. It is possible that the underlying genotypes 
that cause the systemic changes - for example due to altered liver metabolism – affect the 
retina indirectly via the circulation.  On the other hand, it is also possible that the genes that 
contribute to the systemic changes may have independent functions in the retina where they 
directly contribute to the disease.   
 
Conclusion 
In summary, in this study we have revealed putative functional relationships between multiple 
metabolite groups and MacTel disease using state-of-the-art analyses. Several of the changes 
we observed in this study confirm our previously identified genetic MacTel findings where we 
implicated PSPH, PHGDH and CPS1; however, many other changes are novel and represent 
novel risk factors for this disease. Our study provides not only a foundation for future genetic 
and experimental analyses of MacTel pathobiology, but also serves as a template for the use 
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Fig. 1: Visual representation of all 121 significantly differentially abundant metabolites, 
comparing MacTel patients against controls. Each row represents a metabolite. The x-axis 
represents the LogFC. Negative LogFC values indicate reduced metabolite levels in MacTel 
patients compared to controls, and positive LogFC values indicate increased levels in MacTel 
patients. The model results are presented as dots indicating the estimated logFC with 95% 
confidence interval bars. Metabolites are divided into coloured blocks by their metabolic group. 
Mtb=Metabolism 
 
Fig. 2: Changes in abundance of 738 metabolites across the 50 metabolic groups. Each row 
represents a metabolic group. Significantly enriched metabolic groups are labelled with * for 
p<0.05 (corrected for FDR). Each group row is composed of blocks representing metabolites 
contained in the group. The colour of each block represents the Log2 Fold-Change (logFC) of 
that metabolite comparing patients against controls. The colour blue represents depletion and 
magenta represents increased abundance. Mtb=Metabolism 
 
Fig. 3: Graphical overview of the key metabolic pathways that were affected in MacTel 
patients. Metabolites in blue were reduced in patients (p<0.05 in dark blue, 0.05<p<0.1 in light 
blue). Metabolites in red were increased in MacTel patients (p<0.05 in dark red, 0.05<p<0.1 
in light red). Grey indicates no change between patients and controls, and metabolites on a 
white background were not measured. Double borders around metabolites indicates multiple 
metabolites within a group. The gene names of enzymes mentioned in the text are in yellow 
ovals. Note the generally reduced metabolite levels in glycine-serine and adjacent metabolic 
pathways, and generally increased levels in glycerophospholipid metabolism. 
 
Fig. 4: Circos plot displaying 152 significantly differentially co-abundant metabolite pairs 
across 46 metabolic groups. Differential co-abundance between metabolic groups is 
represented by a line connecting the relevant groups. Thickness indicates the number of 
significant differential co-abundances. Correlations that were lost in patients are displayed in 
blue (positive correlation in controls and correlation lost in patients) and cyan (negative 
correlation in controls and correlation lost in patients). Newly formed connections in patients 
are presented in red (positive correlation in patients not observed in controls) and magenta 
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(negative correlation in patients not observed in controls). The transparency of the lines 
represents correlation magnitude (more transparency = lower magnitude). Note that 
connections involving the sphingomyelin group are most strongly suppressed in patients. 
Mtb=Metabolism 
 
Fig. 5: Hive plots comparing co-abundance between metabolites in the sphingomyelin (13), 
phosphatidylethanolamine (14) and glycine-serine metabolism (11) groups in controls and 
MacTel patients. Specific metabolites are represented by circles. Co-abundance correlation 
between metabolites is represented by a line. Line transparency represents the correlation 
magnitude. Red lines represent positive correlations while blue lines represent negative 
correlations. Note that the majority of connections evident in controls are lost or markedly 






















4.3 Discussion  
The work presented above confirmed the impact on the metabolome of MacTel 
patients due to the genetically induced depletion of glycine and serine that these 
patients harbour. The updated schematic of the study findings is presented in 
Figure 31. However, the analysis also revealed novel risk factors for the disease. 
Among these, we found that strong dysregulation of sphingolipids, as well as 
phosphatidylethanolamines over-abundance, are likely to be part of the disease 
risk. The study also found interesting overlaps between the metabolic biomarkers 





Figure 31: Main findings schematics displaying the drivers and traits associated 
with MacTel. Genetic traits are displayed as green rounded squares. Metabolites 
are displayed as blue circles. Metabolic pathways are displayed as purple 
diamonds. Phenotypic traits are displayed as red squares. Associations are 
represented by dotted black lines while associations changed by interaction are 
displayed by dashed red arrows. Causality is indicated by unidirectional solid 





5 Contribution to Gantner et al. Serine and Lipid 






This chapter describes an investigation into the role of serine depletion and 
subsequent deoxy-sphingolipids accumulation on MacTel disease which will be 
published by the New England Journal of Medicine this year (83). RB performed 
several statistical investigations for this research. This chapter will first introduce 
the rationale behind the study and introduce the main findings, which were 
obtained without RB’s contribution, followed by a rationale for the analyses 
directly performed by RB. Then, methods, results and discussion of analyses 
performed by RB and reported in Gantner et al, and related unpublished analyses 






5.1.1 Serine depletion might induce deoxy-sphingolipid accumulations 
 
In the previous chapters, we described how genetic influences affecting MacTel 
patients are likely to induce metabolic disturbances which in turn are likely to be 
a key contributor to MacTel aetiology. Amongst these observations, we found that 
MacTel is likely caused by serine depletion as well as alanine overabundance. As 
mentioned in Chapter 3, serine depletion might be compensated for by glycine. 
However, we have observed MacTel patients having genetic variants which 
prevent glycine from being biosynthesised correctly, hence impeding its conversion 
into serine.  
 
The biological mechanism through which serine depletion may cause MacTel is 
largely unknown, and is likely complex, given the central role that serine plays in 
several metabolic pathways. Serine is an essential amino acid for a specific 
pathway which is central for this chapter called the sphingolipid pathway. In fact, 
serine is central for the biosynthesis of all sphingolipids requiring a sphinganine 
base. To synthesise sphinganine (SA), the enzyme palmitoyltransferase (SPT) 
needs to condense serine with palmitoyl-CoA (84). However, when serine is 
depleted, the SPT enzyme may condense palmitoyl-CoA with alanine (85). The SA 
created by this process lacks the hydroxyl group that differentiates serine from 
alanine. This alternative compound, deoxy-sphinganine (doxSA) generates 
subsequent deoxy-sphingolipids (doxSL). A schematic from Gantner et al (83) 





Figure 32: Schematic from Gantner et al depicting different sphinganines 
resulting from the reaction of palmitoyl-CoA with serine or alanine (83). 
 
DoxSL have been previously associated with different medical conditions such as 
several metabolic syndromes, type 2 diabetes, liver syndromes and other serine 
deficiency disorders (83). DoxSL lipids have also been observed to have toxic effects 
on different cell types, specifically neurons, including retinal photoreceptors. 
 
 
5.1.2 Hereditary Sensory Neuropathy Type 1 
SPT is a trimer formed from the products of three genes; SPTLC1, SPTLC2, and 
SPTLC3 (86). Rare coding mutations in the first two of these genes have been 
reported in patients suffering from a peripheral neuropathy disease called 
Hereditary sensory neuropathy type 1 (HSAN1) (84). Specifically, these mutations 
have been described to modify the structure of the SPT enzyme, increasing its 
affinity for alanine. This aberration in affinity results in an accumulation of 
doxSL, even when the abundance of metabolic serine is within the normal 
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physiological range. An extract from Gantner et al showing this mechanism is 
presented in Figure 33. 
 
 
Figure 33: Schematic of conditions leading to elevated doxSA levels. The top 
scenario displays SPT condensing palmitoyl-CoA with alanine because of rare 
mutations affecting enzyme specificity. The bottom scenario displays SPT 
condensing palmitoyl-CoA with alanine because of lack of available serine. Both 
scenarios result in deoxy-sphinganine production (83). 
 
 
A very early onset MacTel patient was observed, and whole exome sequencing 
revealed a mutation in SPTLC1. The same subject was also discovered to be 
affected by HSAN1 disease. This extraordinary finding together with the 
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functional similarity between the SPTLC1 mutation and serine depletion provided 
the first insight into the metabolic basis of MacTel from a Mendelian disease 
perspective. Researchers from the MacTel consortium set out to investigate 
MacTel comorbidity among patients suffering from HSAN1.  
  
5.1.3 HSAN1 patients carrying specific mutations are affected by MacTel 
disease 
 
The authors of Gantner et al investigated mutations shared among first-degree 
relatives of the early-onset patient and found the father and a sibling of the 
original proband to be affected or “possibly affected” by MacTel disease, while the 
mother and another sibling were unaffected. All MacTel affected individuals were 
also affected by HSAN1 (initially misdiagnosed as Charcot-Marie-Tooth disease, 
another more common and similar neuropathy, with many known genes). WES 
analysis, performed by our MacTel collaborator Dr Rando Allikmets, Columbia 
University, New York, revealed all affected subjects to carry the p.Cys133Tyr 





Figure 34: Extract from Gantner et al showing affected HASN1 individuals (grey) 
and affected MacTel (black) with their respective mutation in the SPTLC1 gene 
(83).  
 
This mutation is specifically associated with HSAN1 subtype A. Due to this 
finding, 11 other individuals, also affected by HSAN1 from different families with 
no known relationship with the aforementioned patients were examined for 
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MacTel. Among these, 8 were affected, bringing the total to 11 out of 14 HSAN1 
patients comorbid with MacTel. The enrichment of MacTel prevalence among this 
HSAN1 cohort was extremely significant, due to the known low MacTel prevalence 
(p<2.2e-16). Strikingly, of the three patients affected by HSAN1 disease but not 
MacTel, two presented with the known pathogenic p.Cys133Trp mutation in 
SPTLC1, while the remaining patient also had the p.Cys133Tyr mutation, but was 
young compared with the average age of MacTel onset, suggesting incomplete 
penetrance. Additionally, two of the patients affected by both MacTel and HSAN1 
presented with the p.Ser384Phe mutation in SPTLC2. 
 
5.1.4 Induced plasma serine depletion increases doxSL abundance in the 
mouse retina and causes nervous dysfunction 
The relationship between circulating serine and levels of doxSL in the retina is 
unknown. To investigate whether the depletion of serum serine affects retinal 
levels of doxSL, our colleagues investigated retinal serine concentrations in mice 
fed a low glycine and serine diet. These mice had lower levels of circulating serine 
which was also associated with excessive circulating doxSA; the same was 
mirrored in the retina. Functional testing revealed that mice on the low glycine 
and serine diet developed retinal and sensory deficit after 10 months, mirroring 






5.1.5 Study aims: Exploring doxSA levels on MacTel patients as well as 
their relationship with other metabolites and disease progression 
 
The aforementioned findings showed that lower serine, as well as rare mutations 
in genes encoding the SPT enzyme, produce greater doxSL levels, which in turn 
are likely to contribute to neurodegeneration in the retina, characteristic of 
MacTel. However, no direct study of the levels of doxSL in MacTel patients has 
ever been performed. Measuring doxSL levels on individuals suffering from 
MacTel as well as in healthy controls allows exploration of several hypotheses.  
 
A. If serine depletion is associated with a higher abundance of doxSA, then 
MacTel patients should present with elevated doxSA compared to controls.  
B. Among both MacTel patients and controls, the levels of circulating doxSA 
should correlate negatively with serine, and positively with alanine 
concentrations. 
C. As we might expect doxSA accumulation to disrupt the function and turn-
over of downstream lipid species, there might be differences in SA levels 
between MacTel patients and controls. 
D.  T2D is known comorbidity with MacTel and doxSA levels have been 
previously associated with type 2 diabetes. We may then expect that 
patients suffering from both MacTel and T2D might present different levels 
of doxSA from patients suffering from any of the two diseases alone. 
E. If doxSA is important for the onset of MacTel, levels of this metabolite might 
also contribute to disease progression. 
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F. Identifying additional associations with other metabolites with doxSA 
levels untargeted metabolomics fashion might shed light on the more 
complex metabolic disturbances observed in previous chapters. 
 
All the aforementioned hypotheses, excluding the last, were explored and 
published in Gantner et al, and all are further described in the following sections. 
 
5.2 Methods 
5.2.1 Analysis of deoxy-sphingolipids in MacTel  
To test the aforementioned hypotheses we conducted a new, targeted 
metabolomics analysis. The targeted metabolites in this new study were, doxSA, 
SA, serine, alanine and 11 additional amino acids quantified in 125 unrelated 
MacTel patients and 95 unrelated controls by the Christian Metallo group at the 
University of California, San Diego (as detailed in Gantner et al). DoxSA and SA 
were measured in separate batches from the other metabolites. All subjects were 
confirmed not to have HSAN1 through WES sequencing. For all subjects, we 
collect information including sex at birth, ethnicity, age and T2D status. 
Geographical origin of the samples, as well as metabolomics analysis batch, were 
recorded to account for potential systematic variation in the data. Patients were 
assessed for Ellipsoid Zone loss (EZ loss) area which, as mentioned in Chapter 1, 
is a result of the loss of the mitochondria-rich photoreceptor inner segments and 
is a symptom of MacTel progression. To correct the skewed distribution of the 
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measured metabolomic abundances we applied a log2 transformation. Similarly, 
we applied a square root transformation to the skewed distribution of EZ loss area, 
obtaining a proxy for EZ loss radius from the centre.  
 
To test for association between metabolomics levels with MacTel disease, EZ loss 
and T2D, as well the association between metabolites we adopted a linear mixed 
model regression strategy of the form  
𝑀U = 𝛽𝑥U + 𝛼𝐶U + 𝛾U\	 + 𝑒U 
 
Where 𝑀]is the log2 abundance of metabolite 𝑀 for a subject 𝑖 measured in batch 
𝑗, 𝛽 is the fixed effect of the factor of interest 𝑥U, 𝛼 the vector of fixed effects of 
covariates measured in the vector 𝐶U, and 𝛾U\is the random effect capturing the 
influence of batch used to measure on the abundance of metabolite 𝑀 in subject 𝑖, 
𝑒U is the error term assumed to be normally distributed and centred around zero.  
 
This method enabled us to test for association between different factors while at 
the same time taking into account all collected covariates as well as the batches 
used to perform metabolomics measurements. Given the imbalance between cases 
and controls among batches, we included batch information as a random effect 
rather than a fixed effect. 
 
The hypothesis that DoxSA increment is a result of the co-presence of MacTel and 
T2D was tested by including an interaction term between MacTel status and T2D 




𝑑𝑜𝑥𝑆𝐴U = 𝛽0	 + 𝛽1𝑀𝑇U 	+	𝛽2𝑇2𝐷U 	+	𝛽3𝑀𝑇U ∗ 𝑇2𝐷U 	+ 𝛼𝐶U + 𝛾VOQGT(U)	 + 𝑒U 
 
Where 𝑑𝑜𝑥𝑆𝐴U is the doxSA abundance for subject 𝑖 measured in batch 𝛾VOQGT(U), 
𝛽1is the fixed effect of MacTel status for subject 𝑖measured through 𝑀𝑇U, 𝛽2is the 
fixed effect of T2D status for subject 𝑖measured through 𝑇2𝐷U, 𝛽3is the fixed effect 
of the interaction between MacTel and T2D status, 𝛽𝑥𝑖is the contribution of 
additional covariates and 𝛾VOQGT(U)	is the random effect capturing the influence of 
the batch used to measure abundances of 𝑑𝑜𝑥𝑆𝐴 in subject.  
 
When testing for association between different metabolites, the batch of the 
metabolite was included as a dependent variable as a random effect while the 
estimated batch effect for the metabolite was included indirectly by adjusting the 
other metabolite for batch effect and including this residual instead of the original 
metabolite in a mixed model: 
 
	𝑀1U = 𝛼𝐶𝑖 	+ 𝛿𝑀2𝑟𝑖 	+ 𝛾𝑚1𝑖		 + 𝑒𝑖 
 
where 𝑀1U is the abundance of metabolite M1 measured using batch 𝑚1,and 𝛿is 
the effect of the residualised abundance 𝑀2gU of metabolite M2 obtained by 
subtracting its own batch effect estimated prior to the model using the formula 
 




where 𝑀2U is the abundance of metabolite 2 and 𝛾𝑚2	𝑖i  is the best unbiased linear 
estimation of the random effect the effect of batch 𝑚2 used to measure metabolite 
𝑀2U estimated through the following mixed model 
 





Average and maximum EZ loss was calculated for all individuals, averaged across 
both eyes where binocular data was available. P-values were calculated using the 
Satterthwaite degrees of freedom as implemented by the R package LmerTest (87, 88). 
 
5.2.2 Exploring untargeted metabolomic associations with deoxy-
sphingolipids 
Untargeted metabolomics association with doxSA levels were tested by combining 
the targeted metabolomics datasets used in this study with the cleaned untargeted 
metabolomics dataset presented in Chapter 4. Unfortunately, not all subjects from 
the targeted metabolomics study (125 cases and 95 controls) were also included in 
the initial untargeted metabolomics cohort (60 cases vs 58 controls). The combined 
dataset contained 739 metabolites measured for 93 subjects (55 cases and 38 
healthy controls). The estimated batch effect on doxSA levels was extracted a 
priori from the original doxSA levels as described above and the association was 
tested using linear regression models, correcting for multiple covariates including 
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disease status, which may have a confounding effect on the association between 
metabolites. To this end, we used the model  
 
𝑑𝑜𝑥𝑆𝐴gU = 𝛼𝐶U 	+ 𝛿 𝑀Uk 	+ 𝑒U 
 
where 𝑑𝑜𝑥𝑆𝐴gU is the batch-residualised abundance of 𝑑𝑜𝑥𝑆𝐴, 𝛿 is the effect of the 
abundance of metabolite 𝑀Ukmeasured in the data presented in Chapter 2 and 
Chapter 4 and cleaned with the same process presented in Chapter 4. 
 
To test for independence of effects between different metabolites on doxSA levels 
we adopted a stepwise conditional modelling approach, whereby the most 
significantly associated metabolite was included in the model and the remainder 
were tested for associations. This process was iterated until no significant 
metabolites remained. Differences in the association between metabolites, given 
disease status, were tested using an interaction term between the metabolite of 
interest and the disease status using the following model  
 
𝑑𝑜𝑥𝑆𝐴gU = 𝛼𝐶U 	+ 𝛿1𝑀Uk 	+ 𝛿2𝑀𝑇U 	+ 𝛿3𝑀𝑇U ∗ 𝑀U + 𝑒U 
 
where 𝛿2 is the effect of MacTel status 𝑀𝑇U and 𝛿3 is the interaction between 
MacTel status 𝑀𝑇U and abundance of metabolite 𝑀U.  
 
To explore whether metabolites were interacting with doxSA and modifying 
MacTel risk, we performed a logistic regression model including MacTel status as 
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the dependent variable and testing for interaction of each metabolite with doxSA 
using the following model  
 
 
𝑙𝑜𝑔𝑖𝑡(𝑃\Tkn.S)U	 = 𝛼𝐶U 	+ 𝛿1𝑀Uk 	+ 𝛿2𝑑𝑜𝑥𝑆𝐴gU 	+ 𝛿3𝑑𝑜𝑥𝑆𝐴gU ∗ 𝑀Uk + 𝑒U 
 
Where the 𝑙𝑜𝑔𝑖𝑡(𝑃\Tkn.S)U is the probability of observing MacTel on the logit scale 
and 𝛿3represents the interaction between metabolite 𝑀and doxSA levels. 
 
To test whether some metabolites were responsible for the interaction effect 
between MacTel and TD2 on doxSA levels we used a triple interaction linear model 
defined as follows: 
 
𝑑𝑜𝑥𝑆𝐴gU = 𝛽0	 + 𝛽1𝑀𝑇U 	+	𝛽2𝑇2𝐷U 	+ 
+	𝛽3𝑀𝑇U ∗ 𝑇2𝐷U 	+ 𝛽4𝑀𝑇U ∗ 𝑀Uk 	+ 𝛽5𝑇2𝐷U ∗ 𝑀Uk + 
+	𝛽6𝑀𝑇U ∗ 𝑇2𝐷U ∗ 𝑀Uk 	+ 𝛼𝐶U + 𝛾VOQGT	 + 𝑒U 
 
Where 𝛽6 measured the effect of metabolite 𝑀U on the interaction between MacTel 
status 𝑀𝑇U and diabetes status 𝑇2𝐷U. 
 
Entire pathway abundances were included in the regression models by performing 
Principal Component Analysis on a dataset containing only the metabolites of a 
particular metabolic pathway and extracting the first principal component as 
described in Chapter 4. To correct for false discovery arising from multiple testing 







5.3.1 Analysis of deoxy-sphingolipids in MacTel 
MacTel patients presented on average with an increment of 0.61 on the log scale 
of doxSA levels compared to the controls (p-value<1e-7). None of the covariates 
(T2D status, age, etc) were associated with doxSA levels when correcting for 
MacTel status. 
 
As expected serine was significantly decreased in MacTel patients (𝛽=-0.23, p<1e-
5) and doxSA abundance negatively correlated with serine after correcting for 
disease status (𝛿=-1.28, p<1e-7). Interestingly, in the same model, MacTel effect 
on doxSA was also significant (𝛽=0.32, p= 7.8e-5) indicating an over-abundance of 
doxSA in MacTel patients not explained by serine depletion. In a separate model, 
we found a significant positive association between alanine and doxSA (𝛿=0.64, 
p=4.7e-5), as well as a significant overabundance of doxSA in MacTel cases 
(𝛽=0.53, p<1e-7). When serine, alanine and MacTel were included in the same 
regression model, we intriguingly found both amino acids to increase in 
significance (𝛿G.gUN.=-1.36, 𝑝G.gUN.	<2e-16 ; 𝛿TSTNUN.=0.78, 𝑝TSTNUN.	<1e-9), as well as a 
concomitant decrease in MacTel status significance (𝛽=0.18, p=0.013), suggesting 
that the relationship of these metabolites with doxSA was able to explain most of 




When testing for differences in SA levels between MacTel cases and healthy 
controls while correcting for all possible covariates we found no significant effect 
of MacTel status on SA abundance (𝛽 =0.04, p=0.476). Similar results were 
obtained when removing all non-significant covariates from the model. 
 
When testing the effect of T2D on doxSA concentrations in MT cases, we found 
higher doxSA in cases with T2D (𝛽3= 0.33, p-value=0.054). From the same model, 
we also observed MacTel patients without T2D to present higher doxSA levels 
when compared to controls without T2D (𝛽1= 0.52, p=5e-7). Interestingly, we did 
not find any significant difference between patients suffering from T2D alone 





Figure 35: Distribution differences in batch-corrected doxSA levels between 
MacTel cases and controls shown according to type 2 diabetes status.  
 
The relationship between EZ loss radius and doxSA levels was tested using 117 
MacTel patients for whom EZ loss data was available. Maximum EZ loss (i.e. from 
the most affected eye) and mean loss across both eyes were positively associated 
with doxSA levels (𝛽=0.14, p=0.046; Figure 36; and 𝛽=0.155, p=0.064 
respectively).  
 













5.3.2 Exploring untargeted metabolomic associations with deoxy-
sphingolipid abundances 
 
We tested for association between all metabolite abundances and doxSA levels. To 
distinguish between metabolites, present in both datasets, we will refer to them 
as either “new” (measured in targeted metabolomics study) or “original” 
(measured in untargeted metabolomics study). We found age and MacTel status 
to be necessary covariates in the model when using the combined targeted and 
untargeted metabolomics dataset.  
 
We identified the original serine concentration (serine_original) to be the most 
significantly associated metabolite with doxSA (𝛿=-0.49, P(fdr)=9.4e-5). The new 
serine concentrations (serine_new), showed a more modest association with doxSA 
(𝛿-0.34, P(fdr)=0.0157). New SA levels (sphinganine_new), were the second-most 
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associated with doxSA (𝛿=0.38, P(fdr)=0.0064). All significantly associated 








size p-value P(fdr) 
serine_original Gly, Ser, Thr Mtb -0.49 1.0E-07 9.4E-05 
sphinganine_new Sphingolipids Mtb 0.38 1.7E-05 0.006 
1-stearoyl-2-adrenoyl-GPE (18:0/22:4)* Phosphatidylethanolamine 0.38 4.0E-05 0.008 
1-palmityl-2-oleoyl-GPC (O-16:0/18:1)* Plasmenylcholin -0.37 4.1E-05 0.008 
1-stearoyl-2-docosapentaenoyl-GPE (18:0/22:5n6)* Phosphatidylethanolamine 0.37 7.1E-05 0.011 
serine_new Gly, Ser, Thr Mtb -0.34 0.0001 0.016 
1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (P-
16:0/22:6)* Plasmenylcholin -0.31 0.0003 0.031 
gamma-glutamylisoleucine* Glutathione Mtb 0.31 0.0003 0.031 
threonine Gly, Ser, Thr Mtb -0.34 0.0005 0.032 
lactosyl-N-nervonoyl-sphingosine (d18:1/24:1)* Cerebrosides -0.30 0.0006 0.032 
taurolithocholate 3-sulfate Bile Acid Mtb -0.29 0.0006 0.032 
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erythritol Xenobiotics 0.30 0.0006 0.032 
allantoin Purine Mtb 0.30 0.0006 0.032 
1-nervonoyl-GPC (24:1n9)* Lysophosphatidylcholine -0.29 0.0006 0.032 
arabitol/xylitol Pentose Mtb 0.30 0.0006 0.032 
1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)* Plasmenylcholin -0.30 0.0007 0.032 
1-adrenoyl-GPC (22:4)* Lysophosphatidylcholine 0.30 0.0007 0.032 
docosahexaenoate (DHA; 22:6n3) Fatty Acid (Polyunsaturated) -0.29 0.0008 0.032 
2-hydroxy-3-methylvalerate Leu, Ile, Val Mtb 0.29 0.0009 0.032 
N-acetyltaurine Met, Cys Mtb 0.29 0.0009 0.032 
1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (P-18:0/22:6)* Plasmenylcholin -0.29 0.0009 0.032 
N-palmitoyl-sphinganine (d18:0/16:0) Ceramide 0.32 0.0009 0.032 
1-methylxanthine Xanthine Mtb -0.28 0.0012 0.040 
1-eicosenoyl-GPC (20:1)* Lysophosphatidylcholine -0.28 0.0013 0.040 
5-methyluridine (ribothymidine) Pyrimidine Mtb -0.28 0.0013 0.041 
valylarginine Dipeptide -0.27 0.0015 0.045 
5-(galactosylhydroxy)-L-lysine Lys Mtb 0.28 0.0017 0.047 
alpha-hydroxyisovalerate Leu, Ile, Val Mtb 0.28 0.0018 0.047 




 Table 1: Table of the significant metabolites associated with doxSA levels. Mtb = 
metabolism. 
 
We then tested for the independence of these association from the doxSA-serine 
association. By including serine_original as an additional covariate in the model 
we found that sphinganine_new was again the most associated metabolite (𝛿=0.36; 
P(fdr)=0.0014). With sphinganine_new also included in the model, we found six of 
the ten remaining metabolites belonging to the sub-family of Plasmenilcholines. 
Four of these were the topmost associated metabolites (result not shown). To test 
for significance of the entire Plasmenilcholines group, we included the first 
principal component calculated on this group found a significant negative 
association (𝛿=-0.25, p=0.0003). No significant metabolites remained after the 
additional inclusion of Plasmenilcholines first PC. Exploratory correlation 
analysis among doxSA, serine_original, sphingnaine_new, and Plasmenilcholines 





Figure 37: Pearson correlations between doxSA, serine, sphinganine and 
plamenylcholines (first PC), stratified by MacTel disease status. 
 
As expected from the linear regression model serine, sphinganine and 
Plasmenilcholines correlated with doxSA but not with each other. Interestingly, 
almost all correlations were reduced if calculated in MacTel cases only.  
 
Since some of the associations between metabolites and doxSA were observed to 
be different between MacTel cases and controls we explored which metabolites 
significantly changed in association with doxSA levels depending on MacTel 
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status. Although not surviving correction for multiple testing, we found choline to 
be the metabolite most differentially associated with doxSA depending on MacTel 
status (𝛿3= 0.68, p=1.8e-4, P(fdr)=0.14). In fact, the association between choline 
and doxSA was completely inverted, at r = -0.45 for controls and r = 0.37 for cases 
(Figure 38). 
 
Figure 38: Correlation between doxSA and choline in cases and controls.  
 
We found no significant interaction between any metabolites and doxSA on 
MacTel disease risk, although, among the top 10 nominal results (0.15<pFDR<0.2) 
the first 9 were sphingomyelins (1.5<𝛿3<1.09, 4.3e-4<p<1.9e-3) and the tenth was 
serine_original (𝛿3=1.38, p=0.0028). Similarly, to the Plasmenilcholines group 
analysis above we took the first principal component calculated on the 
sphingomyelin group and tested its interaction with doxSA on MacTel risk. This, 
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as expected, was nominally significant (𝛿3=1.15, p=0.0009). To visually explore the 
meaning of these interaction terms we divided doxSA levels into three groups, 
capturing the 1st, 2nd and 3rd tertiles of the doxSA distribution. We then examined 
the abundance of serine and sphingomyelins first principal components by 
differentiating between cases and controls in all of the three doxSA abundance 




Figure 39: Visualisation of sphingomyelin first principal component abundance 




We observed that sphingomyelin levels were comparable between MacTel cases 
and controls with high doxSA, but MacTel sphingomyelin abundance decreased 
much more than controls as doxSA decreases. In contrast, serine was lower than 
controls in MacTel subjects with low doxSA; and higher than controls in the 
highest doxSA tertile. 
 
We looked for metabolites still associated with MacTel disease status even after 
correction for doxSA levels. We found the top two metabolites to be 2-
hydroxyglutarate and glycine possibly due to their connection with the gene CPS1 
and partly disconnected from the serine-doxSA-MacTel pathway (results not 
shown). As a confirmation of this observation of this compartmentalisation of these 
two metabolites, when including the additional interaction effect between doxSA 
levels and the first sphingomyelin group principal component, 2-hydroxyglutarate 
remained significant but the effect of glycine disappeared, likely due to its 
connection with serine. 
 
When investigating which metabolites might impact the differential association 
between MacTel and doxSA levels for T2D we interestingly found three 
plasmenylcholines as the topmost significant metabolites. When including an 
interaction term between MacTel status, T2D and the Plasmenylcholine first PC 
we indeed found this to be significant (p=0.004). To visually explore these triple 
interactions we split the Plasmenylcholine first PC by the median value and 
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compared the doxSA levels among MacTel patients and controls further, 




Figure 40: Abundance distribution of doxSA levels divided by MacTel status, T2D 
status, and plasmenylcholine PC. 
 
This image reveals that in a low Plasmenylcholine environment doxSA levels 
appear to be different between cases and controls only if the individuals are 
affected by T2D. Moreover, we see that healthy controls also unaffected by T2D 
appear to have generally higher doxSA levels compared to the other MacTel 
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controls. MacTel patients with high plasmenylcholines levels presented higher 
abundances of doxSA independent of T2D status. 
5.4 Discussion 
This study investigated connections between the effect of deoxy-sphingolipid 
accumulation and risk of Macular Telangiectasia Type 2. Through statistical 
analyses, we further investigated how deoxy-sphingolipid accumulation might 
arise from either specific rare genetic mutations (eg. SPTLC1 or SPTLC2 
mutations) or systemic depletion of serine.  
 
5.4.1 MacTel patients with serine depletion accumulate deoxy-
sphingolipids in blood and likely in retina 
In this study, we observed that mice fed a serine- and glycine-depleted diet 
accumulated deoxy-sphingolipids in both circulating blood and retinal cells. This 
is likely to result from SPT utilizing alanine in place of serine. Our previous 
studies presented in Chapter 2, 3 and 4 detailed depleted levels of serine in MacTel 
patients, likely caused by specific mutations in genes that modulate serine 
biosynthesis or glycine availability. Pleasingly, in this study, we observed that 
MacTel patients have high levels of deoxy-sphingolipids in circulating blood, which 
correlates negatively with serine and positively with alanine. Concordant with 
this, alanine was identified in Chapter 3 as a metabolite with a possible causative 
effect on MacTel risk, where we identified high abundances of genetically 




Although studies on retinal tissue from individuals affected by MacTel are still 
needed, in this study lower circulating serine concentrations were sufficient to 
increase deoxy-sphingolipid levels in the mouse retina. It is reasonable to assume 
that a similar relationship between human blood and retinal serine concentrations 
exists. Lastly, it is interesting to note that, as mentioned in Chapter 1, MacTel 
often occurs in the lower temporal side of the macula and its clinical signs are 
usually confined to a specific area. Hence, analysis of deoxy-sphingolipids in 
human retinal samples, including from subjects affected by MacTel, and observing 
the specific macular layers or regions prone to deoxy-sphingolipid accumulation 
given the distinct anatomy of this disease might give insights into why MacTel 
symptoms are confined to the macula in the eye. 
 
5.4.2 Deoxy-sphingolipids are likely not the only MacTel disease drivers 
This study found the very first causative genetic mutation that explained the 
comorbidity of MacTel and HSAN1, suggesting that the accumulation of deoxy-
sphingolipids, without serine depletion, is sufficient for the development of 
MacTel. However, we observed that not all mutations that increase deoxy-
sphingolipids and produce HSAN1 were causative for MacTel. In fact, HSAN1 
patients with mutation p.Cys133Trp in gene SPTLC1 did not develop MacTel. 
Moreover, some MacTel patients without HSAN1 mutations were observed to have 
physiological deoxy-sphingolipids levels comparable to controls. This contrasting 
finding highlights that deoxy-sphingolipids are not likely to be the only causative 
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drivers behind MacTel and other metabolic or phenotypic disturbances will need 
to be taken into account. 
5.4.3 Deoxy-sphingolipid accumulation affects retinal health and 
correlates with MacTel progression 
In the mouse diet study, we observed impaired retinal function in serine-deprived 
animals. As MacTel is associated with abnormalities in retinal cell layers, it is 
likely that deoxy-sphingolipid accumulation in both blood and retina might be the 
cause for the insurgence of the first MacTel symptoms. We also noticed that deoxy-
sphingolipid abundance suggestively correlated with ellipsoid zone (EZ) loss 
progression in MacTel patients. As deoxy-sphingolipids are incorporated into cell 
membranes, and cannot be degraded via beta-oxidation, we expect that MacTel 
patients slowly accumulate deoxy-sphingolipids over the course of their life. This 
accumulation might become increasingly toxic for the retina which is likely to 
deteriorate faster in higher deoxy-sphingolipids surroundings. Interestingly, in 
Chapter 3 we presented results on the causative role of serine depletion where we 
found that low levels genetically predicted serine to increase the risk of MacTel 
progression markers, which further supports an important role for deoxy-
sphingolipids accumulation in MacTel progression.  
 
We recognise, however, that the cross-sectional setting of this study was not suited 
to analyse progression outcomes. Moreover, as mentioned in Chapter 1 we 
observed in a previous study that EZ loss progression in MacTel patients appears 
to be non-linear, and is characterised by a slow initial progression with a 
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subsequent spike in EZ loss, followed by a final plateau, usually confined to the 
“MacTel area” (16). Additionally, longitudinal measurement of deoxy-
sphingolipids in blood will be required to determine their prognostic utility 
relative to EZ loss. In lieu of this, a suitable proxy for such a study may be 
measurements of deoxy-sphingolipids in MacTel patients at a single time point 
combined with longitudinal observations of EZ loss. 
 
5.4.4 Prospects for MacTel treatment: serine supplementation and 
fenofibrate 
 
We observed that a diet lacking serine and glycine alone might be sufficient to 
cause deoxy-sphingolipids accumulation which is known to cause MacTel in 
humans. Oral serine supplementation might, therefore, be used to prevent or limit 
the accumulation of deoxy-sphingolipids. Glycine supplementation appears not to 
be a viable treatment as this is thought to be depleted only to counteract serine 
insufficiency. 
 
High serine abundance has been associated with increased cancer risk and 
progression (89–91), casting doubt on the promise of serine supplementation in 
MacTel patients, especially those older than 50 years who are more prone to cancer 
development. However, we are encouraged by a recent manuscript by Lotta et al 
which found no causative relationship between serine abundance and cancer risk 




As mentioned, not all MacTel patients have depleted serine, and hence elevated 
deoxy-sphingolipid levels. MacTel patients with HSN1 disease due to mutations 
affecting the SPT enzyme might be expected to have normal serine levels. 
Moreover, we observed that alanine increases doxSA levels independently of 
serine. Hence direct assessment of serine abundance in MacTel patients prior to 
prescription of serine supplementations would be crucial to evaluate the 
appropriateness of such treatment as it may lead to unintended outcomes.  
 
The study by Gantner et al also treated serine-deprived mice with compounds 
altering lipid metabolism. Specifically, they observed that the PPARα agonist 
fenofibrate was able to rescue cell death in retinal organoids that were previously 
subjected to elevated levels of deoxy-sphingolipids. The appropriateness of these 
potential treatment options will depend on the accurate measurement of patient 
metabolic phenotypes and evaluation of their genetic risk factors, i.e. needs to be 
personalised. 
5.4.5 Sphinganine independently correlates with deoxy-sphingolipids but 
not MacTel 
 
In addition to results presented in Gantner et al., we found that serine, 
sphinganine, and plasmenylcholines were each independently associated with 
higher levels of deoxy-sphingolipids. These independent associations might 
indicate that the metabolic pathways connecting each metabolite to doxSA are 
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different. Because of this, it can be speculated that such metabolites might be 
involved in separate causative disease mechanisms. Our current understanding of 
sphingolipid metabolism in MacTel (Figure 37) involves dependence between 
serine, and sphinganine, via SPT. However, it is interesting to note that our 
previous analysis (Chapter 4) and well as the analysis presented here, did not find 
differential abundances of sphinganine between MacTel patients and controls. In 
fact, we observed that MacTel patients exhibit comparable levels of sphinganine 
to healthy individuals, as well as a positive correlation between these molecules 
and doxSA. To reconcile these results with current biochemical models of 
sphinganine biosynthesis requires further study, but suggests the existence of a 
secondary mechanism which compensates the accumulation of doxSA with 
sphinganine accumulation - a process apparently not related to the disease.  
 
As presented in Chapter 4, untargeted metabolomics analysis identified different 
metabolites connected to MacTel which are located downstream of the pathway 
connecting serine to sphinganine and doxSA. In fact, we observe that patients 
generally have elevated levels of ceramides as well as depleted abundances of 
sphingomyelins and choline. Understanding these results will require detailed 
analysis of the sphingolipids pathway, including all sphingolipid subspecies in 
MacTel patients, in order to elucidate how such imbalances, connect and 




5.4.6 Plasmenylcholine independently affects deoxy-sphingolipid levels 
and might be key to decode comorbidity between MacTel and type 2 
diabetes 
 
We observed that plasmenylcholines negatively affect doxSA levels independent 
of disease status, and serine and sphinganine serum concentrations. Interestingly, 
plasmenylcholine glycerophospholipids predicted doxSA variability only after the 
inclusion of serine and sphinganine in the model. This indicates that several 
factors might act simultaneously to affect doxSA. To discover unconfounded 
associations, such factors need to be taken into account at the same time. As 
presented in Chapter 3, plasmenylcholines were, in concordance with this study, 
depleted in MacTel patients, further strengthening the assumption of a genuine 
role of such metabolites on disease development. 
 
Intriguingly, when analysing the effect of different metabolites on the interaction 
of MacTel status with T2D on doxSA levels, we found plasmenylcholines to be the 
most significant metabolites. Specifically, we observed that lower 
plasmenylcholine levels were generally associated with increased doxSA levels, 
independent of MacTel status, but dependent on T2D status. More specifically, we 
found that MacTel patients with T2D and low plasmenylcholine levels had some 
of the highest doxSA levels, while healthy controls with the same characteristics 
were among the lowest. Little is currently known about the relationship between 
plasmenylcholines and T2D, however, associations between such lipids and type 1 
diabetes have been described previously (92). Our results suggest that 
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investigations of plasmenylcholines in MacTel patients who also suffer from T2D, 
compared to those that do not, are required. 
 
5.4.7 Sphingomyelin and serine distinguish MacTel among subjects with 
low deoxy levels 
 
In this study, we investigated which metabolites might play a role in MacTel 
disease in the context of different deoxy-sphingolipids strata. With this analysis 
we found sphingomyelins to best distinguish between cases and controls, 
depending on doxSA abundances. Specifically, we found that although MacTel 
patients and healthy individuals with high deoxy-sphingolipids had similar levels 
of sphingomyelins, this was not true for individuals with low levels of deoxy-
sphingolipids where MacTel patients presented substantial depletion of 
sphingomyelins. This effect is likely to explain some of the heterogeneity that was 
found in our previous study (Chapter 4) where these lipids were found to be 
generally depleted in MacTel patients but not to be the most depleted ones.  
 
It may be that sphingomyelins are extremely depleted only among MacTel 
patients which are affected by a different biological mechanism from doxSA 
accumulation, making sphingomyelins an important biomarker that needs to be 




Sphingomyelins are formed downstream of the sphinganine pathway and directly 
connected with ceramides and glycerophospholipid metabolism, which was found 
to be dysregulated in MacTel patients (Chapter 4). Moreover, in our previous 
chapter, sphingomyelins were found to be one of the most significant differentially 
co-expressed metabolic groups, and the only one connecting the two most 
differentially abundant metabolomics groups (glycine-serine metabolism and 
phosphatidylethanolamines).  
 
Further, our conditional GWAS analysis (Chapter 3) revealed loci which 
contribute to disease aetiology independent of genetic factors that influence the 
serine-glycine pathway. This analysis identified SNP rs36259, located on gene 
CERS4 as an independent contributor to MacTel risk. CERS4 is a gene whose 
products are important in the sphinganine and sphingomyelin conversion. CERS4 
products are expected to act independently of doxSA concentrations to influence 
sphingolipid concentrations. The results presented in this chapter confirm a 
potential role of sphingomyelin pathway disturbance on MacTel which might 
contribute to disease aetiology from a separate, but possibly not independent, 
mechanism of deoxy-sphingolipids accumulation. 
 
5.4.8 Glycine and 2-hydroxyglutarate depletion as additional MacTel 




Lastly, when investigating metabolites associated with MacTel after accounting 
for deoxy-sphingolipids, glycine and 2-hydroxyglutarate remained significantly 
depleted in MacTel patients with respect to control, with the latter significant even 
after inclusion of the doxSA-sphingomyelin interaction effect. These results are 
expected, since these are involved in processes and pathways other than 
sphingomyelin biosynthesis.  
 
Levels of 2-hydroxyglutarate are biochemically independent of serine depletion 
and likely to be influenced by PHGDH, located in 1p12, identified as a GWAS hit. 
Glycine abundance is directly linked to serine abundance. As covered in Chapters 
3 and 4 CPS1, contained in another GWAS hit, is important for glycine 
concentrations and not directly involved in serine abundance. In this study, the 
relationship between glycine and MacTel risk dissipated when we included the 
significant interaction term between sphingomyelin and doxSA. It can be 
hypothesised that the additional effect of glycine on disease risk might not be 
independent of the aforementioned risk brought by sphingomyelin depletion.  
 
The inclusion of doxSA as a covariate in the model may also reveal additional 
metabolic connections that are easily missed in the preliminary analysis. We 
suggest therefore that a more careful and in-depth evaluation of the MacTel 
metabolomic profile, similar to that presented in Chapter 4, should be performed, 







In this chapter, we investigated the causal role that deoxy-sphingolipids have on 
MacTel risk and progression. The updated schematic of the study findings is 
presented in Figure 41. This causal relationship is likely to happen through either 
direct influence of deoxy-sphingolipids biosynthesis or through the indirect effect 
of serine depletion. However, we demonstrate that this is likely not the only causal 
mechanism affecting MacTel, and careful evaluation of different metabolic 
biomarkers are required to inform the likely success of treatments targeting 
deoxy-sphingolipids. Such considerations are becoming more important in the 
burgeoning era of personalised medicine. Lastly, we further confirmed the 
importance of sphingomyelin concentrations in distinguishing MacTel patients 
with normal deoxy-sphingolipid abundance, and identified the potential role of 
plasmenylcholine in MacTel and type 2 diabetes comorbidity, which we think 




Figure 41: Main findings schematics displaying the drivers and traits associated 
with MacTel. Genetic traits are displayed as green rounded squares. Metabolites 
are displayed as blue circles. Metabolic pathways are displayed as purple 
diamonds. Phenotypic traits are displayed as red squares. Associations are 
represented by dotted black lines while associations changed by interaction are 
displayed by dashed red arrows. Causality is indicated by unidirectional solid 





In this thesis, we presented four different studies investigating several different 
aspects of MacTel disease. Each study integrates several types of ‘omic data.  
 
The following chapter will summarise and discuss the main findings of these four 
studies while placing their discoveries on the bigger spectrum of macular and eye 
disorders as well as suggesting avenues for future studies. 
 
6.1 MacTel is a disease with heterogeneous pathology and 
genetic causes 
 
One of the main findings from this thesis is that MacTel is indeed a complex  
disease likely to have multiple causes. In this thesis, we specifically focused on 
metabolic disturbances involved in MacTel and how this interplay with genetic 
risks. However, there are still several genetic loci involved in the disease that are 
independent of the main metabolic dysregulation. This key finding comes from 
extensive analysis of the data examined in this thesis where these genetic loci 
remain independent risk factors, even when we correct for all known metabolic 
drivers and surrogates. 
 
Among the metabolic causes of MacTel we highlight that the accumulation of 
doxSL reaching toxic levels is likely to be one of the main disease drivers. However, 
216 
 
even within the doxSL framework, we observed a certain level of heterogeneity. 
We discussed how certain patients might develop a higher abundance of doxSL 
because of rare mutations on genes catalysing SPT enzymes, impacting the affinity 
of this enzyme to legate palmitoyl-CoA to alanine rather than serine. This, in turn, 
results in higher abundances of doxSL even with physiological levels of circulating 
serine. Other MacTel patients might be presenting with abnormally high levels of 
alanine, resulting in an imbalance between the two and inducing SPT to use 
alanine instead of serine. Others again are instead believed to accumulate doxSL 
because of specific genetic perturbations impairing the biosynthesis of serine. 
Among these, the genetic mutations impairing serine biosynthesis and its 
availability are likely to be different. Some patients might be unable to properly 
produce serine because of genetic impacts on genes such as PHGDH and PSPH. 
Others might be unable to convert glycine into serine due to mutations on the 
CPS1 gene, resulting in overstimulation of the CPS enzyme which catalyses 
glycine into other substrates as part of the urea cycle.  
 
With the integration of metabolomics data on MacTel individuals, we discovered 
many other metabolic disturbances related to the disease. Some of these are likely 
to be distinct from doxSL. For example, we presented in Chapter 4 and Chapter 5 
how sphingomyelin, located downstream from the doxSL biosynthesis, appears to 
be another driver. Other identified pathways were almost entirely disconnected to 
doxSL. Among these were phosphatidylethanolamines, lyso-
phosphatidylethanolamines, plasmenylcholines, long-chain fatty acids, 




In addition, we found non-metabolic genetic signatures affecting MacTel risk. The 
first was locus 5q14.3, tagged by SNP rs73171800, which was associated with both 
vasculature calibre as well as macular thickness (63, 64, 93, 94). Although MacTel 
commonly presents symptoms affecting retinal vasculature, we were unable to 
find any causative effect of vasculature calibre on MacTel disease. The second, 
locus 3p24.1 (tagged by SNP rs35356316) in chromosome 3 was found by exploring 
genetic factors affecting disease risk independently from serine genetic influences. 
This locus is likely to affect the disease by a mechanism which is independent of 
either metabolic disturbance or retinal vasculature. Interestingly, this locus is 
within the linkage region for the sensory neuropathy HSAN1b, similar to HSAN1a 
but additionally presenting cough and gastroesophageal reflux (95). We speculated 
in the previous chapter that this locus might be involved in altering the expression 
of the gene SLC4A4 which would impact the physiological pH of the photoreceptor 
layers by creating a toxic environment that impedes photoreceptor regeneration. 
Work on this locus is ongoing. 
 
Heterogeneity was not only observed in the causes of MacTel and their metabolic 
signature but also in its clinical presentation and progression rate. By combining 
genomics data with phenomics data, in the form of retinal imaging data, we 
discovered that MacTel clinical presentation and progression might be modulated 




The final updated schematic on MacTel heterogeneity and some of its possible 
causes are presented in Figure 42. 
 
Figure 42: MacTel heterogeneity schematics.  
 
The first GWAS into MacTel already identified multiple genetic loci (61). The work 
in this thesis has identified further heterogeneity, marking MacTel as an 
extremely complex diseases, despite its estimated high heritability, at around 70% 
(Chapter 2). In fact, other more common and likely more heterogeneous disorders 
have a much lower heritability, such as Age-Related Macular Degeneration (65%) 
(96) or Diabetic retinopathy (25% - 50%) (97). It is interesting to speculate why 
MacTel has such high heritability despite this apparent heterogeneity. Several 
factors are likely to contribute to this. Firstly, the initial GWAS was successful, 
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identifying four loci, despite its relatively small sample size compared to other 
GWAS studies performed on more common diseases, including other 
retinopathies. This indicates that certain loci involved in MacTel had strong 
enough effect sizes allowing them to be detected and figuratively placing them in 
the middle of the negative relationship line presented in Figure 12. Secondly, we 
found that even with a moderate sample size of 500 MacTel individuals we were 
able to cluster loci into functional groups based on their effect on retinal 
endophenotypes. These results were concordant with external studies. Thirdly, we 
observed that metabolic signatures of MacTel had a high signal to noise ratio, and 
even our small-scale metabolomics study (60 cases, 58 controls) was sufficient to 
identify complex metabolic signatures present in this disease. We even observed 
correlations of some of these signatures with the progression rate. Lastly, we 
discovered that there was at least one rare allele affecting the SPTLC1 gene that 
is able to cause MacTel by itself, with a very high penetrance, albeit observed with 
a very low frequency, thereby resolving a small number of the MacTel cases and 
directly identifying the cause for their pathology as being dysregulation of the 
sphingolipid pathway. This discovery was possible due to the prior knowledge 
provided by the GWAS results, resulting in the first Mendelian gene for MacTel.  
 
To conclude, we confirm that MacTel is a complex disorder and further 
investigations are still required to determine as yet unsolved mechanisms behind 
this disease pathology. Although complex, we also discuss how observed MacTel 
heterogeneity is likely to be contained to a much smaller set of pathways. Lastly, 
we warn that as we move toward the aim of discovering rarer and rarer MacTel 
220 
 
causes, sample sizes required might increase exponentially and careful evaluation 
of the rarity and uniqueness of such etiological mechanisms need to be assessed 
based on known disease knowledge. 
 
6.3 Careful evaluation of MacTel patients’ metabolic profile is key 
for treatment prescription 
 
No treatment is yet available for MacTel. Impressive progress has been made with 
the usage of CNTF implants, which have been shown to slow down or block disease 
progression (21, 22). However, these implants are invasive, costly and have not 
been observed to allow recovery of the photoreceptors. Furthermore, their precise 
mode of action is currently unknown. In this thesis, we discussed which of the 
factors causing MacTel might be targeted with potential treatments through 
clinical trials. For example, doxSL levels can be reduced by compounds promoting 
their catabolism into different subunits, effectively reducing their amount to non-
toxicity levels. In fact, as shown in Gantner et al usage of FumonisinB1 and 
Fenofibrate, which are already known to reduce doxSA, were shown to be 
sufficient in organoid cell cultures to recover from cell death caused by toxic levels 
of doxSL. Similarly, serine oral or localised supplementation might be a 
prospective treatment as increasing serine levels might reduce the production of 
doxSL and effectively slow the MacTel progression or even allow for cell 




Although these considerations are promising for prospective treatment 
developments, caution is advised. Firstly, we demonstrated and argued that 
MacTel is not uniquely caused by alteration of the serine to doxSL pathway. For 
example, certain patients carry the mutation p.Cys133Trp in the SPTLC1 gene 
and are expected to present with high abundances of doxSL, despite normal serine 
levels. For such patients, supplementation of serine would not only be ineffective, 
but will likely result in a serine overabundance inducing other possible 
complications. Other patients have normal doxSL levels but severe depletion of 
serine and sphingomyelin. Similarly, treatment of such patients with either 
FumonisinB1 or Fenofibrate might prove ultimately ineffective if not deleterious. 
Through Mendelian Randomization we identified high alanine as a possible 
additional causal driver for MacTel which might increase levels of doxSL 
independently of serine abundance. Prospective treatments targeting alanine 
might be better suited for such individuals. Again, we noticed that 
plamenylcholine levels could distinguish between MacTel patients with and 
without T2D. These metabolites, as well as T2D status and insulin levels, should 
be taken into account when considering prospective treatments. Lastly, we showed 
how MacTel can develop independently of metabolites and would need a different 
treatment approach. 
 
To conclude, prospective treatment studies on MacTel using drugs targeting serine 
or doxSL levels should be a priority. However, careful evaluation and monitoring 
of the main MacTel biomarkers will be required for patients receiving such 




6.4 The genetic mechanism affecting vascular phenotypes is still 
unclear 
 
One of the main clinical signs of patients suffering from MacTel disease is leakage 
of the retinal vessels on different subretinal layers followed, in certain cases, by 
abnormal vasculature structure as well as advanced cases of neovascularization. 
Intriguingly, our initial GWAS identified locus 5q14.3 on chromosome 5, which 
was previously associated with retinal vascular integrity. However, none of the 
other loci affecting the vasculature calibre impacted MacTel risk, thereby 
weakening the initial hypothesis of a causative role of retinal vasculature 
diameter. Locus 5q14.3s was additionally found in our study and others (94) to 
impact macular thickness. We recognise that macular thickness can be mostly 
considered as a bi-standard phenotypes proxy, reflecting a multitude of retinal 
phenotypes. For example, neuronal degeneration, as well as EZ layer breaks, 
induce retinal thinning while vascular leakage may induce retinal thickening. 
This suggests that the effect of locus 5q14.3 might act primarily on retinal 
vasculature and subsequently resulting in a cascade of factors impacting macular 
thickness.  
 
In a study by Madelaine et al, the mutations in locus 5q14.3 were found to affect 
the activity at the CNE1 locus, which acts as an enhancer and cis-regulator of 
transcription of the microRNA gene called MIR9-2 (64). Suppression of MIR9-2 
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expression was responsible for several retinal vasculature defects in zebrafish. The 
same study argued that SNPs variations in the CNE1 locus reduce expression of 
MIR9-2 predisposing subjects to a lifetime exposure of dysregulated gene activity. 
This suggests that patients carrying such mutations were predisposed to retinal 
vascular malformations. The study by Madelaine et al provides a rationale on the 
possible role of locus 5q14.3 on retinal vasculature phenotypes observed in MacTel 
patients. As mentioned above, certain MacTel patients not only present vascular 
leakage and vascular abnormalities but develop neo-vascularisation in later 
disease stages. This suggests that although mutations in the 5q14.3 locus could 
explain several vascular malformations in most MacTel patients, neo-
vascularization is likely caused by further mutations at different loci. 
Interestingly, early attempts of VEGF retinal injection - which reduces neo-
vascularisation in the wet subtype of Age-Related Macular Degeneration - in 
MacTel patients were not successful and were deemed deleterious for patients 
without such phenotypes. 
 
These observations suggest the need for further prospective studies on the role 
that genetic variants in locus 5q14.3 have on MacTel and especially their role on 
late-stage neo-vascularisation. Additionally, GWAS could be used to identify 
different genetic variants that might differentiate between subjects carrying such 
phenotype from those without and provide further insights into the mechanism 




6.5 MacTel might have an inverse causative role on type 2 
diabetes 
 
We discussed how the high comorbidity of T2D with MacTel displays an intriguing 
connection between the two diseases. However, while MacTel patients have a high 
incidence of T2D, the vast majority of patients with T2D rarely present with 
MacTel.  
 
In Chapter 3 we found the genetic risk of T2D to increase MacTel risk hence 
suggesting a potential causative role. However, this association was comparatively 
small with other causal genetic scores tested in the same study. Diabetes has been 
connected to glycine depletion and, in our study, we speculated that T2D might 
not be a causative factor for MacTel disease and we hypothesised that the opposite 
might be likely. In fact, expecting a causative role of T2D on MacTel should, in 
theory, translate to most T2D patients presenting with MacTel and only few a few 
MacTel patients presenting with T2D. Since the opposite is true, we hypothesize 
that genetic alterations causing metabolic disturbances of MacTel disease are 
likely to impact on biological mechanisms, like glycine depletion, which in turn 
influence the incidence of T2D. Intriguingly, when exploring MacTel doxSL levels 
in Chapter 5, we noticed that diabetic MacTel patients had elevated doxSL levels 
compared to diabetic controls, while a much lower difference was observed among 
non-diabetic individuals. We additionally identified plasmenylcholines as key 
metabolites which could explain the role of doxSL on the comorbidity between 
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MacTel and T2D. Importantly, MacTel patients usually do not present typical 
phenotypes of diabetic retinopathy, a retinal disorder affecting some individuals 
with T2D.  
 
The deep metabolic connections between MacTel and T2D arising from our results 
still require further investigation and several approaches may be implemented to 
further explore such relationships. Firstly, a GWAS study restricted to MacTel 
patients only comparing diabetic and non-diabetic patients is needed to identify 
distinct genetic signals that might inform on the main causal biological pathways 
leading to T2D development among MacTel patients. Secondly, a bi-directional 
MR may prove informative to dissect the genetic relationship between the two 
pathologies and assess the direction of a causative relationship. However, we 
highlight that careful evaluation of genetic variants used for such analysis is 
required and adequate sample sizes are required to robustly divide the two 
different disease signals. Thirdly, deep metabolomics investigations comparing 
the metabolic signatures of T2D-MacTel from non-T2D-MacTel may also prove 
informative. Lastly, correlation of genetic and metabolic signatures of MacTel 
disease with those of diabetic retinopathy might inform on shared biological 





6.6 Metabolic impact of serine depletion seems to have a broad 
effect on retinal health 
 
Serine plays a crucial role in MacTel and its depletion results in a clear cascade of 
metabolic disturbances, ultimately resulting in retinal photoreceptors 
degeneration. This suggests that other retinal pathologies could be related to 
serine depletion than those identified so far in the scientific literature. In fact, in 
work performed by our collaborators (unpublished data), the authors tested for 
causal associations of genetically predicted metabolites on all disease divided by 
ICD10 codes on the UK Biobank dataset. Although never significant because of 
the large multiple testing burden faced in such a study, several eye and retinal 
pathologies were among the top most significant diseases associated with serine 
depletion. This suggests that metabolic serine levels might be of preeminent 
importance for general retinal health suggesting that serine is a key metabolite in 
the, as yet very poorly understood energy metabolism of the retina. Moreover, we 
observed that diseases like age-related macular degeneration and diabetic 
retinopathy are connected with MacTel through shared connections of either 
clinical signs or common comorbidities. The role of serine on such diseases and 





6.7 Future directions 
 
In this section we discuss potential prospective studies that might be performed 
to either validate or clarify several insights drawn from this thesis. Studies are 
divided into three main categories (genomics, metabolomics, clinical) and only 
studies focusing on data analysis and data integration will be presented.  
 
6.7.1 Prospective genomics studies  
 
Our initial GWAS focused entirely on chromosomal SNPs and excluded 
mitochondrial DNA. A mitochondrial GWAS should be performed to elucidate on 
the potential role of variants in mitochondrial DNA. 
 
We observed genomic influences on the progression of MacTel. However, analyses 
performed to check such influences were restrained to datasets never tailored for 
proper time-related disease progression analysis. A prospective GWAS study and 
subsequent MR on longitudinal phenotypic MacTel dataset is likely to elucidate 
the genetic and biological mechanism that might be targeted to slow down or 
completely stop disease progression. 
 
MacTel patients not only differ from each other in the disease progression rate but 
also in late-stage neo-vascularisation and T2D comorbidity. When adequate 
sample size becomes available, GWAS investigations and subsequent MR analysis 
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on differences between MacTel patients presenting such traits might inform on 
possible causal mechanisms that further differentiates patients and might 
instruct for more adequate and specific treatments, deemed to become of pivotal 
interest in the upcoming era of personalised medicine.  
 
To truly validate an inverse causative role on MacTel to T2D, adequate sample 
size, as well as better informed instrumental variables used to define MacTel risk, 
should be used to perform a bidirectional MR comparing T2D with MacTel. 
 
A follow-up study on patients treated with CNTF implants in the light of 
conclusions drawn in this thesis might help interpret treatment responses and 
identify patients not likely to derive any beneficial effect from the implants. This, 
in turn can help plan future trials, targeting those patients most likely to benefit.  
 
The previously mentioned UK Biobank dataset continues to expand and now 
contains retinal structural images as well as genetic information form tens of 
thousands of individuals. However, this dataset lacks functional visual 
assessments which are informative on the visual ability of MacTel patients. 
Recently a publication predicting fine visual function from structural retinal 
images in MacTel patients has been published (98), highlighting the possibility to 
automatically assess functional from structural changes on retinal images. 
Predicting visual function in such dataset would allow interrogation for causal 
metabolic influences on general visual impairments using MR, which, as 
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mentioned earlier, is likely to be impacted by some of the metabolic signatures 
identified in this thesis. 
 
We found several connections between diabetic retinopathy, age-related macular 
degeneration and general macular thickness with MacTel. Such traits should then 
be tested for genetic correlation with MacTel which might inform on the degree of 
the shared genetic signal between the different traits. 
 
The first MacTel GWAS study attempted disease prediction using SNP data. 
However, the methodologies used in that study are not comparable to modern 
machine learning methods that might instead prove extremely useful to 
investigate a potential prediction tool aiding in clinical diagnosis. Such a tool 
might become of increasing interest for future population screening studies and 
for careful diagnosis of MacTel disease and is worthwhile revisiting.  
 
Although we explore eQTLs effect of MacTel candidate SNPs on gene expression, 
no data was available for retinal eQTLs. Recently a study exploring 
transcriptional signatures and eQTLs in the human retina has been published 
(99). This study opens the possibility of assessing retinal transcriptomics 
influences of MacTel genetic variants as well as performing a Transcriptome Wide 
Analysis Study, which, through a concept similar to MR, identifies genes which 




Lastly, the role of locus 5q14.3 in chromosome 5 and locus 3p24.1 in chromosome 
3 is yet to be fully understood, especially in the human retina. Following the 
informative example published by Madelaine et al, epigenetic studies on such loci 
in human retinal organoids might elucidate their specific function.  
 
6.7.2 Prospective metabolomics studies 
 
Although MacTel progression is yet to be understood, metabolic dysregulation 
appears to also play a role. Performing a metabolomics study on longitudinal 
progression data on MacTel patients has the potential to inform on metabolites 
which might be targeted for future treatment. Such a study is also necessary to 
validate our previous findings on doxSL impact on MacTel progression. 
 
A new metabolomics study on MacTel patients also taking into account doxSL 
levels should be performed. Such a study not only would inform on the broad 
metabolic impact of doxSL accumulation but could validate the previous finding of 
the serine and sphingomyelin roles in distinguishing MacTel subjects from healthy 
controls in a cohort with normal doxSL levels. 
 
6.7.3 Prospective clinical studies 
The results presented in the previous chapter outline the need for a prospective 
clinical trial on the possible treatment of MacTel using serine supplementation in 
conjunction with doxSL suppressors. However, we again stress how careful 
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evaluation prior to and during the trial should be exerted on the genetic and 
metabolic profiles of the enrolled patients. This will ensure a deep understanding 
of the clinical trials outcomes and treatment efficacy as well as addressing future 
improvements towards personalised therapies.  
 
On a final note, glycine and serine are available as “over the counter” food 
supplementation at any pharmacy/chemist. Hence, although a clinical trial is 
clearly warranted, as outlined above, this will be difficult to perform in the age of 
consumer awareness and social media. The patients moderated MacTel Facebook 
Group (954 followers) from August 2017 has posted more than 370 posts informing 
on all publicly available MacTel studies, studies on other eye disorders as well as 
supplementations for eye health. The group has indeed not missed the hint of 
potential involvement of glycine and serine in MacTel and discussions among 
patients regarding serine and glycine supplementation and diet were already 
shared right after the Scerri et al 2017 publication. Hence clinical trials will be 
very difficult to perform in such a climate because compliance, baseline and 
continued blinding throughout the study may be very difficult to achieve. This is 
not a challenge unique to MacTel, but MacTel is possibly one of the diseases where 
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